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Aims and Outline of the Thesis 
 
Colorectal cancer is the second leading cause of cancer-related death in the 
Western industrialized world. Already more than 15 years ago, Fearon and 
Vogelstein formulated a genetic model for colorectal tumorigenesis, the so-called 
adenoma-carcinoma sequence, that nowadays still represents the paradigm and 
the basis of our understanding of the molecular and genetic basis of this disease. 
By exploiting the possibility to recognize different histological stages of tumor 
development in the colon, each progression step has been related to specific 
genetic “hits” in defined oncogenes and tumor suppressor genes. The genetic 
mutations accumulated during tumor development are responsible for the 
deregulation of key signal transduction pathways like Wnt, TGF-b and receptor 
tyrosine kinase (RTK) pathways responsible for uncontrolled cell growth, inhibition 
of apoptosis, and immortalisation. Still, little is known about the multiple 
interactions and mutual influences of these defective pathways and on the 
mechanisms responsible for the ‘just-right’ level of genetic instability that 
contributes to the establishment of the multiple genetic defects necessary to 
promote tumor progression and malignancy. In this thesis, I have made an attempt  
to the molecular and cellular analysis of the major genes mutated along the 
adenoma-carcinoma sequence (APC, KRAS, and SMAD4) and the cross-talk of 
the signalling pathways they regulate (Wnt, RTK, and TGF-b?) in particular with 
regard to their role in the onset and malignant behaviour of the intestinal tumor cell.    
The first part of the introduction encompassed in Chapter 1 describes in details the 
adenoma-carcinoma sequence as the experimental model of choice for the studies 
enclosed in my thesis, followed by an overview of the different genetic defects 
underlying tumor initiation and progression. The second part of the introduction is a 
review on the mechanism of chromosomal instability in CRC and the involvement 
of the APC tumor suppressor gene in this form of genetic instability in intestinal 
tumor initiation and progression. 
Forty to fifty percent of colorectal carcinomas carry activating mutations in the 
KRAS proto-oncogene, usually in association with poor prognosis. The generation 
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and molecular analysis of the Apc
+/1638N
/pVillin-KRASV12G compound mutant mouse 
model and the corresponding in vitro model systems as described in Chapter 2,  
enabled us to address whether the concomitant activation of the KRAS and Wnt 
pathways in colorectal tumors results in enhanced tumor onset and accelerated 
adenoma-carcinoma progression through a cumulative or synergistic interaction 
between the two signalling cascades. 
In the study included in Chapter 3, we assessed the contribution of genes 
frequently mutated during the adenoma-carcinoma progression, namely APC, 
KRAS and p53, to chromosomal instability, measured as tumor-specific aneuploid 
changes by BAC arrayCGH. The identification of chromosomal aberrations in early 
intestinal lesions from Apc
+/1638N
 mice supports a model where loss of APC  
function causes mitotic spindle defects and thus abnormal chromosomal 
segregation. As discussed, the integration of genomic and expression profiling data 
from mouse and human intestinal tumors represents a powerful tool for the 
mapping and identification of conserved chromosomal loci and candidate genes 
involved in malignant progression. 
In Chapter 4, the analysis of Smad4+/E6sad mouse intestinal tumors revealed that 
the somatic loss of the wild type Smad4, a key element for the transduction of 
TGF-b signals, occurs only at later stages of tumor development thus 
demonstrating that haploinsufficiency underlies Smad4-driven tumor initiation in the 
GI tract. Furthermore, the generation and detailed phenotypic and molecular 
analysis of two distinct Apc/Smad4 compound heterozygous mouse models, either 
in the cis (CAS) or trans (TAS) allelic phases, enabled us to dissect the differential 
roles of TGF-b ?signaling in distinct steps of tumor initiation and progression, and 
provided a unique in vivo model to study the concomitant effects of Wnt and TGF-b 
signaling. 
The further characterization of Smad4 haploinsufficiency presented in Chapter 5,  
demonstrates that the ~50% reduction in protein expression observed in the 
heterozygous Smad4+/- cells leads to a correspondent decrease in TGF-b and BMP 
signal transduction pathways, as measured by specific reporter assays. Also, the 
expression profiling analysis of hetero- (Smad4+/-) and homozygous (Smad4-/-) ES 
cells led to the identification of a subset of dosage-dependent target genes 
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involved in different cellular pathways and functions. The validation by quantitative 
RT-PCR of these transcripts on intestinal tissues from Smad4+/E6sad animals 
confirms that Smad4 haploinsufficiency results in a broad spectrum of downstream 
transcriptional defects that may promote the tumorigenesis process in intestinal 
cells.  
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Introduction  
1.1. Introduction to cancer 
Cancer is, in essence, a genetic disease that originates through a multistep 
process. In this model, the first stage, the initiation, is caused by the acquisition in 
a cell of a mutation that can provide a growth advantage and/or irreversible 
alterations in cellular homeostasis and differentiation. The next step, the 
promotion, can be a potentially reversible or interruptible clonal expansion of the 
initiated cell by a combination of growth stimulation and inhibition of apoptosis. 
Further progression steps occur upon clonal expansion of the initial cells and 
accumulation of a sufficient number of mutations and epigenetic alterations to 
acquire growth stimulus-independency and resistance to growth inhibitors and 
apoptosis, ultimately leading to an unlimited replicative potential. The acquisition of 
the ability to invade the surrounding tissue defines the malignant character of 
cancer cells, while the process through which cells can migrate to distal organs 
and acquire the potential to form metastasis represents the achievement of a full 
malignant cancerous phenotype. 
Colorectal cancer represents an ideal model to investigate and elucidate the 
genetic alterations involved in tumor onset and progression, mainly because it 
arises and progresses through a series of well-defined histopatological changes, 
the so-called adenoma-carcinoma sequence. 
 
1.2 Histopathology of colorectal cancer development 
The digestive surface of the human large intestine is characterized by a monolayer 
of specialized epithelial cells that forms invaginations called crypts. At the base of 
each crypt 4-6 intestinal stem cells are located from which the four cellular types 
that constitute the intestinal layer originate: columnar absorptive cells, the mucus-
secreting goblet cells, the neuroepithelial cells and the Paneth cells. By 
asymmetrical division, these stem cells are able to renew the complete layer in 3-8 
days. 
The first recognisable manifestation of epithelial alteration during colorectal tumor 
development are the Aberrant Crypt Foci (ACF), small hyper- or dysplastic lesions 
characterized by: (1) bigger size than the normal crypts; (2) increased pericryptal 
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space that separates them from the normal crypts; (3) a thicker layer of epithelial 
cells that often stains darker compared with normal crypts; (4) generally oval rather 
than circular openings. The ACF can be observed as single altered crypts or as a 
group of altered crypts that appears to form a single unit or focus. They frequently 
are microscopically elevated above the mucosa but also may be depressed, i.e., 
they usually are not in the same focal plane as the surrounding normal crypts. 
(McLellan & Bird, 1988). 
From a practical perspective, although only a small number of ACF will ultimately 
progress to CRC, larger ACF with altered morphology, dysplastic histology and 
associated gene mutations remain high-risk candidates for adenoma and CRC 
formation (Hurlstone & Cross, 2005). 
Upon increase of birth/loss ratio among epithelial cell, their progressive 
accumulation results in a benign tumor mass or polyp (i.e. any abnormal 
accumulation of cells). In the intestine, a tumor is clinically recognized as a 
protrusion into the lumen from the wall. From an histological perspective, there are 
at least two major types of polyps: the hyperplastic or non-neoplastic polyp and the 
dysplastic or adenomatous polyp. Whether the first kind of lesion consists of large 
number of cells with a normal morphology that line up in a single row, the 
adenomatous polyp is represented by abnormal cells which show intracellular and 
intercellular irregularities, with disruption of normal tissue architecture. The nuclei 
of these cells are often hyperchromatic and larger in size than in normal intestinal 
cells, with irregular positioning along the crypt-villus axis due to loss of cell polarity 
and nuclear stratification. Several layers of these abnormal cells form on the 
lamina propria, occasionally giving rise to branching glands. According to the their 
architecture, adenomas may be divided in tubular, when coarsely lobulated and 
pedunculated, or villous, when sessile, covering a broad area directly onto the 
muscularis mucosae (the muscle layer underlying the epithelial lining) and 
submucosa (the underlying stromal layer). Villous adenomas are thought to have 
higher risk of malignant progression (Takata et al., 2003). 
When an adenoma progresses, more undifferentiated cells appear, with a marked 
pleomorphism (variation in size and shape) and a nuclear:cytoplasm ratio close to 
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1.  Moreover, tumor cells show aberrant orientations and grow in disorganized 
fashion. These lesions are can also be referred to as carcinoma in situ, i.e. 
advanced high dysplastic lesions still confined within the epithelial layer. Finally, 
malignant adeno-carcinomas are characterized by the ability to invade the 
surrounding tissues through the muscularis mucosae and into the stromal 
compartment, and migrate to distal organs (e.g. the liver) where they can form 
metastasis (Vinay Kumar, 2004) .  
 
 
Figure 1. The adenoma-carcinoma sequence: a stepwise progression from normal 
epithelium to carcinoma due to a series of genetic changes. Macro- and 
microscopical representations of the progression changes are depicted. See text 
for details. 
 
The development of carcinoma from adenomatous lesions is substantiated by a 
number of observations: first, the peak of incidence of adenomatous polyps 
precedes by some years that of colorectal cancer; secondly, small carcinomatous 
foci are found within advanced adenomatous polyps. Also, cancer risk is directly 
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related to the number of adenomas, as shown by the very high incidence of 
carcinoma in patients with >100 polyps such familial adenomatous polyposis (FAP) 
(Vinay Kumar, 2004). 
 
1.3 Genetic events along the adenoma–carcinoma sequence 
The stepwise progression from normal to dysplastic epithelium and to carcinoma is 
earmarked by specific genetic alterations at known oncogenes and tumor 
suppressor genes. This molecular pathway to colorectal cancer is triggered within 
a single cell that acquires a genetic alteration that provides it with a specific type of 
growth survival advantage. Loss of function mutations at the APC tumor 
suppressor gene on chromosome 5q21 occur in over 80% of colon 
adenocarcinoma (Smith et al., 1993; Kinzler & Vogelstein, 1996), thus representing 
the earliest and rate-limiting genetic event in colorectal tumor initiation (Powell et 
al., 1992) . Indeed, APC mutations are present already at the ACF stage and they 
are related with the degree of dysplasia of these early lesions (Jen et al., 1994b; 
Smith et al., 1994). The APC protein has multiple functions as discussed in 
paragraph 1.4 of this introduction. It has been shown that APC’s main tumor 
suppressor activity resides in its capacity to regulate intracellular levels of b-catenin 
(Korinek et al., 1997; Morin et al., 1997; Smits et al., 1999), a key member of the 
Wnt signal transduction pathway. In fact, mutations of members of the Wnt 
pathways, including b-catenin, Axin-1 and Conductin (Axin-2) have also found in 
colorectal cancer (Sparks et al., 1998; Satoh et al., 2000; Clevers, 2000). The 
inactivation of both alleles of the APC gene can be detected in most of the 
intestinal tumors at early stages of development (Powell et al., 1992; Miyoshi et al., 
1992), in agreement with Knudson's two hit hypothesis. However, APC second 
mutational hits are not randomly selected, but distributed according to the resulting 
levels of residual b-catenin down-regulating activity (Lamlum et al., 1999;  
Albuquerque et al., 2002). In the situation in which a germline mutation is inherited 
or spontaneously occurred as in the FAP syndrome, the rate of initiation of colonic 
polyps is dramatically increased with the development of thousands of colorectal 
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adenomas and the inevitable progression of some of these into carcinoma, unless 
the intestine is not surgically resected (Kinzler & Vogelstein, 1996). 
Activation of the KRAS oncogene represents the second step in the evolution 
towards intestinal cancer. The proto-oncogene KRAS encodes a 21 kD protein that 
binds guanine nucleotides and is localized on the inner cell membrane. The 
identification of KRAS mutations has been the first major breakthrough in the 
molecular genetic analysis of colorectal cancer (Forrester et al., 1987). KRAS  
mutations are found in at least 50% of colorectal adenomas larger than 1 cm and 
in carcinomas but are infrequent in adenomas smaller than 1 cm in size 
(Vogelstein et al., 1988), indicating a role in adenoma progression rather than 
initiation. Alternatively, mutations in other oncogenes like BRAF encoding for 
members of the same RAS pathway, are often found among adenomas (Beach et 
al., 2005). KRAS mutations affect only specific codons (12-13,59-61) relevant for 
the endogenous guanine triphosphatase activity, leading to the constitutive 
activation of the Ras/Raf/MEK/ERK signal transduction pathway. Activation of this 
signaling pathway results in the transduction from the surface receptors to the 
nucleus of signals for the transcriptional activation of target genes involved in cell 
proliferation and apoptosis inhibition like Cyclin-dependent kinases, Cyclins and 
Bcl-2 (Kim & Lance, 1997) and thus malignant transformation. 
Further malignant progression towards the carcinoma stage is accompanied by 
loss of all or part of the long arm of chromosome 18 (18q). At least 50% of large 
adenomas and 75% of carcinomas show LOH at chr. 18q  (Vogelstein et al., 1988;  
Vogelstein et al., 1989; Jen et al., 1994a). The first candidate tumor suppressor 
gene in this chromosomal interval, the "deleted in colorectal cancer" gene (DCC), 
has now been identified as a component of a receptor complex that mediates axon 
guidance in neurons (Keino-Masu et al., 1996). However DCC mutation are rarely 
found in colorectal cancers (Cho et al., 1994). Other tumor suppressor genes have 
been subsequently identified in this region and, among others, two intracellular 
mediators of the TGF-b signal transduction pathway SMAD2 and SMAD4. 
Binding of TGF-b to the TGFBR2 receptor promotes the formation of heterodimer 
with the TGFBR1 receptor and phosphorylation of members of the SMAD family of 
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intracellular mediators like SMAD2. Activated SMAD2 binds SMAD4 with its 
consequent nuclear translocation where the complex activates the transcription of 
genes responsible for a broad spectrum of cellular functions such as cellular 
growth inhibition, apoptosis, differentiation, and matrix production (Heldin et al., 
1997; Duff & Clarke, 1998). Thus, when SMAD2  or SMAD4 are mutated, TGF-b 
signal is not transduced into the nucleus of the cell.  TGFBR2 mutations are also 
frequently found to affect TGF-b signaling in CRC, mainly among microsatellite 
instable (MSI) tumors but also in approximately 55% of microsatellite stable (MMS) 
tumors (Grady et al., 1999) (For more details on the types of genetic instabilities in 
colorectal cancer see Chapter 1.4, page 25). Overall, there is convincing 
mutational evidence for the major role of TGF-b pathway inactivation in the 
adenoma-carcinoma transition and, more in general, as primary tumor suppressor 
in human colorectal carcinogenesis. 
Most malignant colorectal tumors are also characterized by loss of the short arm of 
chromosome 17 (17p). LOH or cytogenetic alterations at this locus correlate with 
the transition from benign adenoma to invasive cancer (Vogelstein et al., 1988;  
Baker et al., 1989; Baker et al., 1990). The TP53 gene, encoding for p53, maps to 
this chromosomal interval. p53 is a multifunctional protein essential to cell growth 
control (Lane, 1992) often regarded to as the "guardian of the genome" due to his 
ability to block cell proliferation via transcriptional activation of cyclin inhibitors, like 
p21, in the presence of DNA damage  (Waldman et al., 1995). p53 also promotes 
apoptosis via transcriptional activation of genes such BAX in situations where the 
DNA repair machinery cannot cope with the DNA damage load (Burns & El-Deiry, 
1999). P53 alterations, often measured as aberrant overexpression in 
immunohistochemical assays, by direct DNA sequencing or by 17p allelic loss, 
have been reported in 4-26% of adenomas, approx. 50% of in situ carcinomas, and 
in 50-75% of adenocarcinoma (Ohue et al., 1994; Yamaguchi et al., 1994;  
Kaklamanis et al., 1993; Kaserer et al., 2000; Boland et al., 1995). The latter is 
indicative of the central role of loss of p53 function in the adenoma to carcinoma 
transition. 
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Figure 2. Schematic representation of the accumulation of alterations in different 
pathways along the adenoma-carcinoma sequence. In red are shown the genes 
frequently mutated in CRC. The different cellular alterations  resulting from the 
accumulations of these signaling defects are listed in the right column.  
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In conclusion, the identification of stepwise acquisition of specific mutations in 
colorectal adenoma-carcinoma sequence has provided important clues relative to 
the cellular processes underlying tumorigenesis in the gastro-intestinal tract and 
has opened new avenues for tailor-made therapeutic approaches. 
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The Role of the APC Tumor Suppressor
in Chromosomal Instability
P. Alberici, R. Fodde
Department of Pathology, Josephine Nefkens Institute, ErasmusMC, 
Rotterdam, The Netherlands
Abstract
Colorectal cancer (CRC) still represents the model of choice to study the mechanisms
underlying tumor initiation and progression. Accordingly, CRC has been central in the analy-
sis of the role played by chromosomal instability (CIN) in tumor initiation and progression.
Although loss of APC tumor suppressor function initiates the adenoma-carcinoma sequence
in the vast majority of CRCs through constitutive activation of Wnt/-catenin signaling, the
APC gene also represents a candidate CIN gene in CRC. Accordingly, two studies published
in 2001 showed that truncating Apc mutations can lead to both quantitative and qualitative
ploidy changes in primary mouse cell lines, mainly due to kinetochore and centrosome
abnormalities. Here, we review and discuss the more recent literature on APC’s functional
activities possibly related to its role in eliciting CIN in tumor initiation and progression. We
propose a model where loss and/or truncation of APC cause mitotic spindle defects that,
upon somatic inactivation of other putative CIN genes (e.g. spindle and cell cycle checkpoint
genes, DNA repair, telomere maintenance, etc.) underlie aneuploidy as observed in the
majority of CRCs.
Copyright © 2006 S. Karger AG, Basel
Chromosomal Instability in Tumorigenesis
Genetic instability has long been postulated as an essential condition for
tumors to develop and progress towards more malignant stages. Chromosome
number variations and loss of genome integrity in cancer have been observed
since the very first cytological and molecular analyses, thus implying that cancer
cells contain multiple gene mutations [1, 2]. Nevertheless, the majority of chro-
mosomal abnormalities are not tumor-specific, which may indicate that genetic
instability is an intrinsic feature of cancer cells [3]. The concept according to
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which tumors develop through the accumulation of genetic alterations in onco-
genes and tumor suppressor genes is widely accepted [4]. However, normal muta-
tion rates are likely to be too low to allow the multiplicity of mutations observed
in cancer cells. Hence, defects that increase mutation rates are essential to account
for the large numbers of abnormalities observed in human tumors [3, 5, 6]. From
this perspective, genetic instability, here referred to as an increased dynamic rate
of changes, is likely to represent an essential prerequisite to accumulate the large
number of alterations that occur during the tumorigenic process. The latter is sup-
ported by different mathematical models [7, 8]. However, alternative models indi-
cate that the clonal evolution model is still in agreement with the concept of
selection being the main driving force behind tumor initiation and progression [9,
10]. Colorectal cancer (CRC) has been instrumental in this debate as its different
histological stages allow the dissection of the genetic events underlying tumor ini-
tiation and progression [11].
Chromosomal Instability in Colorectal Cancer
Colorectal tumor initiation and progression towards malignancy occur
through well-defined histopathological and molecular steps, the so-called
adenoma-carcinoma sequence [12]. Two main types of genetic instability have
been recognized in human CRC, microsatellite instability (MSI or MIN) and
chromosomal instability (CIN) [3]. MSI results from loss of mismatch repair
(MMR) function and is earmarked by tumor-specific frame-shift mutations in
stretches of short repetitive DNA sequences (microsatellite repeats) distributed
throughout the genome [13, 14]. Notably, MIN tumors have increased nucleotide
mutation rates when compared with normal cells but share near-diploid chro-
mosomal contents [15–17]. Germline defects in MMR genes account for the
hereditary non-polyposis colorectal cancer syndrome (HNPCC), an autosomal
dominant predisposition to colorectal, uro-genital and skin cancers [18]. MSI
and/or somatic defects in the same MMR genes are found in approximately 15%
of sporadic colon cancers.
The first indication of the presence of specific genetic alterations underly-
ing changes in tumor histology came from cytogenetics. Karyotype analyses of
colorectal cancers have revealed characteristic patterns of chromosomal abnor-
malities [19–21]. In fact, the vast majority of CRCs are characterized by abnor-
mal chromosomal contents with a heterogeneous and broad spectrum of both
numerical and structural changes such as inversions, deletions, duplications
and translocations [22]. These abnormalities define aneuploidy. Experimental
evidence indicates that aneuploidy arises in these cancers as a result of CIN,
here defined as the accelerated rate of gains or losses of entire chromosomes or
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part of them [22, 23]. Clones from various colorectal cancer cell lines,
expanded through a given number of passages and then analyzed by fluorscent
in situ hybridization (FISH) with centromeric DNA probes of each individual
chromosome, indicated that, whereas MSI cell lines are mostly near-diploid,
microsatellite stable (MSS) colorectal cancer cells showed an increased fre-
quency of chromosomal gains and losses at each cell division. CIN may provide
additional growth advantage to the cancer cell by accelerating the rate of loss of
heterozygosity at tumor suppressor loci and/or by amplifying chromosomal
regions encompassing oncogenes. CIN may also represent a mechanism by
which the cancer cell can fine-tune its growth characteristics to meet changes in
the environment, thus possibly underlying therapeutic failures.
Over 90% of all CRCs show chromosomal aberrations, some of which are
recurrent and represent key chromosomal changes underlying colorectal cancer
initiation and progression, e.g. loss of chromosome 18, gain of chromosome 7,
and other structural rearrangements, e.g. at chromosomes 1 p and 17 p. However,
conventional cytogenetic analysis is limited by its low-resolution. In more recent
years, the introduction of techniques like comparative genomic hybridization
(CGH) and FISH, has allowed the high-resolution detection of chromosomal aber-
rations throughout the progression from low-grade adenoma to carcinoma [24].
By means of array CGH, Hermsen and colleagues showed evidence for the pres-
ence of specific subsets of chromosomal gains and losses strongly associated
with adenoma-carcinoma progression [25].
To assess more functional aspects of genomic instability, colorectal cancer is
often the experimental tumor of choice as it offers a well-defined model of step-
wise progression, tissue samples from different stages are available from gas-
troenterology and surgical units for molecular analysis, and because a large
number of well-characterized cell lines have been established from several CIN
and MIN tumors. Analysis of CRC-derived cell lines that do not harbor MMR
defects showed high rates of chromosome gain and loss, with acquisition of chro-
mosomal changes at rates 10–100 times faster than in MMR-deficient cells [22].
These experiments also indicated that MSI and CIN may be mutually exclusive
pathways of genetic instability in colorectal cancer [3]. However, the existence of
a subgroup of colorectal cancers with apparently stable, near-diploid chromo-
somes and stable microsatellites (MACS) was more recently reported [26].
To date, many potential mechanisms have been shown to play a role in CIN
by contributing to aneuploidy: mitotic and cell cycle checkpoints, telomere
shortening and telomerase expression, centrosome number regulation, double-
strand break repair, kinetochore function, and chromatid segregation [3, 27] (table
1). In particular, mutations at the mitotic checkpoint genes BUB1 and BUBR1
[28, 29], the cyclin E regulator CDC4 [30], and the TP53 tumor suppressor [31]
have been implicated as rate-limiting events in eliciting CIN in CRC. However,
A
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Table 1. Possible mechanisms of chromosomal instability in tumors and a selection of genes involved
Cell structural defect Mechanisms leading to CIN Genes implicated References
Centrosome Segregation defect p53 pathway, ATR, BRCA1, BRCA2, 31; 125–133
XRCC2/3, RAD6, Aurora-A, Survivin
Mitosis check point Chromosome missegregation BUB1/BUBR1, MAD2 28; 29; 134; 135
DNA damage check point Enhanced/aberrant mitotic ATM, ATR, BML, BRCA2, 136–142
recombination FANCA-L, NBS1
Microtubules and spindle dynamics Spindle defects APC, GSK3- 35; 36; 69; 97; 98; 143; 144
Kinetochore assembly Premature anaphase HEC1 145
Chromatin cohesion and  Disjunction failure Securin/PTTG 146; 147
chromosome condensation
Cell cycle control Cell cycle disturbance TP53, CDC4, CCNE1 30; 148–150
Telomeres Chromosome fusion PINX1, TERC, TERF1/PIN2 151
Cytokinesis Multinucleate cells BRACA2 123
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mutations in these alleged CIN genes are relatively rare [28, 29], and occur at
late stages of the adenoma-carcinoma sequence [4], whereas aneuploid changes
have been observed already at early adenoma stages [32–34]. More recently, we
and others have found that mutations in APC give rise to polyploid and aneu-
ploid chromosomal changes in mouse primary cell lines and may therefore
trigger CIN at the very start of the adenoma-carcinoma sequence [35, 36].
Here, we will review the functional aspects of the APC tumor suppressor
protein with respect to chromosomal stability at mitosis and its role in CIN
in CRC.
Functional Aspects of the APC Tumor Suppressor Protein
Inactivation of the adenomatous polyposis coli (APC) tumor suppressor
gene represents the very first and rate-limiting step of the adenoma-carcinoma
sequence in CRC. Notwithstanding its well-known multi-functionality [37],
APC’s main tumor suppressing function resides in its capacity to regulate Wnt
signaling as elegantly shown by the identification of -catenin (CTNNB1) gene
mutations in sporadic colorectal cancers with an intact APC gene [38, 39]. 
-catenin is the main intracellular signaling protein of the canonical Wnt path-
way and its cellular level is regulated by a ‘destruction’ complex composed by
several proteins among which there is APC (see below). Loss of APC function or
oncogenic -catenin mutations that make it resistant to APC-driven proteolytic
degradation, result in the constitutive activation of the Wnt signal transduction
pathway that regulates epithelial homeostasis along the intestinal villus-crypt
axis [11, 40]. Notwithstanding the latter, the APC gene encodes a 312 kDa
protein encompassing multiple and diverse functional motifs that, upon APC
truncation and/or complete loss of function, may play additional roles in tumor
progression and malignant transformation [37] (fig. 1).
The N-terminus of APC contains several regions of heptad repeats respon-
sible for the formation of coiled-coil domains and often involved in oligodimer-
ization [41–43]. Whereas the N-terminal 55 amino acids of APC form a dimeric
coiled-coil [41], residues 129–250 can result in an intramolecular coiled-coil
[44]. The N-terminus of APC also encompasses two nuclear export sequences
(NES), both required for shuttling APC between nucleus and cytoplasm
[45, 46]. Seven armadillo (ARM) repeats, a motif first found in the fruit fly 
-catenin homolog Armadillo, are also found in the N-terminal region of APC
[47]. Additional binding motifs for the protein phosphatase PP2A, the guanine
nucleotide exchange factor (GEF) Asef, and Kap3, a linker protein for kinesins
[48–50], partially overlap with the ARM repeats. Although it is not clear how
these complex interactions occur and are regulated at specific phases of the cell
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cycle and in specific cellular types, it is important to point out that truncated
APC proteins encompassing the N-terminus positively affect GEF activity and
cell motility by Asef when compared with full length APC [51]. The latter is
consistent with the alleged dominant-negative effect exerted by truncating APC
mutations on apoptosis, cell motility and cytoskeletal organization [52, 53]. The
recent report of the putative interaction between the N-terminal third of APC
and its C-terminal region may support this hypothesis [54].
The middle region of the APC protein encompasses the domains responsi-
ble for -catenin regulation in Wnt signaling. Three 15 a.a. and seven 20 a.a.
repeats mediate binding and downregulation of -catenin, respectively. Three
Ser-Ala-Met-Pro repeats (SAMP) are interspersed among the 20 amino acid
repeats and allow interaction with the scaffold proteins axin/conductin [47].
APC regulates Wnt signaling by catalyzing the formation of a multi-
protein complex, the so-called ‘destruction complex’, comprehensive of the scaf-
folding proteins axin and conductin, the glycogen synthase kinase 3 (GSK3)
and casein kinase (CKI), and APC itself [55–58]. In the absence of the Wnt lig-
and, the destruction complex is formed which results in Ser/Thr-phosphoryla-
tion of -catenin and its subsequent proteosomal degradation [59–61]. In the
presence of the Wnt ligand, Dishevelled (Dsh) inactivates GSK3, thus result-
ing in the intracellular stabilization of -catenin and its nuclear translocation.
Once in the nucleus, -catenin binds to DNA-binding proteins of the T-cell fac-
tor (TCF) family, to serve as an essential co-activator of transcription [62, 63].
The activity of TCF is tightly controlled, as TCFs are complexed with potent 
co-repressors such as Groucho in the absence of Wnt signaling [64].
Finally, the C-terminal third of the APC protein, the least conserved through-
out evolution, encompasses distinct domains that mediate interactions with sev-
eral cytoskeletal proteins. A stretch of approximately 200 amino acids, enriched
Fig. 1. Schematic representation of the APC protein with its functional motifs.
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in positive charges, is responsible for the interaction of APC with microtubules
(MT) [65–67]. The C-terminal 170 amino acids of APC bind the end binding pro-
tein 1  (EB1), a small microtubule end-binding protein [68], whereas the very last
15 residues encompass the binding site for PDZ domains [69, 70].
Although previous reports indicated active nuclear-cytoplasmic shuttling
of APC [71] and its putative role in transcriptional regulation via its ability to
bind DNA [72], to date there is no evidence that APC directly acts as a tran-
scriptional regulator. Moreover, a recent study questioned the specificity of
many commonly used anti-APC antibodies and showed that both wild-type and
truncated APC were primarily cytoplasmic in colon cancer cells, but increased
in the nucleus after leptomycin B treatment, consistent with CRM1-dependent
nuclear export [73]. The predominantly cytoplasmic subcellular localization of
APC possibly reflects its physical interaction with the cytoskeleton. APC can
bind both directly and indirectly to microtubules [66, 67], and clusters at the
distal tips (the ‘plus ends’) of microtubules in cellular protrusion of migrating
cells [74]. The association with the plasma membrane is highly dynamic and
requires an intact actin cytoskeleton [75]. In highly polarized cells from the
inner ear, APC localizes at the plus end of microtubules oriented towards the basal
membrane [76]. The observation that truncated APC proteins lacking the MT
binding site fail to interact with the microtubules though retaining KAP3 bind-
ing, suggests that the relation of APC with the cytoskeleton is due to a combi-
nation of direct and indirect interactions that possibly modulate its subcellular
distribution [50]. APC has been shown to promote microtubule polymerization
in vitro [66, 77]. Also, microtubules bound to APC are more stable under
depolymerizing conditions both in vivo and in vitro [78]. Notably, Cdc42-
dependent phosphorylation of GSK3 occurs specifically at the leading edge of
migrating cells, and induces the interaction of APC with the plus ends of micro-
tubules, essential to promote cell polarization and control the direction of cell
protrusion [79]. The latter suggests that interaction of APC with the cytoskele-
ton, similar to its interaction with -catenin, is regulated by binding to GSK3.
Accordingly, binding of APC to microtubules is modulated by phosphorylation
[78], suggesting that APC is alternatively employed as scaffolding protein in the
regulation of Wnt/-catenin signaling and as microtubule-stabilizing protein in
the regulation of cell polarity and migration.
Truncated APC proteins lacking the N-terminal ARM repeats or the 
C-terminal MT-binding site fail to form proper aggregates at the plus ends of
the microtubules, thus affecting their subcellular distribution pattern [80].
An additional interaction between microtubules and APC occurs through
EB1. EB1, initially isolated by a two-hybrid screen as a protein binding to the
C-terminus of APC [81], is highly conserved throughout evolution, from yeast to
mammals. EB1-like proteins have been shown to be involved in almost all the
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microtubule-based processes including maintenance of cell polarity, anchorage
to nucleation sites, and the regulation of spindle formation and chromosome seg-
regation at mitosis [82, 83]. The C-terminal domain of the EB1 protein interacts
with the C-terminus of APC [84–86], and this APC/EB1 complex has been
described to stabilize microtubule ends in vivo [87]. However, in colon cancer
cell lines carrying truncated APC not encompassing the EB1-binding site,
endogenous EB1 localization is unchanged, suggesting that EB1 can bind to
microtubule tips independently of APC [88, 89]. Also, CRC cell lines transfected
with several different GFP-mutant APC show that the interaction with EB1 is
responsible for directing APC to the tip of microtubules. In fact only the mutant
APC that express the EB1 binding motif show localization at the plus ends of
microtubules [68].
A more recent study [90] suggests that the major EB1 interaction site in
APC involves the dipeptide segment 2805–2806 and that the same interaction is
negatively regulated by cyclin-dependent mitotic kinase Cdc2 phosphorylation
of the Ser2789 residue of APC. Thus, C-terminal phosphorylation of APC
appears to play a key role in the regulation of its interaction with EB1 through-
out the cell cycle and in particular during mitosis [68].
Although the majority of APC mutations in human tumors encode trun-
cated proteins lacking the EB1 binding domain [91, 92], no cancer-associated
mutations in the EB1 gene have been found to date [93]. Moreover, mice carry-
ing targeted Apc truncations that remove the EB1-binding motif without affect-
ing its capacity to regulate Wnt/-catenin signaling, do not develop tumors
[94]. However, the possibility remains that loss of EB1-APC binding plays a
role in tumor progression by affecting cell migration, polarity and/or chromo-
somal segregation (see below).
A Role for APC in Chromosomal Instability
During mitosis, APC clusters at the plus-ends of the spindle microtubules
and co-localizes with the kinetochore, the attachment site of the mitotic spindle to
the newly duplicated chromosomes [35, 36] (fig. 2). These observations strongly
suggest a role for APC in mitotic spindle formation and chromosome segregation.
Multicolor FISH analysis of mouse embryonic stem (ES) cell lines homozygous
for the Min allele, lacking the C-terminal third of the protein, revealed ploidy
defects and structural chromosomal aberrations. Genetic evidence that the
observed chromosomal abnormalities do not result from Wnt signaling defects
but from deletion of the C-terminal APC functional domains was provided by the
confirmation of the aneuploid and polyploid changes in ES lines homozygous for
the Apc1638T targeted mutation, previously shown to retain wild type -catenin
The Role of the APC Tumor Suppressor in Chromosomal Instability 157
Fig. 2. Mitotic spindle defects in Apc mutant cells. In (a) a representation of a normal
mitotic figure with localization of APC at the kinetochore and at the plus-ends of the micro-
tubules is shown. The hypothetical binding of APC on astral microtubules to the cortical anchor
structure allows to keep the mitotic spindle parallel to the epithelial plane. In (b) there is repre-
sented a mitosis in an APC mutant cell with defects in the spindle organization and the failure of
the APC binding to the kinetochore and to the cortical anchor structure. In (c) examples of spin-
dles formed in Apc wild type and mutant ES cells lines are shown. In green the -tubulin stain-
ing marks the spindle, whereas in red the CREST/kinetochore structure is stained. Note in the
Apc mutants the spindle abnormalities with most of the microtubules projecting in a chaotic man-
ner in the cytoplasm. In the right Apc/ picture, the white arrow designates an extra centrosome. 
Cortical anchor structure
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regulatory function [35, 94]. The co-localization of APC at the kinetochore of the
metaphase chromosomes is abolished by colcemid treatment, an agent that selec-
tively depolymerizes microtubules. Microtubule staining of Apc mutant ES cells
shows a disorganized mitotic spindle with most microtubules projecting ran-
domly into the cytoplasm in contrast with the properly aligned spindles observed
in wild-type cells (fig. 2). Also, Apc-mutant ES lines showed high incidence of
mono- and multicentric spindles and supernumerary centrosomes at mitosis when
compared with wild type ES cells [35, 36]. Notably, APC and EB1 co-localize
with the centrosome in both mammalian and Xenopus mitotic cells, and are thus
likely to play a role in centrosomally driven spindle formation by anchoring cyto-
plasmic MT minus ends to the centriole [35, 36, 69, 95, 96]. However, the latter
could also represent a consequence of APC’s role in directly supporting spindle
formation and stability in vivo, as suggested by the observation of microtubule-
resistance against nocodazole treatment in cells expressing full-length or 
C-terminal APC [78]. Moreover, APC acts, possibly within a protein complex
together with EB1 and the formin mDia, a component of the Rho-GTPase path-
way, to selectively stabilize microtubules in fibroblasts [87].
Another observation of APC involvement in CIN comes from an experiment
in which the overexpression of a dominant-negative C-terminal APC fragment
encompassing the EB1-binding domain in the APC-proficient and near-diploid
HTC116 CRC cell line resulted in a 2.5–5 fold increase in the frequency of
numerical chromosomal aberrations [97].
Since these first reports, additional studies have provided additional
insights on the role of loss and/or truncation of APC in eliciting CIN. Green and
Kaplan [98] have shown that CIN tumor cells exhibit inefficient microtubule
plus-end attachments during mitosis, accompanied by impairment of chromo-
some alignment at metaphase. These abnormalities correlate with the APC
mutational status. Notably, it was also found that a single truncating mutation in
APC acts dominantly to interfere with microtubule plus-end attachments and
causes a dramatic increase in mitotic abnormalities [98]. Consistent with the latter,
N-terminal APC fragments expressed in HCT-116, a near diploid colon cancer
cell line with two wild-type APC alleles, result in spindle checkpoint defect and
aneuploidy [97]. Although these alleged dominant-negative effects of truncated
APC need to be confirmed by additional in vitro and in vivo studies with
knock-in and inducible APC mutations to exclude artifacts due to changes in
the expression levels and subcellular localization of the transfected recombi-
nant proteins, they may have important implications for the further elucidation
of APC-driven tumorigenesis. In a previous study by somatic cell fusion analy-
sis, MSI was shown to behave as a recessive trait, whereas CIN appeared to be
dominant [22]. However, complete loss of APC function also results in spindle
abnormalities similar to those observed in cells with truncated APC: depletion
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of APC from Xenopus extracts leads to a decrease in microtubule density and
changes in tubulin distribution in spindles and asters [69].
Notably, it has also been observed that the level of Bub1p was enriched at
kinetochores during metaphase in cells transfected with the truncated APC con-
struct [98]. Similarly, kinetochore-bound BubR1 is also significantly increased
in HTC-116 expressing a mutant N-terminal APC fragment [97]. This is of
interest in view of a previous study showing that the dissociation of Bub1 and
BubR1 from the kinetochores of aligned chromosomes depends on microtubule
attachment and tension, respectively [99]. The observed stabilization of check-
point proteins at the kinetochore during metaphase may indeed result from the
dominant-negative effects exerted by truncated APC on kinetochore-microtubule
attachment and tension.
In mitotic cells, APC and Bub3 are juxtaposed in prometaphase and
metaphase along kinetochore microtubules, as also confirmed by co-immuno-
precipitation [36]. These observations, together with the fact that Bub1-Bub3
and BubR1-Bub3 complexes can phosphorylate APC in vitro with high speci-
ficity, are suggestive of a role for APC phosphorylation by Bub kinases in the
regulation of kinetochore-microtubule attachment through the different stages
of mitosis.
An additional function of APC in spindle formation and stabilization pos-
sibly related to its capacity to elicit CIN when mutated, lies in its microtubule-
capture activity at the cell-cortex, homologous to the yeast cortical microtubule
capture site composed by Bim1 (homolog of mammalian EB1) and Kar9 [100,
101]. In yeast, Kar9 represents a central link between the actin cytoskeleton and
microtubules in establishing correct spindle orientation [102, 103]. Although
Kar9 does not seem to be conserved throughout evolution, functional similari-
ties can be observed between Kar9 and the C-terminus of APC encompassing
the EB1-binding site [104]. Recently, APC has been described to be distributed
in a punctuated fashion along the path of microtubule growth and, in addition,
to localize at the basal cortex of mammalian cells where it provides attachment
for growing microtubules thus contributing to the organization and stabilization
of the microtubule network at the cortex [101]. Interestingly, a direct APC-EB1
interaction is not required for either APC or EB1 localization to the micro-
tubules at the basal cortex [101].
Hence, APC, like Kar9, is a component of the cortical template and may
act in mammalian cells as a guide to capture microtubules at specific sites
along the plasma membrane. Whether this anchor function also ensures the cor-
rect position of the mitotic spindle and thus chromosomal segregation during
mitosis is a fascinating though yet to be demonstrated hypothesis.
In summary, the above data indicate that, during mitosis, APC contributes
both to spindle formation radiating from the centrosome, and to the proper
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attachment of the growing ends of microtubules to the kinetochore (either
directly and/or through EB1). Hence, APC mutations are likely to affect several
structural complexes and pathways (kinetochore, microtubules, centrosomes,
and spindle checkpoints) known to be implicated in both numerical and struc-
tural CIN [105] (fig. 2). Accordingly, both tetraploidy and aneuploidy were
found to represent the main chromosomal defects in mouse primary Apc-
mutant cell lines [35, 36].
In vivo Consequences of APC Mutations on 
Chromosomal Instability
Although loss of APC-mediated regulation of Wnt/-catenin signaling
represents the main initiating event in colorectal tumorigenesis, it is safe to
assume that APC mutation affects a multitude of additional cellular functions
thus providing the nascent tumor with additional selective advantages likely to
play important roles in progression towards malignancy. The latter is also sug-
gested by the observation according to which tumors with oncogenic -catenin
mutations are usually smaller and less aggressive than those with APC muta-
tions [106]. Accordingly, additional defects in cell migration, apoptosis, and
differentiation have been reported in mouse cells carrying Apc truncating muta-
tions [53, 107, 108].
Whether loss of APC function directly results in CIN is at present still a
matter of debate. In general, aneuploidy has been reported in larger adenomas,
suggesting its increase with tumor progression [25, 32]. Shih and colleagues
[34] demonstrated allelic imbalance (AI), indicative of losses or gains of
defined chromosomal regions, in small benign colorectal tumors thus suggest-
ing that CIN occurs at very early stages during colorectal neoplasia. On the
other hand, Sieber et al. [109] failed to detect any chromosomal changes in the
majority of APC-mutant adenomas analyzed. These apparent discrepancies may
be explained by the different detection sensitivity of the methods employed in
the two studies, namely digital PCR vs. a combination of flow cytometry and
conventional CGH and LOH analyses [34, 109]. In a more recent study, we have
shown aneuploid changes at specific chromosomal regions (Cardoso et al., sub-
mitted) in a small but significant fraction of FAP adenomas with established
APC mutations by array CGH. This approach allows to measure relative DNA
abundances with a sensitivity that theoretically ranges from abnormalities
affecting complete chromosome arms to few megabases. Digital PCR, when
employed to assess AI, is even more sensitive than array CGH to detect gain and
loss events affecting chromosomal regions 1 Mb. Both digital PCR and array
CGH are also likely to detect ploidy changes present in subpopulations of
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neoplastic cells that only become completely clonal at later stages of tumori-
genesis. In contrast, although flow-cytometry is the method of choice when
analyzing ploidy status of tumor samples, aneuploid changes below specific
thresholds are likely to go undetected. Therefore, based on the above functional
and observational studies, we hypothesize that loss of the MT- and EB1-binding
functions of APC, triggers a broad spectrum of mitotic spindle defects that may
elicit a subtle but significantly increased rate of CIN. As truncated APC pro-
teins may act in a dominant-negative fashion in eliciting similar mitotic defects
[53, 97, 98], CIN may even precede the rate-limiting somatic hit at the wild type
APC allele.
Discussion
CIN in CRC has been previously associated with mitotic spindle check-
point defects [28]. Cells with defective spindle checkpoint prematurely exit
mitosis after colcemid treatment. However, these findings contrast with the
report by Tighe and colleagues that CIN cells do undergo mitotic arrest in
response to spindle damage and have a robust checkpoint [110]. Apc-mutant ES
cells also fail to show differences in mitotic index in comparison to wild type
line [35], whereas analysis of Mad2- or Bub3-mutant embryonic cells revealed
a dramatic drop in mitotic index levels [111, 112], due to the mitotic arrest upon
microtubule depolymerization. Mutations in known spindle checkpoint genes
are found in human cancers, though at overall low frequencies [27–29, 113].
It seems plausible that loss of APC function is necessary but insufficient to
result in full-blow CIN. In APC-mutant aberrant crypt foci and small adenomas,
a subtle but significant defect in microtubule dynamics and mitotic spindle
assembly may occasionally lead to ploidy changes. Additional mutations in dif-
ferent categories of genes involved in mitotic and cell cycle checkpoints, telom-
ere shortening and telomerase expression, centrosome number regulation, and
double-strand break repair [3, 27] may work synergistically with the kineto-
chore and chromosome segregation defects caused by APC mutation in eliciting
CIN. In fact, CIN may initially be suppressed by active cell cycle and mitotic
checkpoints. Experimental evidence for the latter was provided by studies in
ApcMin//BubR1/ compound mutant mice [114]. While BubR1/ animals do
not develop colonic tumors, compound ApcMin//BubR1/ mice are affected by
increased intestinal tumor multiplicity and progression towards advanced
stages when compared with ApcMin/ animals. Mouse embryonic fibroblasts
(MEFs) derived from ApcMin//BubR1/ embryos show enhanced mitotic
slippage in the presence of nocodazole and exhibit a higher rate of genomic
instability than that of wild type or BubR1/ or ApcMin/ MEFs, as indicated by
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premature separation of sister chromatids, increased rates of micronuclei for-
mation and aneuploid metaphases. It is therefore likely that even haploinsuffi-
ciency at spindle checkpoint genes like BubR1 may elicit CIN in the presence of
the mitotic spindle assembly defect caused by APC mutation.
Notwithstanding the above, the spectrum of genes that may act synergisti-
cally with APC in eliciting CIN in CRC is likely to extend beyond those impli-
cated in checkpoint functions. Supporting evidence for the existence of specific
CIN-genes able to synergize with APC to exert genomic instability has been
provided by studies with Apc-mutant mouse models. Expression of CDX2, a
homeodomain transcriptional factor involved in the development, differentia-
tion and physiology of the intestinal epithelial lining, is markedly reduced in the
later stages of human colorectal carcinogenesis, namely, high grade dysplasia
and invasive carcinoma [115, 116]. Compound heterozygous Apc/716/Cdx2/
mice show a marked increase in colonic polyp formation when compared with
the single mutant animals, with lesions frequently characterized by an increased
anaphase bridge index (ABI), indicative of CIN [117]. Notably, normal colonic
epithelium from compound heterozygous animals shows an increased ABI
when compared to single mutant littermates, indicative of a putative synergism
between APC and CDX2 mutations in eliciting CIN.
In general, telomere abnormalities are known to be associated with promo-
tion of epithelial cancer [118, 119], and genes related to telomere maintenance
may co-operate with APC to exert CIN in CRC. Indeed, progressive telomere
dysfunction increases intestinal tumor multiplicity in the second and third gen-
eration ApcMin//Terc/ mice, when telomere shortening becomes critical
[120]. Notably, these tumors are characterized by high ABI incidence leading to
the formation of dicentric chromosomes and high rate of chromosome loss.
Also, the presence of short telomeres in colorectal carcinoma [121, 122],
together with the increase of anaphase bridges at the adenoma-carcinoma
transition [120] points to a role for defective telomere dynamics in genomic
instability during colorectal carcinoma progression.
Recently, it has been reported that loss of the BRCA2 tumor suppressor
gene causes a cytokinesis defect, i.e. an impairment of the completion of cell
separation upon mitosis [123]. As for APC, BRCA2 was already known to cause
both qualitative (aneuploidy) and quantitative (polyploidy) chromosomal
changes. Whereas the first can be explained by the failure to repair double
strand DNA breaks by mutant BRCA2, the latter appears now to result from
impeded cell separation accompanied by abnormalities in myosin organization
during late stages of cytokinesis. Accordingly, BRCA2 was shown to localize to
the cytokinetic midbody [123]. Though no evidence to date has been reported
for a role of APC in cytokinesis, tetraploidy is a main feature of APC-mutant
cells [35, 36] and it may represent the primary consequence of the loss of its
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multiple functional roles in mitosis (attachment of the mitotic spindle to the
kinetochore, centrosome and cell cortex) and a first step towards aneuploidy.
The subtlety of this initial and random CIN defect might represent the ‘just-
right’ type of genetic instability [124] as it allows the occasional generation of
cells carrying specific genetic defects on which clonal selection operates with-
out excessive accumulation of genetic damage above viability thresholds.
Additional somatic mutations in different categories of genes will act in a
cumulative and/or synergistic fashion to progressively elicit increasing levels of
CIN along the adenoma-carcinoma sequence.
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APC and Oncogenic KRAS Are Synergistic in Enhancing Wnt Signaling in Intestinal
Tumor Formation and Progression
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Background & Aims: Synchronous activation of the Wnt
signaling pathway, mostly because of loss of function of the
APC tumor suppressor, and of the oncogenic KRAS-signaling
pathway is very frequent in colorectal cancer and is associated
with poor prognosis. Methods: We have generated a com-
pound transgenic mouse model, KRASV12G/Apc/1638N, to reca-
pitulate the human disease and compared it with single trans-
genic littermates. Results: Compound mutant mice are
characterized by a 10-fold increase in tumor multiplicity and by
accelerated tumor progression, resulting in strongly enhanced
morbidity and mortality. Tumors from compound mutant
mice proliferate faster and show decreased levels of apoptosis.
Several lines of evidence indicate that the observed increase in
tumor multiplicity and malignant transformation is caused by
the synergistic activation of Wnt signaling in cells with onco-
genic KRAS and loss-of-function Apc mutations. Activated
KRAS is known to induce tyrosine phosphorylation of -cate-
nin, leading to its release from E-cadherin at the adherens
junction. This results in an increased -catenin pool in the
cytoplasma, its subsequent translocation to the nucleus, and
the transcriptional activation of Wnt downstream target genes.
Accordingly, intestinal tumors from KRASV12G/Apc/1638N mice
show a significant increase in cells with nuclear accumulation
of -catenin when compared with Apc/1638N animals. Moreover,
Apc/KRAS-mutant embryonic stem cells show a significantly
enhanced -catenin/T-cell factor–mediated transcriptional
activation, accompanied by increased -catenin nuclear local-
ization. Conclusions: This KRAS-induced increase in Wnt/
-catenin signaling may enhance the plasticity and self-renewal
capacity of the tumor, thus resulting in the drastically aug-
mented tumor multiplicity and malignant behavior in com-
pound mutant animals.
Colorectal cancer (CRC) and in particular the adenoma-carcinoma sequence still represents a paradigm for the
molecular and genetic mechanisms underlying tumor forma-
tion and progression.1,2 Cancers of the colon and rectum are
among the most frequent cause of morbidity and mortality
among Western industrialized countries.3,4 In the vast majority
of sporadic CRC cases, mutations in genes known to play
rate-limiting roles in the canonical Wnt/-catenin signal trans-
duction pathway such as the adenomatous polyposis coli (APC)
tumor suppressor gene and the -catenin (CTNNB1) oncogene
trigger adenomatous polyp formation, the first step toward
colorectal neoplasia.5 Activating mutations of the KRAS onco-
gene accompany adenoma growth and progression, whereas
loss of heterozygosity (LOH) and mutations at the SMAD4 and
TP53 tumor suppressor genes underlie malignant transforma-
tion at later stages.1 Loss-of-function mutations at APC have
been observed in more than 60% of colonic adenomas and
carcinomas.6 Also, germ-line APC mutations are responsible for
familial adenomatous polyposis (FAP), an autosomal dominant
predisposition to the development of multiple colorectal pol-
yps.7 Loss of APC function results in constitutive activation of
Wnt signaling because of impaired -catenin down-regulation,
leading to its cytoplasmic accumulation and nuclear transloca-
tion.8,9 In the nucleus, upon association with members of the
T-cell factor (TCF) family of transcriptional activators, -cate-
nin differentially modulates the expression of Wnt downstream
target genes implicated in cell proliferation, migration, differ-
entiation, and apoptosis10 (http://www.stanford.edu/rnusse/
pathways/ targets.html11). Approximately 50% of colorectal ad-
enomas and carcinomas carry activating mutations of the RAS
protooncogene.1,12 The KRAS gene is an effective marker for
molecular diagnosis and tumor progression in colorectal, pan-
creas, and lung cancer. Oncogenic RAS proteins are locked in
their guanosine triphosphate (GTP)-bound (active) form and
mediate their tumorigenic effects through multiple down-
stream effectors, the most prominent of which, the RAS effector
RAF kinase, activates on its turn the extracellular signal-regu-
lated kinase (ERK)-mitogenactivated protein (MAP) kinase
(MAPK) cascade.13–15 Activated MAP kinases phosphorylate
downstream transcription factors, thus inducing the expression
of regulatory genes required for entry into the S phase of the
cell cycle.16,17 Thus, activation of the Wnt as well as of the RAS
signal transduction pathways plays a rate-limiting role in hu-
man CRC formation and progression. Both APC and KRAS
mutations occur in aberrant crypt foci, microscopic precursor
lesions that have been postulated to precede the development of
adenomatous polyps.18 APC mutations are associated with dys-
plasia in small precursor lesions, whereas KRAS mutations are
more often found in nondysplastic lesions.19 Also, synchronous
detection of activated KRAS and of -catenin nuclear accumu-
lation, the hallmark of canonical Wnt-signaling activation,
identifies a group of CRC patients with poor prognosis and
Abbreviations used in this paper: APC, adenomatous polyposis coli;
CRC, colorectal cancer; CSC, cancer stem cell; ES, embryonic stem;
GTP, guanosine triphosphate; LOH, loss of heterozygosity; MAPK, mi-
togen-activated protein kinase; TCF, T-cell factor; WT, wild-type.
© 2006 by the American Gastroenterological Association (AGA) Institute
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resistance to standard chemotherapy.20 However, whether the
frequent concurrent activation of RAS and the Wnt pathways in
colorectal tumors is due to a cumulative effect or to a more
synergistic interaction between the 2 signaling cascades is still
largely unknown. To address this clinically relevant issue, we
have generated a mouse model that carries both a targeted
loss-of-function mutation at the endogenous Apc gene21,
Apc1638N, and a transgene encoding for the activated form of the
human KRAS oncogene, the pVillin-KRASV12G (hereafter further
referred to as KRASV12G).22 Compound animals are character-
ized by a striking increase in intestinal tumor multiplicity and
progression, leading to high morbidity and mortality. Molecu-
lar analysis of these tumors and of primary cell lines carrying
both mutations indicate that enhanced Wnt-signalling activity
by oncogenic KRAS is likely to underlie the increased tumor
initiation and progression toward malignancy in the compound
Apc/KRAS animals.
Materials and Methods
Animal Models
All experiments on mice were performed in accordance
with institutional and national guidelines and regulations. The
Apc1638N mouse lineage in the inbred C57Bl/6J background21
was bred with the transgenic model22 pVillin-KRASV12G in the
genetic background B6D2 (C57Bl/6J  DBA/2). To control for
genetic background effects, littermates were always used as
controls. Mice were maintained under a 12-hour light-dark
cycle and fed with standard diet and water ad lib. Genotyping
was performed on DNA extracted from mouse tails as previ-
ously described.22,23
Tumor Analysis and Tissue Processing
The median age of the analyzed animals was 5.5
months (KRASV12G/Apc/1638N), 7 months (Apc/1638N), and 9
months (KRASV12G). Animals were killed at the ages indicated or
at the appearance of signs of distress, and the gross study of the
tissues was carried out as described.22 Macroscopically visible
tumors were resected and embedded in paraffin according to
standard procedures. Tumors were classified according to stan-
dard World Health Organization (WHO) histopathologic crite-
ria by an experienced pathologist. In addition to the processing
for histopathologic analysis, a subset of freshly isolated tumors
was also snap frozen in liquid nitrogen and stored at 80°C.
Frozen tumors were either used for DNA/RNA extraction (Qia-
gen, Hilden, Germany) or embedded in Tissue-Tek (Sakura B.V.,
Zoeterwoude, The Netherlands) and processed for cryosections.
Kidneys, liver, and lungs of all animals were also investigated
for the presence of metastases by macroscopic and, in a selected
number of cases, microscopic analysis of serial sections. For
protein analysis, snap-frozen mouse tissue or scrapings of in-
testinal mucosa were lysed in ice-cold lysis buffer (50 mmol/L
Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L benzamidine, 1
mmol/L PMSF, 1 mmol/L DTT, 2 mmol/L EGTA, 1% Triton
X-100, 1% NP-40, Mammalian Protease Inhibitor Cocktail;
Sigma Chemical Co, St. Louis, MO) using a 1-mL Dounce
Homogenizer. After centrifugation (15,000g, 15 minutes, 4°C),
supernatants were collected, and protein concentration was
determined (Bio-Rad assay, Richmond, CA).
LOH Analysis
LOH of the Apc and Tp53 genes was determined by PCR
amplification of dinucleotide repeat markers.22,24 DNA was
isolated from microdissected tumors and from normal intesti-
nal tissue with an RNA/DNA extraction kit (Qiagen). Primer
sequences were obtained from the Mouse Genome Data-
base.22,25 The following polymorphic markers were used for the
Apc locus: D18Mit64, D18Mit111, D18Mit132, and D18Mit17
and for the Tp53 locus: D11Mit4, D11Mit30, and D11Mit278.
LOH was defined at P  .05 for 3 independent PCR reac-
tions.22,26 A functional assay previously described was used to
validate the pathogenicity of molecular changes at the Tp53
gene.22,26,27
RT-PCR Analysis of Wnt Downstream
Targets in Intestinal Tumors
C-myc and cyclin D1 messenger RNA (mRNA) expres-
sion levels were analyzed in normal mucosa and tumors (n  5
mice/genotype). RNA was harvested from snap-frozen tissues
using the RNeasy extraction kit (Qiagen). Up to 2 g of total
RNA was then subjected to reverse transcription using Super-
script II Reverse Transcriptase (Invitrogen Life Technologies,
Carlsbad, CA) and oligo dT primers (pd(N)6, Roche, Mann-
heim, Germany). Reactions were carried out in SybrGreen PCR
Master mix (Applied Biosystems, Courtaboeuf Cedex, France)
under recommended conditions, run on ABI PRISM 7900, and
analyzed with Sequence Detector Software (Applied Biosys-
tems). Relative quantities were calculated using the ddCT for-
mula and normalized to the transcript levels of the housekeep-
ing gene TATA binding protein (TBP). Assays were performed
in triplicate. Primer sequences used were as follows: TBP:
forward, CCACGGACAACTGCGTTGAT; reverse, GGCTCAT-
AGCTACTGAACTG. c-myc: forward, TAGTGCTGCATGAG-
GAGACA; reverse, GGTTTGCCTCTTCTCCACAG. cyclinD1:
forward, CACAACGCACTTTCTTTCCAG; reverse, CGCAG-
GCTTGACTCCAGAAG.
Detection of Liver Micrometastases by
RT-PCR
Mouse livers were dissected under sterile conditions to
avoid contamination. Liver RNA was extracted from different
tissues using the RNA Now Kit (Ozyme, St Quentin, France).
RT-PCR reactions were performed as previously described.22,28
Primers were used that amplify specifically the transgenic
KRASV12G gene under control of the villin promoter. The sense
primer is specific to the villin promoter, CAAGCCTGGCTC-
GACGGCC, and the antisense primer recognizes the coding
sequence of the human KRASV12G gene, ATTTGCGGCCGCTT-
TACATAATTACACACT, yielding a fragment of 400 base pair.
PCR reactions were repeated twice for each sample, and RNA
was extracted twice from each tissue to confirm the result.
Direct sequencing of the fragment confirmed the identity of the
transgenic KRASV12G.
Western Blot Analysis
Equal amounts (40 g) of protein lysate were sepa-
rated on 13% polyacrylamide gels and further subjected to
immunoblotting according to standard procedures. Primary
antibodies used were as follows: anti-pan-Ras (Transduction
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Laboratories, Lexington, KY), anti--Actin (Sigma), anti--
catenin (Transduction Lab.), anti-E-cadherin, anti-phospho-
(Thr202, Tyr204)-p44/42 MAPK, anti-p44/42 MAPK, anti-
phospho-(Thr308)-Akt, anti-phospho-(Ser473)-Akt, anti-Akt
(all Cell Signaling, New England Biolabs, Beverly, MA). Per-
oxidase-conjugated secondary antibodies (Jackson Immu-
noresearch, West Grove, PA) were visualized with an ECL kit
(Pierce, Rockford, IL).22
GTPase Activity Assays
GTP-Ras pull-down assays were performed on mouse
tissue lysates as previously described.22 GTP-Ras pull-down
assays on embryonic stem (ES) cells followed essentially the
same protocol; the cells were first washed with ice-cold
phosphate-buffered saline (PBS) and then incubated in lysis
buffer.22,28 Samples were run on 13% SDS-PAGE gels and trans-
Figure 1. Increased tumor multiplicity and progression in KRASV12G/Apc/1638N mice (A) Kaplan–Meier survival analysis of KRASV12G/Apc/1638N
mice and their single transgenic littermates. RasAPC, compound mutant mice (n  50 mice/genotype; intergroup difference at P  .001). (B)
Macroscopic view of longitudinally dissected small intestinal tissue specimens representative for 6 months of age. No tumors can be observed in
KRASV12G mice at this age, and few (2–4) lesions in Apc/1638N mice. KRASV12G/Apc/1638N (RasAPC) mice show abundant, multiple lesions
throughout the upper GI tract. Scale bar 1 cm. (C) H&E stained sections from KRASV12G/Apc/1638N animals. Left to right: benign adenoma at 3.5
months; in situ carcinoma at 3.5months; invasive adenocarcinoma at 3.5months; invasive carcinoma at 6months. Scale bars 200m (upper row)
and 50 m (lower row).
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ferred to membranes. Immunodetection was performed with
anti-Ras antibody (Cell Signaling). The amount of GTP-bound
GTPases was normalized to the total amount of GTPases
present in whole cell lysates.
Flow Cytometry
Flow cytometry from mouse tissue was carried out
essentially as described.22 For each genotype, 2 mice were in-
jected intraperitoneally with 0.01 mL/g body weight of a 6
mg/mL solution of 5-bromo-2=-deoxyuridine (BrdU; Sigma).
Animals were killed 2 hours after bromodeoxyuridine (BrdU)
injection and dissected. Bivariate distributions of BrdU content
(FITC) vs DNA content (propidium iodide) were measured
using a FACScan flow cytometer (Becton Dickinson, San Jose,
CA). Doublets and clumps were excluded from the analysis by
gating on a bivariate distribution of the propidium iodide area
vs signal width.
Immunohistochemistry Analysis of Tissue
Sections
Cryosections of Tissue-tek OCT (Sakura) embedded
mouse tissues were cut at 5-m thickness, air-dried, and fixed
with 3% paraformaldehyde at room temperature for 20 min-
utes. The paraformaldehyde-fixed sections were treated with 50
mmol/L NH4Cl in PBS for 20 minutes, and solubilized with
0.1% Triton X-100 for 5 minutes. Antibodies and reagents used
were as follows: anti--catenin (dilution 1:200; Transduction
Laboratories Clone 14); pAb anti-Ki67 (Novocastra, Newcastle,
UK); cleaved caspase-3 (Cell Signaling); Peroxidase-, Cy3-, or
Alexa488-conjugated secondary antibodies (Jackson Immunore-
search); and TRITC-phalloidin and Hoechst 33258 (Sigma).
Cells and tissue sections were viewed using a fluorescence mi-
croscope (Zeiss, Göettingen, Germany) or a confocal micro-
scope (LSM510, Zeiss, Göettingen, Germany). Images were pro-
cessed using Adobe Photoshop Software (San Jose, CA). For
evaluation of -catenin staining, antigen retrieval treatment
was performed (10 minutes in boiling 10 mmol/L Tris/Cl, 1
mmol/L EDTA, pH 8.0), followed by incubation with the spe-
cific antibody overnight at 4°C. Localization of peroxidase
activity was detected with the SIGMA FAST DAB system
(Sigma), after brief hematoxylin counterstaining.
For the comparative evaluation of nuclear -catenin accu-
mulation between tumors derived from Apc/1638N and
KRASV12G/Apc/1638N mice, a previously established protocol was
used29 based on 2 independent blinded observers. In brief,
tumor cells with nuclear -catenin were counted from immu-
nohistochemistry (IHC) sections and scored according to stain-
ing intensity when compared with the few normal crypt cells
within the same section that, as previously reported, also en-
compass nuclear -catenin. The ratio between the tumor area,
measured in millimeters squared, using the PALM MicroBeam
microscope system (P.A.L.M. Microlaser Technologies AG-
Bernried, Germany), and the absolute numbers of positive cells
were calculated for each tumor sample based on at least 2 serial
sections representative of the whole tumor. Statistical analysis
was performed using R software (version 1.9.1., Free Software
Foundation, Boston, MA).
Generation of Apc/KRAS Mutant ES Cell
Lines
ES cell lines containing both Apc and KRAS mutations
were generated by stable cotransfection by electroporation of
wild-type and Apc1638N/1638N ES cell lines (E14; 129 Ola) with a
pPGK expression vector containing either the human wild-type
Table 1. Incidence and Distribution of Intestinal Neoplasia in KRASV12G/Apc/1638N Mice
Genotype
Median age
(range)
Mice,
n
Incidence
n
Tumors/
animal
mean  SD
Tumor range
(absolute
no. of
tumors)
Size distribution
(S/M/L) (%) Tumor localization
KRASV12G 9 mo (4–16) 22 13/22
59%
1.9  2.4 0–8 12/88/0 P: 4%; D: 32%; J: 55%; I:
23%; C: 0%
Apc/1638N 7 mo (4–20) 20 20/20
100%
4.3  2.3 1–10 12/38/50 P: 88%; D: 100%; J: 38%;
I: 0%; C: 19%
KRASV12G/Apc/1638N 5 mo (4–7) 20 20/20
100%
29.5  12.0 12–59 22/58/20 P: 58%; D: 100%; J:
100%; I: 41%; C: 41%
NOTE. Size distribution (diameter): small, 1 mm; medium, 1–3 mm; large, 	3 mm. Tumor localization  incidence of lesions in periampullar
region (P), duodenum (D), jejunum (J), ileum (I), colon (C).
Table 2. Onset and Development of Neoplasia in KRASV12G/Apc/1638N Mice
Genotype
3–5 Mo 6–12 Mo 	12 Mo
Incidence,
n
Tumors/
animal
Size S/M/
L (%)
Incidence,
n
Tumors/
animal
Size S/M/
L (%)
Incidence,
n
Tumors/
animal
Size
S/M/L (%)
KRASV12G 0/4 0 — 6/10 1.4 21/79/0 6/8 3.4 7/93/0
60% 75%
Apc/1638N 7/8 1.9 54/46/0 6/6 3.8 14/36/50 6/6 6.0 3/28/69
88% 100% 100%
KRASV12G/Apc/1638N 14/14 15.4 32/51/17 6/6 32.8 19/56/25 — — —
100% 100%
NOTE. Size distribution (diameter): small, 1 mm; medium, 1–3 mm; large, 	3 mm.
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KRAS or the human oncogenic KRASV12G together with a pPGK-
puromycin selection vector. To select for stable clones, the ES
cells were cultured in the presence of puromycin (Sigma) at a
final concentration of 2 g/mL for 2 weeks.
TOPFLASH/FOPFLASH Reporter Assays
Twenty hours before transfection, 105 ES cells per well
were plated on tissue culture plates coated by primary, mito-
mycin C inactivated, murine embryonic fibroblasts. ES cells
were transfected in each well with 500 ng of pTOPFLASH or
pFOPFLASH vector (kindly provided by Dr H. Clevers) and 5 ng
luciferase from Renilla reniformis using Lipofectamine 2000 (Life
Technologies) as recommended by the manufacturer. After 24
hours, luciferase activities were measured in a luminometer
(Lumat LB 9507, Berthold, Bad Wildbad, Germany) and nor-
malized for transfection efficiency by the Dual Luciferase Re-
porter Assay system (Promega, Madison, WI). Luciferase activ-
ities were evaluated as ratio of pTOPFLASH vs pFOPFLASH
levels for 3 different experiments, each carried out in duplicate.
Annexin V Staining of ES Cells
ES cells were prepared following the Vibrant Apoptosis
Assay kit No. 2 protocol (Molecular Probes). Five thousand
events were analyzed per test in list mode using a FACScan flow
cytometer (Becton Dickinson, San Jose, CA). To quantify
changes associated with cell differentiations, 2 regions were
created on the dot-plot graphs using the Forward Scatter/Side
Scatter. Bivariate distributions of Annexin-V content (Alexa
488) vs DNA content (PI) were measured. Mean  SD of 3
experiments is shown.
Expression Profiling by Oligonucleotide
Microarray
Tumor-specific expression profiles were analyzed in 4
Apc/1638N and 4 KRASV12G/Apc/1638N tumors collected from a
total of 7 mice of 6–8 months of age and same genetic back-
ground. All tumors were highly dysplastic and localized in the
upper duodenum. Samples were laser-capture microdissected
(LCM) from cryosections of Tissue-tek OCT (Sakura) embed-
ded snap-frozen tumors. Ten-micrometer sections were briefly
stained with H&E, and consecutive sections were carefully mi-
crodissected using a PALM MicroBeam microscope system
(P.A.L.M. Microlaser Technologies AG- Bernried, Germany). On
average, 2000 cells were isolated from each sample. The RNA
was isolated using the Rneasy kit (QIAGEN) with a DNase
digestion step. Quality of RNA was checked on 2100 Bioana-
lyzer (Agilent Technologies, Inc, Waldbronn, Germany) and
labeled according to Affymetrix protocols for 2 rounds of am-
plification (Small Sample Labeling Protocol vII). Labeled cRNA
was hybridized to Genechip MOE430A arrays (Affymetrix, Inc.,
Santa Clara, CA) according to standard protocols. Data were
normalized using vsn software (variance stabilization and cali-
brations for microarray data) using a package provided by
Bioconductor.30 The hierarchical t test31 was performed in the
R (version 1.9.1) environment.32 Unsupervised clustering was
performed using the Rosetta software (Rosetta Inpharmatics
LLC, Knowledge Systems Group, Dept. of Computer and Infor-
mation Science, Norwegian University of Science and Technol-
ogy, Trondheim, Norway).
Results
Intestinal Tumor Multiplicity and
Progression Is Significantly Increased in
KRASV12G/Apc/1638N Mice
To study the interaction between oncogenic KRAS and
deregulated Wnt pathway, we bred transgenic mice expressing
the activated human KRASV12G oncogene driven by the intes-
tine-specific villin promoter22 with Apc/1638N mice carrying a
targeted nonsense mutation at the endogenous Apc gene.21
Compound mutant mice showed significant increase in mor-
bidity and mortality when compared with the single transgenic
littermates (Figure 1A, see Supplementary Table 1 online at
www.gastrojournal.org). In fact, no compound mutant animal
survived for more than 33 weeks. We examined and counted the
occurrence of tumors in the gastrointestinal tract from com-
pound KRASV12G/Apc/1638N mice and compared those with
their control littermates at 6–12 months of age or when mor-
ibund. Compound KRASV12G/Apc/1638N animals (n  20) devel-
oped an average of 29.5 tumors per mouse (Figure 1B; Table 1).
This represents a highly significant 15-fold and 7-fold increase
over KRASV12G and Apc/1638N animals, respectively (P  .001,
Mann–Whitney rank sum test). The increase in tumor multi-
plicity was already apparent in young animals (Tables 2 and 3).
Figure 2. Detection of disseminated tumor cells in the livers from
Apc1638N//KRASV12G animals. Detection of the transgenic KRASV12G
transcript with a specific primer combination that only recognizes trans-
genically expressed KRAS but not endogenous KRAS. The mucosa
from a compound mutant animal was used as positive control (R/
A233*). Six out of 22 livers tested were positive (27%). Positive bands
were sequenced in all cases to confirm the identity of the oncogenic
KRAS transcript. The control transcript TBP is expressed ubiquitously;
lanes labeled (RT) and (PCR) indicate negative controls without
reverse transcriptase and without cDNA template, respectively.
Table 3. Histopathologic Staging of Tumors at 3.5 Months of Age
Genotype Mice (n) Adenoma Carcinoma in situ Carcinoma inf. Tumors (n) Adenoma/carcinoma ratio
KRASV12G 4 0 0 0 0 —
Apc/1638N 4 4 3 1 8 1:1
KRASV12G/Apc/1638N 4 3 15 16 34 1:10.3a
NOTE. Carcinoma inf.  infiltrative carcinoma, invasion through the muscularis mucosae into the submucosa.
aP  .0167, Fisher exact test.
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A broad spectrum of tumor stages was found, ranging from
aberrant crypts and small dysplastic polyps, to large invasive
carcinomas (Figure 1C). Pseudoinvasion was ruled out because
the invasive front of the tumor was observed on several serial
sections, invariably encompassing multiple glands and in asso-
ciation with stromal reaction. All compound mutant mice had
lesions in both duodenum and jejunum, and tumors of the
large intestine occurred more frequently (41%) than in
Apc/1638N littermates (19%). To evaluate tumor progression, 4
animals of each genotype were killed at 3.5 months, and tissue
sections covering complete segments of the small intestine were
carefully scored. As expected for this age, we did not detect
lesions in KRASV12G mice.22 In the Apc/1638N littermates, half of
the lesions had progressed to malignancy (adenoma/carcinoma
ratio of 1:1) (see Supplementary Figure 1 online at www.
gastrojournal.org). In contrast, the compound mutant mice
showed an adenoma/carcinoma ratio of 1:10 (P  .0167, Fisher
exact test; Table 3). No metastases were observed by histopatho-
logic analysis of mesenteric lymph nodes, livers, and lungs from
KRASV12G/Apc/1638N mice carrying locally invasive carcinomas.
However, we detected disseminated intestinal tumor cells in
livers from compound mice by RT-PCR. By using primers that
specifically amplify the mRNA from the KRASV12G transgene
under control of the villin promoter, exclusively expressed in
intestinal epithelial cells and in tumor cells derived from these
epithelia, transcripts were detected in 6 of 22 livers from com-
pound mutant animals (Figure 2). To control for the specificity
of the assay, livers from wild-type animals and from tumor-
bearing KRASV12G animals (n  10, mean age: 17.5 months)
were analyzed, and none was found positive.
Somatic Loss of the Wild-Type Apc Allele and
Expression of Oncogenic KRASV12G in
KRASV12G/Apc/1638N Tumors
LOH at the APC locus characterizes the vast majority of
tumors from FAP and sporadic CRC patients and from mouse
models carrying heterozygous Apc mutations.5,33 Out of 10
intestinal lesions from KRASV12G/Apc/1638N animals analyzed,
all showed LOH at the wild-type Apc locus regardless of size and
histologic stage of the tumors analyzed (Figure 3A). In contrast,
we could not detect mutations in the tumor suppressor gene
TP53 in 7 tumors from KRASV12G/Apc/1638N animals, using a
yeast-based functional assay.22 Furthermore, only 1 out of 10
tumors from KRASV12G/Apc/1638N mice revealed LOH at Tp53
(not shown). In KRASV12G tumors, Tp53 LOH and point muta-
tions occur in 40% of the cases.22
Expression levels of the KRASV12G transgene in both normal
intestinal mucosa and tumors were stable but rather low; the
amount of transgene was 12%  3% of total endogenous Ras
(Figure 2B). A GTP-Ras pull-down assay showed clear activity in
small intestinal mucosa and tumor extracts from compound
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 3. (A) Loss of heterozygosity (LOH) at the Apc locus in
tumors from KRASV12G/Apc/1638N animals. (A) Three microsatellite
markers were PCR amplified from control tissue (C) and 3 independent
tumors (T1, T2, T3) of a KRASV12G/Apc/1638N animal. The position of
the employed chromosome 18 markers relative to the Apc locus (15
centiMorgan [cM]) are D18Mit64 (2 cM), D18Mit111 (11 cM), and
D18Mit17 (20 cM). (B) Oncogenic KRASV12G activates MAP kinase, but
not AKT, in mouse intestinal epithelia. Total Ras, GTP-Ras pull down,
MAPK, and AKT activation analysis in intestinal mucosa tissue lysates
from wild-type (WT), KRASV12G (R), Apc/1638N (A), and KRASV12G/
Apc/1638N (RA) mice. Top to bottom: anti-Ras antibody reveals distinct
endogenous Ras and transgenic KRASV12G (arrow) proteins. Ras-GTP
pull-down assay shows strong activity in KRASV12G and compound
KRASV12G/Apc/1638N mice. MAPK1/2 are clearly activated by
KRASV12G as revealed by a phosphospecific antibody. Total MAPK as
well as total and phosphorylated AKT were essentially unchanged. Ac-
tin: loading control. (C) Oncogenic KRASV12G activates MAPK but not
AKT in stable ES cells lines. Representative examples of independent
clones for each line shown: wild-type E14 (WT), Apc1638N/1638N (A),
Apc//KRASV12G (R), and Apc1638N/1638N/KRASV12G (RA). Actin: loading
control. Analysis with pan-Ras antibody reveals significant increase in
protein levels in cell lysates from Apc//KRASV12G and Apc1638N/1638N/
KRASV12G ES cells. Ras-GTP pull-down assay shows activity in com-
pound mutant lines. MAPK1/2 are clearly activated by oncogenic
KRASV12G. Total MAPK levels as well as total and phosphorylated AKT
levels were essentially unchanged.
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mutant animals but not in control tissue (Figure 3). The mito-
gen-activated protein kinases ERK1 and ERK2 were constitu-
tively phosphorylated in intestinal mucosa lysates of KRASV12G
transgene carrying animals, without changes in total levels of
expression (Figure 3B). This stable increase of MAPK activity in
response to oncogenic KRAS signaling was comparable with
single transgenic mice.22 It has recently been shown that sus-
tained expression of oncogenic KRAS causes a decrease in
MAPK activity in mouse embryonic fibroblasts,34 possibly re-
flecting cell type-specific differences between epithelial and mes-
enchymal cells.35 The protein kinase Akt/PKB is a common RAS
effector. However, the expression or phosphorylation levels of
Akt did not differ significantly between transgenic and control
animals (Figure 3B).
To recapitulate the mutations characteristic of the
KRASV12G/Apc/1638N mice in an in vitro model easily amenable
to biochemical analysis, we stably transfected Apc1638N/1638N
mouse embryonic stem (ES) cells36 with a human KRASV12G
expression construct driven by the PGK promoter. In cell lysates
from stably transfected ES clones, expression of total Ras was
quantified, and a pull-down assay with recombinant RalGDS
was performed to test for functional, activated GTP-RAS (Fig-
ure 3C). In accordance with the observations in mouse tissue,
the MAPK cascade was activated upon oncogenic KRAS expres-
sion, but no Akt activation was detectable (Figure 3C).
Tumors From Compound KRASV12G/
Apc/1638N Mice Show Increased
Proliferation and Reduced
Apoptosis Rates
To detect changes in cellular proliferation, we have
performed Ki67 staining on tissue sections and analysis by flow
cytometry after in vivo BrdU incorporation (Figures 4A and B).
In tumors from compound mutant animals, we frequently
detected a striking increase in cellular proliferation pattern. The
S-phase fraction (SPF) fraction was significantly elevated in
adenocarcinomas from KRASV12G/Apc/1638N mice (SPF: 11.1%, n
 13 tumors), whereas normal mucosa samples were not sig-
nificantly different from wild-type. Notably, proliferation rates
in lesions from compound mutant mice were significantly
higher than in tumors from single transgenic KRASV12G litter-
mates (P  .001) and from Apc/1638N mice (P  .013).
Next, we analyzed protein lysates from normal tissue and tu-
mors for the activated, cleaved form of caspase-3 (Figure 4C).
Caspase-3 plays a central role in apoptosis because it is responsible
for the proteolytic cleavage and activation of other caspases and of
additional key apoptotic proteins.37 Tumors from all groups of
animals showed reduced amounts of cleaved caspase-3 when com-
pared with normal control tissue. Notably, tumors from com-
pound mutant mice had significantly lower levels of cleaved
caspase-3 than the single mutant Apc/1638N littermates (P 
.0076), whereas the levels of uncleaved, full-length caspase-3 did
not differ significantly between the different groups (Figure 4C).
The difference in apoptosis between tumor and normal tissue also
significantly differs between single mutant Apc/1638N mice and
compound mutant animals (P .029). Essentially the same result
was observed for poly (ADP-ribose) polymerase 1 (PARP), a main
downstream target of caspase-3 (not shown). In accordance, we
observed a significant reduction of apoptosis in Apc1638N/1638N
mutant ES cell lines upon stable expression of oncogenic
KRASV12G, in committed as well as in undifferentiated cells (see
Supplementary Figure 2 online at www.gastrojournal.org).
The Canonical Wnt/-Catenin Signaling
Pathway Is Enhanced by Oncogenic
KRASV12G
It has been shown that oncogenic KRAS results in the
dissociation of -catenin from E-cadherin at the adherens junc-
tions of epithelial cells.38 This leads to an increase of the
cytoplasmic -catenin pool, which, under physiologic (Apc/)
conditions, is efficiently degraded by the proteolytic machinery.
Thus, in a mutant Apc background, oncogenic KRAS may un-
derlie subtle but significant changes in -catenin subcellular
localization and signaling. To analyze putative changes in nu-
clear accumulation of -catenin between tumors from
KRASV12G/Apc/1638N and Apc/1638N littermates, IHC was per-
formed on a total of 61 lesions (n 18 animals; Figure 5A). The
subcellular distribution of -catenin was heterogeneous
throughout each tumor, as previously reported.39,40 Using a
previously established protocol,29 tumors from KRASV12G/
Apc/1638N animals showed a statistically significant increase of
cells with nuclear -catenin (Table 4). Analysis of tumors from
KRASV12G mice at the same age did not reveal -catenin nuclear
accumulation (data not shown). To corroborate these observa-
tions, we performed coimmunoprecipitation (IP) analyses on
tissue lysates. IPs were first performed with an antibody against
E-cadherin and analyzed by immunoblotting with an anti--
catenin antibody. The fraction of -catenin bound to E-cad-
herin was compared with total -catenin levels. The IP fraction
of -catenin was markedly decreased in tumors from com-
pound mutant mice compared with their control littermates
(Figure 5B).
The ES cell lines stably transfected with oncogenic KRAS in
Apc/ and Apc1638N/1638N backgrounds represent a convenient
mean to validate and strengthen the above observations. First,
we tested the subcellular localization of -catenin by immuno-
fluorescence and confocal microscopy upon LIF withdrawal.
Indeed, nuclear accumulation of -catenin was evident
in the KRASV12G/Apc1638N/1638N ES lines (Figure 6A and see
Supplementary Figure 3 online at www.gastrojournal.org).
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Figure 4. Proliferation and apoptosis rates in tumors from KRASV12G/Apc/1638N mice. (A) Proliferation is increased in tumors from KRASV12G/
Apc/1638N mice (bottom) when compared with Apc/1638N littermates (top) as shown by immunohistochemical detection of the proliferation marker
Ki67. (B) Analysis of cell proliferation by flow cytometry after BrdU incorporation in normal (N) and tumor (T) tissue samples from wild-type (WT),
KRASV12G (R), Apc/1638N (A), and KRASV12G/Apc/1638N (RA) mice. S-phase fractions are indicated asmean SEM. Tumors from compoundmutant
KRASV12G/Apc/1638N mice have significantly higher proliferation rates than tumors from KRASV12G littermates (P  .0001) or from Apc/1638N
littermates (P  .0026). (C) Apoptosis is suppressed in tumors from KRASV12G/Apc/1638N mice. Levels of full-length and cleaved caspase 3 were
quantified from Western blots. Mean SEM was calculated (2 tumors per animal, n 4 mice/group). Compound mutant KRASV12G/Apc/1638N mice
have significantly lower cleaved caspase-3 levels in tumors than single transgenic littermates (P  .005).
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Apc1638N/1638N ES cells showed only occasional -catenin nuclear
accumulation, although not as prominently as in the presence
of oncogenic KRAS. Essentially the same results were obtained
from primary cultures of tumor cells from single and com-
pound transgenic animals (not shown). Immunofluorescence
analysis of intracellular distribution of -catenin clearly indi-
cated a prominent increase of nuclear -catenin in tumor cells
from compound mutant animals, as compared with Apc-only
mutated tumors. We then measured the levels of transcription-
ally active nuclear -catenin levels in the various mutant ES
lines by the TCF/-catenin responsive reporter assay TOP-
FLASH.8,41 Although stable transfection of wild-type ES cells
with oncogenic KRAS was not sufficient to induce reporter
activity, KRASV12G/Apc1638N/1638N ES cell lines showed a 2-fold
increase in TOPFLASH activity when compared with the
Apc1638N/1638N parental cell line (Figure 6A, inset). The increase
in -catenin nuclear accumulation in Apc1638N/1638N cells upon
KRASV12G expression coincides with the observed increase in
Wnt reporter activity, clearly demonstrating a synergistic role of
activated KRAS in enhancing Wnt signaling activation.
Oncogenic KRAS has been shown to induce tyrosine phos-
phorylation of -catenin, leading to a disruption of its binding
to E-cadherin.38 This induces a shift in -catenin intracellular
distribution by increasing the intracellular (Wnt signaling)
pool. Moreover, increased tyrosine-phosphorylation of -cate-
nin has been associated with malignancy.42 Thus, tyrosine-
phosphorylation of -catenin, induced by KRASV12G, might be
responsible for the observed nuclear accumulation of -catenin
and increased Wnt signaling.
To test for putative changes on -catenin tyrosine-phospho-
rylation, we have carried out biochemical analysis on the Apc/
KRAS mutant ES cell lines. Endogenous -catenin was immu-
noprecipitated, and phospho-tyrosine was revealed with a pan
anti-phospho-tyrosine-specific antibody (Figure 5C). In
Apc1638N/1638N cells, a faint phospho-tyrosine band was occasion-
ally observed but never in wild-type or KRASV12G cells on an
Apc/ background. A clearly increased phospho-tyrosine band
was observed in compound KRASV12G/Apc1638N/1638N mutant
cells (Figure 5C). As a positive control for tyrosine-phosphory-
lation, we treated ES cells with pervanadate prior to the immu-
noprecipitation. As expected, a strong increase in phosphoryla-
tion signal was detectable in all cell lines (shown only for
wild-type cells in Figure 5C). Pervanadate, an inhibitor of pro-
tein tyrosine phosphatases, induces the intracellular redistribu-
tion of -catenin from the cell membrane to the cytosol.43
Treatment of Apc-mutant ES cell lines with pervanadate indeed
resulted in -catenin nuclear accumulation (Figure 6B). Nota-
bly, the same treatment did not induce -catenin nuclear accu-
mulation in Apc/ cells. KRASV12G/Apc1638N/1638N ES cells are
already characterized by -catenin nuclear accumulation, and
the intracellular distribution did not change upon pervanadate
treatment. These results indicate that tyrosine-phosphorylation
is per se insufficient to induce nuclear accumulation of -cate-
nin but can significantly promote a marked intracellular redis-
tribution of -catenin upon loss of Apc function.
Expression of Target Genes in Tumors From
Compound KRASV12G/Apc/1638N Mice
We have analyzed the expression levels of known Wnt/
-catenin targets by real-time PCR and immunoblot analysis.
The c-Myc oncogene is a direct target of -catenin/TCF and a
major mediator of tumorigenic effects.44 Furthermore, c-Myc is
known to be stabilized at the protein level by the Ras/Raf/
MAPK cascade.45 A significant increase in c-Myc transcript levels
is evident in tumors from KRASV12G/Apc/1638N animals as com-
pared with tumors from either KRASV12G or Apc/1638N mice
(Supplementary Figure 4 online at www.gastrojournal.org).
The cell cycle regulator Cyclin D1 represents another Wnt
target thought to be relevant for cancer.46 Cyclin D1 transcript
levels were uniformly up-regulated in tumors, with no signifi-
cant differences among the genotypes. Essentially the same was
observed for Cyclin D1 protein levels quantified by Western blot
analysis. These results are in agreement with a more recent
study that argues the role of Cyclin D1 as a Wnt/-catenin
downstream target.47
To analyze further the genome-wide expression differences
between tumors from compound KRASV12G/Apc/1638N animals
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 5. Increase in nuclear -catenin accumulation in tumors from KRASV12G/Apc/1638N mice. (A) Tumor sections from KRASV12G/Apc/1638N
mice (right panel) show increased nuclear -catenin compared with tumors from Apc/1638N animals (left panel). All tumor cells with strong (arrow) and
mild (arrowheads) nuclear -catenin staining were scored (see Results section). (B) Immunoblot analysis and coimmunoprecipitation of total and
E-cadherin-associated -catenin levels in normal (N) and tumor (T) tissue specimens from KRASV12G (R), Apc/1638N (A), and KRASV12G/Apc/1638N
(RA) mice. Top 3 panels: total -catenin, immunoprecipitated E-cadherin, and -catenin bound to E-cadherin. Note the reduction of -catenin
associated to E-cadherin in compound mutant tumors. Bottom panel: actin staining (2 tumors per animal, n  2 mice/genotype). (C). Increase in
tyrosine-phosphorylation on immunoprecipitated -catenin in Apc-mutant ES cells expressing KRASV12G, as compared with Apc-only mutated cells.
Endogenous -catenin was immunoprecipitated from wild-type E14 mouse ES cells (WT), Apc1638N/1638N (A), Apc//KRASV12G (R), and Apc1638N/
1638N/KRASV12G (RA) ES cells. Top to bottom: Immunoprecipitated -catenin, phospho-tyrosine revealed with anti-phospho-tyrosine antibody on the
-catenin IP, and actin as loading control. Note the presence of a faint phospho-tyrosine band inApc1638N/1638N cells, but not in wild-type orKRASV12G
cells, and an enhanced signal in the lane from compound mutant cells (RA, marked by arrow). As a positive control for tyrosine-phosphorylation, ES
cells were treated with pervanadate prior to immunoprecipitation. As expected, strong phosphorylation signals were detectable in all cell lines (shown
here only for WT cells).
Table 4. Nuclear 
-Catenin Accumulation Is Increased in
KRASV12G/Apc/1638N Tumors
Genotype
Tumors
(n)
Mean nuclear

-catenin
expression
ratio
Apc/1638N 27 0.058
KRASV12G/Apc/1638N 34 0.128a
NOTE. Ratio between the absolute number of positive nuclear cells
and the area of the tumor section analyzed (mm2).
aP  .03874, Welch 2 sample t test.
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and from single transgenic mice, we used Laser Capture Micro-
dissection (LCM) and expression profiling by Affymetrix oligo-
nucleotide microarrays. Total RNA was isolated from microdis-
sected parenchymal cells from histology-matched (high
dysplasia) Apc/1638N (n  4) and KRASV12G/Apc/1638N (n  4)
adenomas. Notably, unsupervised hierarchical clustering of the
data revealed that the tumors do not segregate according to
their genotype (see Supplementary Figure 5 online at www.
gastrojournal.org). Analysis by hierarchical t test31 also revealed
no significant differences between the 2 groups. However, we
cannot exclude that further filtering and bioinformatic analysis
of these expression profiling data will detect differentially ex-
pressed genes, as shown above for c-Myc (see Supplementary
Figures 4 and 5 online at www.gastrojournal.org).
Figure 6. Increase in nuclear -catenin accumulation and Wnt/-catenin signaling in Apc-mutant ES cells expressing KRASV12G. (A)
Confocal microscopy analysis of -catenin and E-cadherin intracellular distribution in wild-type E14 (WT), Apc1638N/1638N (A), Apc//KRASV12G
(R), and Apc1638N/1638N/KRASV12G (RA) ES cells. Note: nuclear accumulation of -catenin in compound mutant cells (arrowheads), in addition
to the normal localization at cell-cell contact sites. Overlay with DAPI (nuclear stain) to indicate the position of the nuclei. Yellow in the overlay
indicates colocalization of -catenin and E-cadherin at the cell-cell junctions, demonstrating the presence of -catenin in adhesion complexes.
Inset: TOP Flash reporter analysis of Wnt-signaling activity in wild-type E14 (WT), Apc1638N/1638N (A), Apc//KRASV12G (R), and Apc1638N/1638N/
KRASV12G (RA) ES cells. Mean  SEM for 3 independent replicas. (B) Pervanadate treatment induces -catenin nuclear accumulation in
Apc-mutant but not in wild-type ES cells. Nuclear -catenin (green, arrows) is visible in Apc1638N/1638N (A) and Apc1638N/1638N/KRASV12G (RA) ES
cells but not in wild-type cells.
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Discussion
We have generated a compound mouse model that
recapitulates the tumor-specific mutations characteristic of the
majority of human CRC patients20 by combining loss of Apc
tumor suppressor function with intestine-specific expression of
oncogenic KRAS. Compound KRASV12G/Apc/1638N mice dis-
played an average of 30 intestinal tumors, a 15-fold and a 7-fold
increase over the pvill-KRASV12G and Apc/1638N littermates, re-
spectively. Rather than simply adding up the tumor phenotypes
of the parental strains, the compound mutant animals showed
an increase in progression toward malignancy with severe mor-
bidity and mortality. Tumors from compound mutant animals
proliferated at significantly higher rates than their single trans-
genic littermates. Furthermore, levels of apoptosis were reduced
in tumors, as well as in a complementary ES cell model system
that recapitulates the genetic mutations of the tumors. As
shown here, the synergism between mutant KRAS and APC in
enhancing Wnt/-catenin signaling is likely to underlie the
observed phenotypic differences. Accordingly, TOPFLASH re-
porter analysis shows that KRASV12G expression significantly
enhances Wnt/-catenin signaling in Apc-mutant but not in
wild-type ES cells. The latter is confirmed by the increased
nuclear -catenin accumulation in both Apc-mutant ES cells
and intestinal tumors upon oncogenic KRAS activation. In
tumors from KRASV12G/Apc/1638N mice, a significant increase in
the number of cells with nuclear -catenin accumulation was
observed when compared with age- and histology-matched tu-
mors from Apc/1638N animals. However, the intratumor -cate-
nin pattern is extremely heterogeneous, with the majority of
parenchymal cells showing membranous and/or cytoplasmatic
staining (Figure 5A). This may explain why expression profiling
did not reveal any significant difference between the 2 groups of
tumors. Thus, the synergism between oncogenic KRAS and
mutated Apc is likely to exert its effects through the enhanced
activation of a common downstream signaling pathway, namely
the Wnt/-catenin pathway, in a subset of tumor cells. The
latter is of relevance in view of the role of Wnt signaling in the
regulation of stem cell renewal and differentiation.10,36,48,49 By
synergistically enhancing Wnt signaling, KRAS and APC muta-
tions are likely to increase the relative number of putative
“cancer stem cells” (CSCs) earmarked by nuclear -catenin
accumulation. Previous reports have shown that also in human
CRC, the intracellular distribution of -catenin is very hetero-
geneous: tumor cells with nuclear -catenin are predominantly
located at the invasion front where they undergo epithelial-
mesenchymal transitions when invading stromal compart-
ments. In contrast, the majority of tumor cells retain a mem-
branous staining, comparable with normal colon.39,50,51
Notably, the intratumor heterogeneity of -catenin localization
and its ability to confer “stemness” to the cancer cell appear to
be conserved in other tumor types including leukemia.52 Loss of
APC function is necessary but not sufficient for nuclear -cate-
nin accumulation and full-blown Wnt-signaling constitutive
activation. Locally secreted growth factors and/or other mor-
phogens are likely to synergistically coactivate Wnt/-catenin
signaling in few APC-mutant tumor cells located in the prox-
imity of stromal compartments.53. Enhanced Wnt signaling
may confer additional plasticity and “stemness” to these puta-
tive CSCs that proliferate in asymmetric fashion, thereby in-
creasing tumor mass, and may induce transdifferentiation (ep-
ithelial-mesenchymal transition), thus facilitating local
invasion and metastasis.
In colon and breast cancer cell lines, growth factors secreted
by the tumor microenvironment or by the tumor itself are
known to activate various receptor tyrosine kinases, some of
which can phosphorylate -catenin at specific tyrosine resi-
dues.54–56 The synergism between KRAS and Apc is also likely to
be explained at the molecular level by KRAS-induced tyrosine
phosphorylation of -catenin. It has been shown that onco-
genic RAS triggers tyrosine phosphorylation of -catenin, lead-
ing to the disruption of its binding to E-cadherin within the
adherens junction complex38,56 and to the subsequent increase
of its intracellular (signaling) pool. Mutant HRAS can also
redistribute the intracellular localization of -catenin from
the membrane to the cytoplasm in a PI3K-dependent fash-
ion,57 and oncogenic KRAS can inhibit GSK3-kinase activ-
ity, dependent on PI3K,58 thus suggesting a connection of
the Ras/PI3K and Wnt-signalling pathways.59,60 Our results
are supportive of the role of oncogenic KRAS in inducing
nuclear accumulation of -catenin and enhanced Wnt-sig-
naling activation, although exclusively in an Apc-mutant
cellular background. Co-IP analysis demonstrated a signifi-
cant reduction of E-cadherin-bound -catenin in tumors
from compound mutant mice as compared with those from
Apc-only mutated animals. Notwithstanding the lack of
Tyr-P -catenin-specific antibodies, the role of tyrosine-phos-
phorylation of -catenin in enhancing Wnt signaling was
analyzed by more indirect methods in ES cells. Treatment of
ES cells with pervanadate, an inhibitor of protein tyrosine
phosphatases, induces a clear shift in the intracellular dis-
tribution of -catenin from the membrane to the nucleus.
Notably, the latter was observed exclusively in Apc-mutant
but not in wild-type ES cells. Accordingly, co-IP analysis
revealed enhanced -catenin tyrosine phosphorylation in
compound KRASV12G/Apc1638N/1638N ES cells when compared
with Apc1638N/1638N cells.
The synergistic activation of specific downstream targets
of the KRAS and Wnt-signaling pathways can also explain
the observed increased multiplicity and aggressive tumor
behavior in compound KRASV12G/Apc/1638N mice. An exam-
ple in human CRC is gastrin, which is synergistically acti-
vated by oncogenic Ras and -catenin.59,60 It is well docu-
mented that the oncogene c-Myc is activated both by
activated RAS, at the protein level, as well as by Wnt/-
catenin signaling at the transcriptional level. Indeed, we have
found that c-Myc transcripts as well as protein levels are
significantly increased in tumors from compound mutant
animals as compared with their control littermates. In con-
clusion, our data show that the coexistence of Apc and KRAS
mutations in CRC synergistically enhances Wnt signaling by
translocating -catenin to the nucleus. Notably, the effect on
-catenin intracellular localization is subtle, although signif-
icant, and seems to affect only a minority of tumor cells.
However, its consequences on tumor multiplicity and pro-
gression toward malignancy of KRASV12G/Apc/1638N mice are
remarkable. The failure to detect significant differential ex-
pression between the transcription profiles of these 2 groups
of tumors by standard microarray analysis raises questions
on the prognostic value of this common molecular ap-
proach.61 The intratumoral heterogeneity is likely to obscure
subtle differences in expression patterns, which may go un-
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detected by standard unsupervised analysis of gene expres-
sion profiles. Also, recent studies have highlighted the rele-
vance of the tumor microenvironment in contributing
specific expression profiles with significant differences in
overall survival62 and tumor promoting effects.63 Omics
analysis of specific subpopulations (eg, cancer stem cells,
other differentiated parenchymal cells, surrounding stromal
fibroblasts) microdissected from clinical samples may pro-
vide more accurate predictions of tumor behavior and re-
sponse to treatment.
Appendix
Supplementary data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1053/
j.gastro.2006.08.011.
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Chapter 3. 
 
 
 
Aneuploidy arises at early stages of Apc-driven intestinal 
tumorigenesis and pinpoints conserved chromosomal loci of 
allelic imbalance between mouse and human. 
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Tumorigenesis and Neoplastic Progression
Aneuploidy Arises at Early Stages of Apc-Driven
Intestinal Tumorigenesis and Pinpoints Conserved
Chromosomal Loci of Allelic Imbalance between
Mouse and Human
Paola Alberici,* Emma de Pater,* Joana Cardoso,*
Mieke Bevelander,* Lia Molenaar,* Jos Jonkers,†
and Riccardo Fodde*
From the Department of Pathology,* Josephine Nefkens Institute,
Erasmus University Medical Center, Rotterdam; and the Division
of Molecular Biology,† The Netherlands Cancer Institute,
Amsterdam, The Netherlands
Although chromosomal instability characterizes the
majority of human colorectal cancers, the contribu-
tion of genes such as adenomatous polyposis coli
(APC), KRAS , and p53 to this form of genetic insta-
bility is still under debate. Here, we have assessed
chromosomal imbalances in tumors from mouse
models of intestinal cancer, namely Apc/1638N,
Apc/1638N/KRASV12G, and Apc/1638N/Tp53/, by
array comparative genomic hybridization. All intesti-
nal adenomas from Apc/1638N mice displayed chro-
mosomal alterations, thus confirming the presence of
a chromosomal instability defect at early stages of the
adenoma-carcinoma sequence. Moreover, loss of the
Tp53 tumor suppressor gene, but not KRAS onco-
genic activation, results in an increase of gains and
losses of whole chromosomes in the Apc-mutant ge-
netic background. Comparative analysis of the overall
genomic alterations found in mouse intestinal tumors
allowed us to identify a subset of loci syntenic with
human chromosomal regions (eg, 1p34-p36, 12q24,
9q34, and 22q) frequently gained or lost in familial
adenomas and sporadic colorectal cancers. The latter
indicate that, during intestinal tumor development,
the genetic mechanisms and the underlying func-
tional defects are conserved across species. Hence,
our array comparative genomic hybridization analy-
sis of Apc-mutant intestinal tumors allows the defini-
tion of minimal aneuploidy regions conserved be-
tween mouse and human and likely to encompass
rate-limiting genes for intestinal tumor initiation and
progression. (Am J Pathol 2007, 170:377–387; DOI:
10.2353/ajpath.2007.060853)
Colorectal cancer (CRC) is caused by a multistep pro-
cess that involves the accumulation of several genetic
defects. Genetic instability facilitates the acquisition of
these multiple gene hits, thus underlying colorectal tumor
progression and malignant transformation. Chromosomal
instability (CIN), in particular, is thought to cause aneu-
ploidy as frequently observed in both sporadic and fa-
milial CRC.1,2
Along the adenoma-carcinoma sequence characteristic
of colorectal tumorigenesis, specific genetic alterations
have been identified. Mutations in the adenomatous pol-
yposis coli (APC) gene are considered as a rate-limiting
step for adenoma formation both in familial (familial ad-
enomatous polyposis; FAP) and sporadic CRCs. Muta-
tions in the KRAS oncogene, found in50% of the cases,
promote growth of the nascent adenomas. Loss of het-
erozygosity (LOH) at specific chromosomal regions, in-
cluding 17p and 18q, characterizes more advanced
stages and is thought to be centered around the TP53
and SMAD4 genes, respectively.
The progressive increase in genetic instability levels
along the adenoma-carcinoma sequence in CRC is likely
to be attributable to the acquisition of mutations in care-
taker genes, such as BUB1, BUBR1, and ATM, with a
broad spectrum of functional activities ranging from sur-
veillance of chromosome segregation, response to DNA
damage, cell cycle regulation, and mitotic checkpoint.
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However, only a few of the above genes have been found
to be mutated in CRC, and the incidence of these muta-
tions is rather low.3–6 Notably, loss of APC function has
been shown to result in structural mitotic defects (ie,
microtubule attachment to the kinetochore and centroso-
mal abnormalities) and in both tetraploidy and aneu-
ploidy, thus triggering CIN at the start of the adenoma-
carcinoma sequence.7–10 Accordingly, low but
significant levels of aneuploid changes have been ob-
served at the adenoma stage both in sporadic and he-
reditary cases.2,11 Notwithstanding the latter, additional
somatic hits seem to be necessary to promote the full-
blown CIN phenotype observed in more advanced
stages of CRC.1
Mouse models carrying targeted Apc mutations pro-
vide unique tools for the analysis of Apc-driven CIN and
for identification of those genes that synergize for CIN
with the Apc tumor suppressor along the adenoma-car-
cinoma sequence.12 However, in contrast to what has
been observed in human intestinal tumors, very few so-
matic mutations, if any, have been reported to occur in
these mouse intestinal tumors; in fact, no Kras or Tp53
mutations have been found in gastrointestinal (GI) tumors
from Apc/1638N animals,13 and no other similar studies
have been reported in the literature. Thus, to humanize
the mouse model, we have bred the Apc/1638N mod-
el14,15 with mice carrying transgenic and targeted muta-
tions at the KRAS and Tp53 genes to generate
Apc/1638N/KRASV12G and Apc/1638N/Tp53/ com-
pound mice. Here, we have used array-based compara-
tive genomic hybridization (array CGH) to evaluate quan-
titative and qualitative aspects of CIN in intestinal tumors
from the above mice when compared with those arising in
the Apc/1638N genetic background. Moreover, we have
performed a cross-species comparison of the chromo-
somal regions more frequently affected by aneuploidy
between adenomas from Apc-mutant mice and FAP pa-
tients carrying germline APC mutations.
Materials and Methods
Mouse Strains and Tumor Samples
The Apc/1638N mice used in this study14 have been
backcrossed to C57BL/6J for more than 20 generations
and are regarded as fully inbred. Apc/1638N animals
were bred with the transgenic model pVillin-KRASV12G
expressing the human KRASV12G oncogene under the
control of the villin promoter.16 Because the latter model
was available in the B6D2 (C57BL/6JxDBA/2) genetic
background, the compound Apc/1638N/KRASV12G ani-
mals used for the present study were backcrossed to
C57BL/6J for five to seven generations to limit confound-
ing effects by undesired genetic modifiers.
For the analysis of the effects of loss of Tp53 function
on Apc-driven aneuploidy, Apc/1638N mice were bred
with Tp53/tm1Tyj (Tp53/) animals carrying a constitu-
tive deletion of the endogenous mouse Tp53 gene.17
Compound heterozygous Apc/1638N/Tp53/ mice were
then intercrossed to generate Apc/1638N/Tp53/ exper-
imental animals.
After macroscopic dissection of the GI, tumors of2 to
3 mm3 in size and normal tissues were snap-frozen in
Tissue-Tec (Sakura Finetek Europe B.V., Zoeterwoude,
The Netherlands) embedding medium in dry ice. Ten-m
sections were briefly stained with hematoxylin and eosin
(H&E), and consecutive sections were carefully laser-
capture microdissected (LCM) using a PALM MicroBeam
microscope system (P.A.L.M. Microlaser Technologies
AG, Bernried, Germany) to limit contaminations from nor-
mal cells and obtain almost pure parenchymal cell sam-
ples. Adenomas were scored as either low or high dys-
plastic according to Boivin and colleagues.18 On
average, 1500 parenchymal cells (900,000 m2 area)
were isolated from each tumor or normal specimen.
DNA Extraction and 29 Amplification
DNA extractions and 29 genomic amplifications were
performed as previously described.19 All samples were
quality-controlled by a polymerase chain reaction (PCR)
to amplify for the mouse Myh gene with the following
primers: mY5-2, 5-CCTGGTGCAAAGGCCTGA-3; and
mYe14, 5-GCAGTAGACACAGCTGCAT-3.
CGH Array, Labeling, and Hybridization
The mouse bacterial artificial chromosome (BAC) mi-
croarray slides here used for array CGH encompass
2803 unique BAC clones at 1 Mb spacing and were
obtained from the Central Microarray Facility of The Neth-
erlands Cancer Institute in Amsterdam.20 DNA labeling
was performed as previously described19 using a mixture
of male genomic DNA extracted from the kidneys of two
C57BL/6J mice as reference DNA. The Cy3-labeled sam-
ple and Cy5-labeled reference DNAs were precipitated
together with 135 g of mouse Cot-1 DNA (Invitrogen,
Breda, The Netherlands). DNA pellets were then redis-
solved in 120 l of hybridization buffer (50% formamide,
10% dextran sulfate, 0.1% Tween 20, 2 standard saline
citrate, and 10 mmol/L Tris-HCl, pH 7.4) together with 600
g of yeast tRNA (Invitrogen). Probe DNA was denatured
for 10 minutes at 70°C and incubated for 1 hour at 37°C
before application on the prehybridized BAC microarray
slides. Array slides were prehybridized for 1 hour at 37°C
with 90 l of denatured hybridization buffer containing
540 g of herring sperm DNA and 90 g of mouse Cot-1
DNA. Hybridizations were performed as previously de-
scribed.21 After hybridization, slides were washed seri-
ally in solution 1 (0.05% Tween 20 in phosphate-buffered
saline) for 10 minutes at room temperature, in solution 2
(50% formamide, 2 standard saline citrate) at 42°C for
30 minutes, and twice in solution 1 at room temperature
for 10 minutes. Finally, slides were spin-dried for 5 min-
utes at 1000 rpm. Image scans and their analysis were
obtained by ScanArray Express HT (Perkin-Elmer Life
Sciences, Boston, MA) and GenePix Pro 5.0 software
(Axon Instruments, Union City, CA), respectively.
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Data Analysis
BAC clone position map annotation and chromosomes
order were according to Ensembl Build m34 (http://
www.ensembl.org/mus_musculus/). All of the data were
normalized using the Marray Tool and vsn packages into
R environment as described elsewhere.2 To facilitate de-
tection of data trends and discriminate gain or loss
events from variation introduced by the whole-genome
amplification technique, we performed smoothing of the
log2 ratio of the normalized data with the aCGH-Smooth
software.22 Bioinformatic data analysis was performed
using the Ensembl mouse genome server (http://www.
ensembl.org/mus_musculus/) and the NCBI mouse ge-
nome resources (http://www.ncbi.nlm.nih.gov/genome/
guide/mouse/). The analysis of mouse/human homology
regions was performed by using the NCBI Comparative
Maps, available at http://www.ncbi.nlm.nih.gov/Homology/.
Array CGH Data Validation by Single Nucleotide
Polymorphism (SNP) Analysis
Selection of SNP markers polymorphic between the
C57BL/6J and 129/Ola strains to be used as validation tools
was performed by consulting the Mouse Genome Informat-
ics (MGI) database (http://www.informatics.jax.org/). DNA
extractions from LCM paraffin-embedded tumor sections
from Apc/1638N F1 129Ola/C57BL/6J mice was performed
as previously described.23 Two sets of primers were used to
analyze SNPs rs3707129, rs3707206, and rs3707619 on
chromosome 4 (Mb128.087890-953) and SNPs rs3704911,
rs3704966, rs4136991, and rs4136994 on chromosome 5
(Mb107.544061-122), where two genomic regions were
found to be frequently affected by gain/loss events. The
primer sequences were as follows: chromosome 4 (for-
ward) 5-GCCTTCTGCTGTGTCTGAAG-3; chromosome 4
(reverse) 5-CCTTCTCTGAGGTTTGCTTGA; chromosome
5 (forward) 5-GGGTGGCCAGACTGTTTTAC-3; and chro-
mosome 5 (reverse) 5-TTCCAAAGGTCCTGAGTTCAA-3.
PCR products were sequenced in both directions using the
same primers. Sequencing was performed on an ABI 3700
capillary sequencer (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions.
Results
Genomic Profiling of Apc/1638N Mouse
Intestinal Tumors by Array CGH
To determine the presence of genomic alterations in mouse
intestinal tumors driven by loss of Apc function, we per-
formed array CGH analysis of LCM intestinal tumors derived
from the Apc/1638N mouse model.14 This method is highly
sensitive and quantitative, and it allows the detection of
chromosomal gains and losses in a small number of micro-
dissected tumor cells with a resolution of 1 Mb.2,19
First, we analyzed 10 mouse intestinal tumors derived
from Apc/1638N animals encompassing both low (n  7)
and high (n 3) dysplastic adenomas but no carcinoma.
Chromosomal aberrations were scored after smoothing
the log2 ratio between normal and tumor DNA by aCGH-
Smooth, a tool for automatic breakpoint identification and
smoothing of array CGH data.22 To exclude putative ar-
tifacts attributable to the  amplification procedure (see
Materials and Methods), we excluded gain/loss events
affecting single BACs. The results are depicted in Figure
1 as a heat-map overview of the chromosomal regions
affected by aneuploidy throughout the tumor and normal
samples analyzed in the study.
The four microdissected normal control samples col-
lected from the intestine of inbred C57BL/6J wild-type
animals displayed near-diploid genomic profiles with no
aberrations in one case and up to two independent aber-
rations (an interstitial gain within chromosome 5 in two
cases, and a loss within chromosome 11 in one case) in the
remaining three cases. The same aneuploid changes were
found in three (chromosome 5 gain) and two (chromosome
11 loss) tumors, respectively, and were accordingly ex-
cluded from all of the subsequent statistical analyses.
All Apc/1638N tumor samples showed chromosomal
number imbalances affecting either whole chromosomes
or interstitial segments with a median of 11 events per
sample (range, 4 to 21; SD  6.5) (Table 1). No differ-
ences were observed in the number of aberrations be-
tween adenomas with high and low dysplasia (median,
12 and 10 events per sample, respectively). Notably, loss
events were more frequent than gains among the tumor
samples, with a median of two gain events per sample
compared with 8.5 losses (P  0.001, Wilcoxon signed
ranks test). Gain of chromosome 1 (Mbp 94-130.6; 4 of 10
tumors) and losses of chromosome 2 (Mbp 25.1-33.7; 6
of 10 tumors), chromosome 4 (Mbp 117.4-153.1; 6 of 10
tumors), chromosome 5 (Mbp 108.5-148.5; 7 of 10 tu-
mors), chromosome 8 (Mbp 121.7-125.9; 7 of 10 tumors),
chromosome 10 (Mbp 80.1-80.6; 8 of 10 tumors), and
chromosome 15 (Mbp 74.6-102.3; 9 of 10 tumors) were
among the most frequently observed alterations (Figure
1). Whole chromosome loss/gain events were observed
in three samples, namely loss of chromosome 8 (sample
Apc9), loss of chromosomes 11 and 7 (sample Apc15),
and loss of chromosomes 11 and 7 and gain of chromo-
some 18 (sample Apc18). The less frequent occurrence
of gain/loss events at chromosome 18, where the Apc
gene has been localized, confirms previous reports indi-
cating that homologous somatic recombination is the
principal pathway for allelic imbalance (AI) in adenomas
in Apc/ mice, leading to duplication of the chromo-
some harboring the Apc mutant allele24 (see Discussion).
Array CGH Validation by LOH Analysis Using
SNPs
To validate the results obtained by array CGH on ampli-
fied LCM tumor samples, we performed LOH analysis by
SNPs in an independent set of Apc/1638N adenomas.
Three sets of primers were designed to amplify the
genomic regions on chromosomes 4 and 5 frequently lost
in the Apc/1638N mouse intestinal tumors. Each set of
primers amplifies a region that contains at least three
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SNPs known to be informative between the mouse strains
C57BL/6J and Ola/129. To this aim, we used an indepen-
dent group of tumors collected from Apc/1638N animals
obtained by breeding C57BL/6J Apc/1638N mice with
Ola/129 wild-type mice (Apc/1638N F1 C57BL/6J 
Ola/129).
The presence of allelic imbalance was evaluated by
direct sequence analysis of the PCR-amplified SNPs.
LOH at chromosome 5 (Mbp 108.5-148.5) was observed
in four of seven tumors (57%) with concordant loss within
the same PCR reaction of the Ola/129 alleles (Figure 2).
Similar results were obtained with chromosome 4 (three
of six, 50%) SNPs. The data not only confirm and validate
the array CGH results relative to loss of distinct loci on
chromosomes 4 and 5 but also indicate that allelic imbal-
ance at these loci is a common event during Apc-driven
intestinal tumorigenesis, acting independently of the ge-
netic background.
Figure 1. Heat map visualization of the CGH results for the three groups of tumors analyzed in the present study. After normalization and two-log smoothing of
the array CGH ratios from the 30 tumor samples and four normal intestinal epithelia, the data were loaded onto SpotFire Decision Site 8.1 to obtain the heat map
here represented. Data are ordered in the X bar according to the sample genotypes as normal (N), Apc/1638N (Apc), Apc1638N/KRASV12G (Ras), and
Apc/1638N/Tp53/ (p53), and in the Y bar according to the chromosome and Mb position of the BAC clones (color code at both sides of the heat map). The
color code of the samples indicates BAC copy number changes: green, loss; red, gain; and black, no change.
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Genomic Profiles of Intestinal Tumors from
Apc/1638N/KRASV12G and Apc/1638N/Tp53/
Animals
The above results indicate that aneuploidy occurs at very
early stages of Apc-driven intestinal tumorigenesis, in
agreement with our own array CGH analysis of human
polyps from patients with germline APC mutations2 but
also with the previously reported APC’s function in mitosis
and chromosomal stability.7,8,16 However, it is plausible
that other genes frequently mutated along the adenoma-
carcinoma sequence contribute, together with APC, to
the full-blown CIN phenotype observed in late-stage CRC
in human. To explore this hypothesis, we performed array
CGH analysis of intestinal tumors from Apc/1638N ani-
mals bred with either a transgenic model carrying the
activated human KRAS oncogene under the control of the
villin promoter (KRASV12G)16 or with a Tp53 knockout
model carrying a targeted null mutation at the endoge-
nous p53 tumor suppressor gene (Tp53/).17 Tumors
from these compound animals recapitulate the genetic
status of the vast majority of human colorectal tumors
during adenoma progression (Apc1638N/KRASV12G) and
at later carcinoma stages (Apc1638N/Tp53/), and are
therefore useful to test the above hypothesis. The phe-
notypic and molecular characterization of these com-
pound models has been described elsewhere.15,25
We performed array CGH analysis on 10 tumors from
each of the compound Apc/1638N/KRASV12G and
Apc/1638N/Tp53/ genotypes, encompassing both low
and high dysplastic adenomas (two low and eight high in
the former, and three low and seven high in the latter).
The results of these analyses are reported in Figure 1 and
Table 1. Intestinal adenomas from Apc/1638N/KRASV12G
animals showed a median of chromosomal alterations of
8.5 events per sample (range, 2 to 25; SD  6.8). The
latter does not significantly differ from the average num-
ber of chromosomal alterations found in Apc/1638N tu-
mors (median, 11 events per sample; range, 4 to 21;
SD  6.5). Moreover, no statistically significant differ-
ences were observed between low and high dysplastic
lesions, although the sample size is admittedly limited
(Table 1). Tumors from Apc/1638N/Tp53/ mice pre-
sented a median of 9.5 gain/loss events per sample
(range, 3 to 19; SD  5.08) with low dysplastic adenoma
characterized by a slight though not significant increase
in the number of genomic imbalances when compared
with the high dysplastic group (median, 15 versus 9).
Moreover, no significant differences were found between
the three groups when loss and gain events were ana-
lyzed separately. However, when gains and losses affect-
ing whole chromosomes were considered, tumors from
Apc/1638N/Tp53/ mice revealed a significant increase
when compared with intestinal lesions from Apc/1638N
(median of one event per sample compared with 0; P 
0.008; Wilcoxon signed ranks test) or Apc/1638N/
KRASV12G (median of one event per sample compared
with 0; P  0.005; Wilcoxon signed ranks test). In addi-
tion, when the total number of gains versus losses for all
three tumor genotypes is taken into consideration, loss
events seem to occur at higher frequency regardless of
genotype (median of eight versus two; P  0.001; Wil-
coxon signed ranks test).
Overall, the array CGH analysis performed on intestinal
tumors from Apc/1638N, Apc/1638N/KRASV12G, and
Apc/1638N/Tp53/ mice led to the identification of several
chromosomal abnormalities, with evidence of intertumor
heterogeneity even among tumors from within the same
genotype (Figure 1). However, we also observed the pres-
ence of recurrent genomic aberrations likely to result from
selection of specific chromosomal regions encompassing
Table 1. Aneuploid Changes Observed in Upper GI Polyps from Apc/1638N, Apc/1638N/KRASV12G, and Apc/1638N/Tp53/ Mice
Genotype
Number of
mice
Mean age
(months)
Number of tumors
analyzed
Medians of gains
and losses/tumor
(range)
Medians of gains
and losses/tumor
according to histology*
Apc/1638N 7 6 10 11.5 (4 to 21)†‡ 1 (L); 10 (H)
Apc/1638N/KRASV12G 7 5 10 8.5 (2 to 25)†§ 9.5 (L); 8.5 (H)
Apc/1638N/Tp53/ 4 3 10 9.5 (3 to 19)‡§ 15 (L); 9 (H)
*Average number of chromosome alterations according to: H, high dysplastic adenomas; L, low dysplastic adenomas.
†P  0.513; ‡P  0.593; §P  0.313; Wilcoxon signed ranks test (two-tailed).
Figure 2. LOH analysis performed on Apc/1638N F1 C57BL/6J  Ola/129
mouse tumors by direct nucleotide sequencing of single nucleotide polymor-
phisms (SNPs) validates the array CGH results. The examples are relative to three
SNPs on chromosome 5: rs3704966, rs4136991, and rs4136994. A: Nucleotide
sequence analysis of SNP rs3704966 showing retention of both alleles in the
tumor sample. B and C: Nucleotide sequence analysis of SNPs rs3704966 or
rs4136991 and rs4136994, respectively, each showing hetero- and hemizygosity
in the normal and tumor DNA samples, respectively. The arrows indicate the
polymorphic nucleotide position for each SNP sequence.
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highly relevant genes for intestinal tumor progression. All of
the chromosomal segments found to be affected by copy
number alterations in at least two independent tumor sam-
ples from two independent groups have been plotted and
are depicted in Figure 3. Specific chromosomal regions of
recurrent aneuploidy are present throughout all three ade-
noma groups; in particular, chromosomes 2, 4, 5, 8, 10, and
15 show copy number alterations in more than 60% of the
samples in at least two distinct genotypes. Notably, a total of
six (20%) allelic imbalance events (gains and losses) were
found at chromosome 18, where the Apc and Smad4 tumor
suppressors are localized.
Comparative Genomic Analysis of Mouse and
Human Intestinal Adenomas Reveals Highly
Conserved Regions of Aneuploidy
To identify chromosomal loci conserved between human
andmouse that recurrently undergo gain/loss events during
intestinal tumor progression, we performed a comparative
analysis of the mouse array CGH profiles with those derived
from our previous array CGH analysis of early adenomas
from FAP patients carrying established APC mutations.2 To
this aim, we used the human-mouse comparative maps
available through the National Center of Biotechnology In-
formation, National Institutes of Health (http://www.
ncbi.nlm.nih.gov/Homology/). Based on the analysis of the
homologous segments, the vast majority of the numerical
chromosomal changes found in the mouse correspond to
chromosomal regions of frequent allelic imbalance among
FAP adenomas (Table 2). Notably, chromosomal regions
with the highest deletion frequencies among mouse intesti-
nal tumors are syntenic to human chromosomal regions with
the highest LOH incidence in FAP polyps. Mouse chromo-
somes 4 and 15 for instance, harbor several regions that are
orthologous to human chromosome 1p34-p36 and 22q12-
q13, respectively, both known to be lost in human FAP
adenomas with a percentage that varies between 67 to
75%. In some cases, the analysis of the homology region
between mouse and human chromosomal regions of allelic
imbalance allows the definition of a minimal common re-
gion, thus providing a powerful gene-discovery tool (see
Discussion).
Discussion
Extensive genome-wide chromosomal alterations, indic-
ative of CIN, characterize the vast majority of human
CRCs.26,27 However, the molecular basis of CIN in CRC
is still poorly understood, and although a number of
genes have been characterized that may underlie aneu-
ploidy (eg, BUB1, BUBR1, and CDC4),5,28,29 the fre-
quency at which mutations have been found in their
coding regions is too low to justify the high CIN incidence
found in human CRC.29 Notably, loss of APC function
results in microtubule plus-end attachment defects dur-
ing mitosis and consequent chromosome misalignment
and CIN.7–9 These observations, made in cultured mam-
malian cells, indicate a potential role for the APC tumor
suppressor gene in triggering CIN right from the start of
Figure 3. Overview of the chromosome copy
number changes throughout the 30 mouse in-
testinal tumors analyzed in this study. Total
numbers of all significant gains or loss regions
found to be affected by copy number alterations
in more than or equal to two tumor samples
from at least two independent groups have been
plotted separately according to the tumor geno-
type. Complete or partial chromosome gains
and losses are shown separately. Regions are
ordered according to their mapped positions
along the chromosomes. G, gain; L, loss of the
corresponding regions.
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the adenoma-carcinoma sequence. Accordingly, our ar-
ray CGH analysis of early-stage adenomas from FAP
patients carrying germline APC mutations2 and from Apc-
mutant mouse models (this study) confirm that aneu-
ploidy is indeed found in nascent benign tumors.
It is generally accepted that the main tumor-suppressing
activity of the APC gene resides in its capacity to regulate
intracellular -catenin levels as part of the canonical Wnt
signal transduction pathway.1 Hence, the observation that
aneuploidy occurs at very early stages of the adenoma-
carcinoma sequence is in agreement with a model in which
the initial loss of APC function triggers intestinal tumor for-
mation by constitutive activation of Wnt/-catenin signaling
and simultaneously results in a low but significant level of
CIN. At later stages of tumor progression, somatic muta-
tions in genes involved in mitotic and cell cycle check-
points, telomere shortening and telomerase expression,
centrosome number regulation, and double-strand break
repair may work synergistically with the kinetochore and
chromosome segregation defects caused by APC mutation
in eliciting full-blown CIN.1,10
Overall, our array CGH analysis has revealed chromo-
somal aberrations in each of the 30 mouse GI polyps
analyzed. Even in the case of small low dysplastic
Apc/1638N adenomas (2 mm3), an average of 12 events
(gains and losses) per tumor sample is found. Notably,
both in Apc/1638N as well as in FAP adenomas, loss
events were more frequently observed than gains.2 This
relatively high incidence of aneuploid changes at very
early stages of the adenoma-carcinoma sequence ap-
pears to be in contrast with previous reports in which
intestinal adenomas from Apc/Min mice30 and from FAP
patients with known APC mutations31 were shown to have
stable karyotypes. This apparent discrepancy is likely to
result from the different methods used in these studies.
Conventional karyotype analysis and fluorescence-acti-
vated cell sorting are less sensitive than array CGH in
detecting more subtle subchromosomal changes leading
to allelic imbalance. Accordingly, by using a more sen-
sitive PCR-based method, Shih and colleagues11 also
reported widespread allelic imbalance in human spo-
radic adenomas. As shown in the present and previous
study,2 the quantitative analysis of genomic changes by
coupled LCM and whole genome BAC arrays, allows the
detection of gain/loss events in small intestinal lesions (1
to 2 mm2) with relatively high sensitivity and without the
noise introduced by contaminating normal lymphocytes
and stromal cells.
Although our results do not allow us to speculate on the
mechanisms underlying this early genomic instability, we
have established that aneuploid changes are observed at
early stages of APC/Apc-driven intestinal tumorigenesis in
both human2 and mouse (this study). The question remains
whether this genomic instability precedes the rate-limiting
second hit at the Apc gene or it arises as a consequence of
it. In the mouse genome, the Apc gene maps to chromo-
some 18. In agreement with the Knudson’s two hit model,
the vast majority of intestinal tumors from Apc-mutant mice
show LOH at the chromosome 18 region encompassing the
wild-type Apc allele.13,32,33 As elegantly shown by Haigis
and Dove,24 somatic mitotic recombination (and not aneu-
ploidy) is the principal mechanism underlying loss of the
wild-type Apc allele in the Apc/Min mouse model. Because
mitotic recombination does not affect copy number, it can-
not be detected by array CGH analysis. Accordingly, our
array CGH analysis revealed aneuploidy at chromosome 18
only in a minority of adenomas from Apc/1638N (10%) and
from Apc/1638N/KRASV12G and Apc/1638N/Tp53/ (25%)
animals. Hence, our results indirectly confirm that, in the
majority of the cases, the rate-limiting LOH event at the Apc
locus does not occur by interstitial deletion or nondisjunc-
tion, and is likely to result from mitotic recombination as
shown for Apc/Min. However, aneuploid changes at the
Apc locus on chromosome 18 still take place in a fraction of
the intestinal adenomas initiated by the Apc1638N targeted
mutation, possibly as the result of low but significant CIN
levels. That APC mutations may act in a dominant-negative
manner in elicitingmitotic defects9,34 may underlie the chro-
mosome 18 aneuploid changes observed by array CGH in
adenomas from Apc/1638N. In these cases, genomic insta-
bility may even precede the rate-limiting second hit at the
wild-type Apc allele. Nevertheless, in the majority of the
cases, more significant CIN levels will occur only on com-
plete loss of Apc function, ie, after the somatic hit.
During the adenoma-carcinoma progression in CRC,
genetic instability progressively increases with the accu-
mulation of somatic mutations at specific tumor suppres-
sor genes and oncogenes.35 The occurrence of KRAS
mutations already at early adenoma stages36–38 sug-
gests the possibility that this oncogene may partly con-
tribute to CIN. In fact, few studies have reported positive
correlations between KRAS mutations and aneuploidiza-
tion.39,40 It has been postulated that constitutive KRAS
activation may induce genomic instability via the mito-
gen-activated protein kinase (MAPK) pathway, which af-
fects G1 and G2/M cell-cycle transit times and apopto-
sis.41 Moreover, KRAS can also have a role in
cytoskeletal and microtubule organization of the mitotic
spindle, through the regulation of Rho-like GTPases.42
Notwithstanding these data, our results do not demon-
strate any increase in the incidence and type of allelic
imbalance in tumors from compound Apc/1638N/
KRASV12G mice when compared with Apc/1638N ani-
mals. These results are also corroborated by other stud-
ies on human CRC: no association was found between
the mutational status of the KRAS gene and the number of
chromosomal aberrations43 or genomic instability.44
The case for loss of p53 function and CIN is a more
solid one. First, the p53 tumor suppressor protein has a
well-characterized role as DNA damage checkpoint.45
Moreover, several cancers characterized by aneuploidy
harbor p53 mutations both in human46–48 and in mouse
models.49 Loss of p53 function is also known to result in
an increase in tetraploid and polyploid cells.50,51 Al-
though the CGH array technique used here does not
allow to detect tetraploidy, our results indicate a signifi-
cant increase in whole chromosome gains and losses
among Apc/1638N/Tp53/ adenomas when compared
with tumors from Apc/1638N and Apc/1638N/KRASV12G
mice. It has been shown that p53-deficient cells fail to
arrest in G1 leading to tetraploidization and, on further
progression through the cell cycle, to abnormal mitoses
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Table 2. Analysis of the Mouse-Human Chromosome Synteny and Incidence of Genomic Aberrations in Intestinal FAP Adenoma
and Sporadic CRC
Mouse
chromosome
segment (Mbp)
Incidence
in mouse
adenomas
Human syntenic
region (cytogenetic
band)
Incidence in human FAP2 Incidence in human CRC68–73*
As gain As loss As gain As loss
Gains
1 (94 to 130) 33% 5q21 18q21q22-q23
2q12-q13-q14
2cen-q13 2q21-
q22
5q21 (13%) 18q
(4%)
5q (16%) 18q (42%)
2q (6%)
4 (117 to 153) 6% 1p34-p36 1p36 (57%) 1p
(75%)
1p (17%)
8 (whole chr.) 6% 13q33-q34-q14
8p21-p22-p23-p11
4q31-q32-q33-
q34-q35–21-q28
19p13-p12 22q13
16q11-q12-q13
16q21-q22-q23-
q24 1q42 10p11
1q42 (8%)
10p (2%)
13q (4%) 8p (2%)
19p (73%)
22q13 (63%)
16q (8%) 1q42
(4%)
22q13 (5%)
16q (7%)
8p21p22 (28%)
4q31-q34 (21%)
11 (whole chr.) 6% 22q12 17q25 7p12-
q13
7p (8%) 22q (67%) 17q25
(33%)
22q (6%)
13 (0 to 40) 12% 10p14-p15 1q41-
q42-q43 7p14-p15
6p21-p22-p24-p14
7p (19%) 10p (2%) 1q (4%) 7p (35%) 6p21
(7%)
18 (13 to 23) 12% 18q11-q13 18q (4%) 18q (42%)
18 (whole chr.) 6% 10p11 18q11-q12
2q13-q13-q21
5q21-q22-q23-
q31-q32-q33
18p11-q21-q22-
q23
18q (2%) 10p (2%) 18q (4%)
5q (12%) 18q21
(4%)
18q (42%) 5q (16%)
18p (26%) 18q21
(60%)
Losses
2 (25 to 33) 50% 9q34 9q (36.5%) 9q (8%)
2 (152 to 181) 30% 20q11-q13 20q (36.5%) 20q13 (50%)
4 (117 to 153) 56% 1p34-p36 1p36 (57%) 1p
(75%)
1p (17%)
5 (114 to 148) 66% 12q24 13q12 7p11-
p22-q11-q22
7p (19%)
7q (19%)
12q (50%) 13q
(7.7%)
13q (12%)
7 (0 to 23) 16% 19q13 19q13 (68%)
7 (whole chr.) 16% 19q13 11p15-p14
15q11 2p13 15q26
11q13-q14-p15
16p11-p12-p13
1-q26
19q13 (68%) 15q
(4%) 16p (2%)
16q (8%)
11q (43%)
16p13 (5%)
8 (121 to 125) 63% 16q24 1q42 1q (8%) 16q (8%) 1q (4%)
10 (80.1 to 80.6) 86% 19p13.3 19p (73%)
11 (whole chr.) 20% 22q12 17q25 7p12-
q13
7p (8%) 22q (67%) 17q25
(33%)
7p (25%) 22q (6%)
11 (117 to 118) 60% 17q25 17q (42%) 17q25 (14%)
13 (whole chr.) 10% 10p15 1q41-q42-q43
7p14-p15 6p21-
p22-p23-p24-p25
9q21-q22 5q34-
q35-q31 9q21-q22
8q22 5p15 5q11-
q12-q13- q14-q15
7p (19%)
8q (2%)
10p (2%) 1q (4%)
5q (14%) 5q
(11%) 8q (15%)
7p (35%) 6p21
(7%) 9q21
(6%) 8q
(63%) 5p
(4%)
5q (16%)
13 (48 to 69) 10% 5q34-q35-q31 9q21-
q22 8q22 5p15
5q (14%) 8q (15%) 9q21 (6%) 8q
(63%) 5p
(4%)
5q (16%)
15 (74 to 102) 70% 22q12-q13 12q12-
q13
22q (67%) 12q
(50%)
12q (5%) 12q (15%)
17 (whole chr.) 6% 6q25-q27 5q15
19q13 6p21 21q22
10p13 7p21-p22
3p24 19p13 5q21
18p11 2p21-p22-
p23-p16 18p11
7p (20%) 19p (73%) 5q
(12%) 19q13
(58%) 21q (10%)
5q (16%) 7p
(25%)
5q (16%) 7p (25%)
17 (21 to 32) 20% 19p13 19p (73%)
(table continues)
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and aneuploidy.52 This mechanism seems to be corrob-
orated by the increased incidence of whole chromosome
loss and gain in p53-deficient intestinal tumors.
The array CGH analysis of mouse intestinal adenomas
revealed a number of chromosomal loci where allelic
imbalances recurrently occur in independent tumors and
throughout the three genotypes. It is therefore likely that
mutations in genes encompassed within these chromo-
somal regions are selected at early developmental
stages of intestinal tumor onset and progression. How-
ever, the chromosomal intervals affected by these recur-
rent aneuploidy events are usually very large, which
makes the identification of individual genes underlying
tumor onset and progression a formidable task. Through-
out the mouse intestinal adenomas analyzed here, loss of
chromosome 10 (Mb 80.1 to 80.6) and of the distal region
of chromosome 15 (Mb 74.6 to 102.3) were the most
frequent alterations with frequencies of 86 and 70%, re-
spectively. The limited size (500 kb) delineated by the
loss events within chromosome 10 somewhat facilitates
the search for putative candidate cancer-related map-
ping within the Mb 80.1 to 80.6 interval. In silico analysis
of the mouse genome sequence (http://www.informatics.
jax.org/) revealed 40 annotated expressed sequences,
26 of which are known genes. The localization of the
Stk11 gene within this region is of particular interest in
view of the causative role of this serine/threonine kinase
in Peutz-Jeghers syndrome, an inherited susceptibility to
intestinal cancer characterized by multiple hamartoma-
tous polyps throughout the upper GI tract and a high risk
of developing cancer in the intestine and other organs.53
To further restrict the size of the chromosomal intervals
affected by gain/loss events and pinpoint specific con-
served genes that play rate-limiting roles in intestinal
adenoma formation in the mouse and human, we com-
pared array CGH profiles from early FAP adenomas (ob-
tained from carriers of known APC germline mutations)
and from histology-matched intestinal tumors from
Apc/1638N mice. The results of this comparative anal-
ysis (Table 2) have indicated the presence of a sur-
prisingly high number of chromosomal aberrations
shared between mouse upper GI and human colorectal
adenomas, notwithstanding the different anatomical lo-
cation of these two groups of GI tumors. The above-
mentioned mouse chromosome 10 region (Mb 80.1 to
80.6), where aneuploid changes have been observed
in 86% of the mouse adenomas here analyzed, is or-
thologous to human chromosome 19p13.3, where LOH
has been reported in 73% of FAP adenomas. Besides
STK11, also the APC2 gene,54,55 previously proposed
as potential tumor suppressor gene in ovarian and lung
cancer,56,57 map to the 19p13.3 chromosomal interval.
Another example is provided by the interval on mouse
chromosome 15 (Mb 74 to 102), the second most fre-
quent (70%) site of allelic imbalance in tumors from
Apc/1638N mice. This region is syntenic to human chro-
mosomes 22q12-q13 and 12q12-q13, both previously
reported to undergo LOH in FAP adenomas at high fre-
quencies (67 and 50%, respectively).2 Notably, at least
three genes with known tumor suppressor functions in the
GI tract map in human to chromosome 22q13. ST13
(suppression of tumorigenicity 13) maps to chromosome
22q13.2 and was reported to be down-regulated in CRC
tissue when compared with its expression in adjacent
normal tissue.58 Bi-allelic mutations of p300, a transcrip-
tional co-activator binding E1A also localized to chromo-
some 22q13.2, have been shown in several human can-
cers. In particular, this gene seems to function as a tumor
suppressor gene in the intestinal epithelium,59 and mu-
tations in its coding region are found at high frequency
among CRC cell lines.60 NBK/BIK is another putative
tumor suppressor gene localized within a 0.5-cM region
of chromosome 22q13 known as the target of frequent
allelic loss in human CRC.61 The proapoptotic function of
this BCL-2 family member indeed suggests a role in
tumor suppression for this protein.62
The frequently lost interval on mouse chromosome 4
(Mb 117 to 153) is orthologous to human chromosome
1p34-p36. Among FAP adenomas, chromosome 1p36
shows loss in 60% of the cases,2 thus restricting the
candidate tumor suppressor genes in this 24-Mb region,
to a total of 392 transcripts. Among these, the meningi-
oma suppressor gene ALPL,63 the prostate cancer sus-
ceptibility gene HSPG2,64 and CASP9, a proapoptotic
Table 2. Continued
Mouse
chromosome
segment (Mbp)
Incidence
in mouse
adenomas
Human syntenic
region (cytogenetic
band)
Incidence in human FAP2 Incidence in human CRC68–73*
As gain As loss As gain As loss
18 (whole chr.) 6% 10p11 18q11-q12
2q13-q13-q21
5q21-q22-q23-
q31-q32-q33
18p11-q21-q22-
q23
10p (2%) 18q (4%)
5q (12%) 18q21
(4%)
18q (42%) 5q (16%)
18p (26%) 18q21
(60%)
18 (30 to 93) 13% 18q11-q12 2q13-
q13-q21 5q21-
q22-q23-q31-q32-
q33 18p11-q21-
q22-q23
18q (4%) 5q (12%)
18q21 4%)
18q (42%) 5q (16%)
18p (26%) 18q21
(60%)
19 (0 to 9.4) 53% 11q11-q12-q13 11q (19%)
11q13 (43%)
*Results are described in References 68 to 72 and are summarized in Reference 73.
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component of the caspase cascade,65 represent inter-
esting and worth investigating candidates.
In addition, the mouse chromosome 2 region (Mb 25 to
33) lost in 50% of the Apc1638N adenomas, is syntenic with
human chromosome 9q34. Again, chromosome 9q is fre-
quently lost among FAP polyps.2 The additional information
obtained from the analysis of mouse intestinal tumors allows
restriction of the search for candidate tumor suppressor
genes to the chromosome 9q34 interval where cancer-
related genes such as TSC1 (tuberous sclerosis 1)66 and
DAPK1 (death-associated protein kinase 1),67 are known to
be localized. The use of additional comparative tools, such
as expression profiling analysis, is likely to further pinpoint
critical genes among the still large number of transcripts
(n  227) mapping to this subchromosomal region.
In conclusion, we have shown that allelic imbalance
and aneuploid changes occur at early stages of Apc-
driven intestinal tumorigenesis in mouse. Whereas intro-
duction of an oncogenic KRAS mutation does not alter the
overall frequency and type of aneuploid changes, loss of
Tp53 function increases the incidence of whole chromo-
some loss and gain events. Notably, the chromosomal
intervals frequently affected by aneuploid changes in
Apc-mutant tumors are syntenic to genomic regions
known to be frequently lost or gained in adenomatous
polyps from FAP carriers of germline APC mutations. This
comparative genomic profiling approach, when com-
bined with gene expression signatures from human and
mouse tumors and coupled with functional tumor sup-
pression assays, will allow the identification of novel
genes involved in intestinal tumor onset and progression.
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The Smad4þ /E6sad mouse carries a null mutation in the
endogenous Smad4 gene resulting in serrated adenomas
and mixed polyposis of the upper gastrointestinal (GI)
tract with 100% penetrance. Here, we show by loss of
heterozygosity (LOH) analysis and immunohistochemis-
try (IHC) that, although the majority of the tumors
appear at 9 months of age, somatic loss of the wild-type
Smad4 allele occurs only at later stages of tumor
progression. Hence, haploinsufficiency underlies Smad4-
driven tumor initiation in the GI tract. As both the Apc
and Smad4 tumor suppressor genes map to mouse
chromosome 18, we have bred Smad4þ /E6sad with the
Apcþ /1638N model to generate two distinct compound
heterozygous lines carrying both mutations either in cis
(CAS) or in trans (TAS). Strikingly, both models show
increased tumor multiplicities when compared with the
single mutant littermates, although CAS mice are more
severely affected and became moribund at only 5–6 weeks
of age. Phenotypic and molecular analyses indicate that
Smad4 haploinsufficiency is sufficient to significantly
affect tumor initiation and progression both prior to and
upon loss of Apc function. Moreover, complete loss of
Smad4 strongly enhances Apc-driven tumor formation.
Oncogene (2006) 25, 1841–1851. doi:10.1038/sj.onc.1209226;
published online 14 November 2005
Keywords: Smad4; Apc; haploinsufficiency; TGF-b sig-
naling; LOH; Wnt signaling; gastrointestinal cancer
Introduction
Loss of heterozygosity (LOH) and point mutations at
the SMAD4/DPC4 tumor suppressor gene, a key signal
transducer in the TGF-b and BMP signaling pathways,
are usually found at late stages of sporadic colorectal
cancer (CRC) (Takagi et al., 1996; Thiagalingam et al.,
1996; Koyama et al., 1999). In the classical adenoma-
carcinoma progression sequence originally proposed for
CRC by Fearon and Vogelstein, loss of APC function
triggers tumor initiation, followed by constitutional
activation of the KRAS oncogene during adenoma
progression, and by loss and mutation of the SMAD2/4
and TP53 tumor suppressors at chromosome 18p and
17q, respectively, at more advanced stages of adenoma
growth and malignant transformation (Fearon and
Vogelstein, 1990). On the other hand, germline muta-
tions of the SMAD4 gene are responsible for a subset of
familial Juvenile Polyposis (JP), an autosomal dominant
predisposition to the development of multiple hamarto-
matous polyps and GI cancer (Howe et al., 1998).
In order to elucidate the role played by SMAD4 in
intestinal tumor initiation and progression, several
mouse models have been generated that carry targeted
inactivating mutations in the endogenous mouse Smad4
gene (Sirard et al., 1998; Takaku et al., 1999; Xu et al.,
2000). In all cases, homozygosity for the Smad4
mutation results in embryonic lethality prior to E9.5
due to defects in gastrulation and mesodermal develop-
ment. Heterozygous Smad4þ / mice develop gastric and
duodenal tumors with features reminiscent of human
juvenile polyps. Notably, Xu and co-workers detected
LOH at the Smad4 locus only at late stages of tumor
progression, namely in large dysplastic polypous
tumors.
More recently, our laboratory has reported the Sad
(Smad4E6sad) mouse model, characterized by a null
mutation of the mouse Smad4 gene, namely a single-
nucleotide deletion in the exon 6 splice acceptor site
resulting in an unstable mRNA and undetectable levels
of the Smad4 protein (Hohenstein et al., 2003). Older F1
(129OlaC57BL/6) Smad4þ /E6sad animals are predis-
posed to late-onset (18 months) serrated adenomas and
mixed adenomatous and hyperplastic polyps, mainly
localized immediately distal to the pyloric/duodenal
transitional area. In our original report, LOH of the
wild-type Smad4 gene could only be assessed in mice
older than 18 months and it was found in the majority of
tumors collected from Smad4þ /E6sad mice. To address the
issue of haploinsuffciency in Smad4-driven intestinal
tumorigenesis, we now have closely monitored inbred
C57BL/6J (F5-F8 backcross generation) Smad4þ /E6sad
mice at different ages, from 6 to 18 months, to evaluate
the onset of the tumor formation and of Smad4 LOH
during tumor initiation and progression.
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Furthermore, to examine the role of Smad4 status
in Apc-driven intestinal tumorigenesis, we bred the
SmadE6sad mutation with the Apcþ /1638N model, pre-
viously developed and characterized in our laboratory
(Fodde et al., 1994). As both Apc and Smad4 map to
mouse chromosome 18, two different Apcþ /1638N/
Smad4þ /E6sad compound heterozygous models were
generated, in trans (mutations on different chromo-
somes) and, by meiotic recombination, in cis (mutations
on the same chromosome).
Phenotypic and tumor analysis of the compound
Apcþ /1638N/Smad4þ /E6sad mice indicates a differential role
for Smad4 in combination with the mutated Apc in
intestinal tumor initiation and progression.
Results
GI tumor incidence, distribution, and histopathology
in Smad4þ /E6sad mice
We previously described the identification and initial
characterization of the Smad4þ /E6sad mouse model
(Hohenstein et al., 2003), characterized by hyperplastic
and serrated adenomas resulting from a germline null
mutation at the endogenous Smad4 gene. To provide a
more detailed characterization of their phenotype and
pattern of GI tumor initiation and progression in a
genetic background comparable to the other described
models (Sirard et al., 1998; Takaku et al., 1999; Xu
et al., 2000), Smad4þ /E6sad mice were backcrossed for 5–8
generations to C57BL/6JIco and analysed at the age of
6, 9, 12, 15 and 18 months. For each time point, at least
nine mice of both genders were analysed. Microscopic
examination of the GI-tract in 6-month-old mice did not
reveal any neoplastic lesions, thus confirming the late-
onset nature of the tumor phenotype in this model (not
shown). However, already at 9 months, 100% of the
Smad4þ /E6sad mice analysed revealed the presence of
polyps in the stomach (fundus) (Table 1). At the same
age, tumors were also found in the peri-ampullary
region in approximately 50% of Smad4þ /E6sad mice. At
age 12 months and older, the latter proportion increases
up to 80–100% of the animals, while a subset (3/11, 27%
at 12 months; 3/10, 30% at 15 months; 6/9, 66% at 18
months) showed carpeting (here defined as an area
where an extremely high polyp density did not allow
counting) of the whole pyloric/duodenal transition area
with polyps.
Additional tumors were found throughout the rest of
the small intestinal tract (duodenum, jejunum, and
ileum) starting from age 9 months, whereas colorectal
polyps were only found in few animals at later stages
(1/10, 10% at 15 months; 2/9, 22% at 18 months).
The average number of gastric polyps per mouse did not
increase over time though a slight increase in gastric
tumor size was observed (from 3mm71 at 9 months up
to 8mm72 at 18 months). The number of polyps
present throughout the entire intestinal tract clearly
increased over time, from an average of 3 at 9 months to
9 at 18 months of age. Analysis of these tumors by
histopathology confirmed previously observed features:
polyps were hyperplastic with branching villi (Figure 1a)
and occasionally with serrated aspects. In the more
advanced cases, dilated cysts and foci of frank dysplasia
with increased nuclear cytoplasmic ratio and nuclear
stratification of the cells were present (Figure 1b).
Macroscopic examination of >1-year-old Smad4þ /E6sad
animals did not reveal the presence of tumors in other
tissues/organs including the pancreas.
Haploinsufficiency at the Smad4 gene in GI tumors from
Smad4þ /E6sad mice
To investigate the role of LOH as a tumor-initiating
event in the Smad4þ /E6sad mouse model, a total of 50
tumors and normal controls were analysed both by
DNA- and protein-based methods. To enrich in tumor
DNA, DNA samples were isolated from tumor cells
obtained by laser capture microdissection (LCM) of
histological sections. For each age group, from 9 to 18
months of age, at least 10 tumors and two normal
intestinal tissue controls, were microdissected by LCM
for DNA isolation. LOH of the wild-type Smad4 allele
was established using two CA repeat markers, d18Mit81
and d18Mit80, located, respectively, 7 cM proximal and
2 cM distal to the Smad4 gene on chromosome 18, as
previously described (Hohenstein et al., 2003).
LOH of the Smad4 allele was not detected in polyps
from Smad4þ /E6sad mice up to 15 months (Table 2). At
Table 1 Incidence and distribution of intestinal neoplasia in Smad4E6sad mice at different time points
No. of
mice
Age
(months)
Incidence
(%)
Tumor multiplicity/
animal
Tumor
range
Histology Tumor localization
9 6 0 — — — —
10 9 100 3 2–5 Hyperplastic polyps S: 100%; P: 50%; D: 10%; J: 30%; I: 0%;
C:0%
10 12 100 5 2–7 Hyperplastic polyps S: 100%; P: 80%; D: 10%; J: 0%; I: 10%;
C: 0%
10 15 100 7 4–12 Low dysplastic polyps S: 100%; P: 100%; D: 20%; J: 20%; I: 40%;
C: 10%
9 18 100 9 3–13 Low dysplastic polyps S: 100%; P: 100%; D: 10%; J:10%; I: 11%;
C: 22%
Tumor localization: incidence of one or more lesions in the corresponding part of the intestinal tract: S¼ stomach, P¼ periampullar region,
D¼duodenum, J¼ jejunum, I¼ ileum, C¼ colon.
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Figure 1 Histopathology and immunohistochemical analysis of Smad4E6sad small intestinal polyps at different ages and progression
stages. (a) Polyp originated in the gastric epithelium from a 12-month- old Smad4þ /E6sad animal. Inset: higher magnification of a
hyperplastic region. Note the gastric epithelium (HE). (b) Advanced polyp from a 15-month-old Smad4þ /E6sad mouse showing areas of
frank dysplasia. Inset: higher magnification of a dysplastic region (HE). (c) Smad4 IHC analysis of normal small intestinal epithelium
from an Smad4þ /E6sad animal shows nuclear and cytoplasmatic staining with a crypt-villus decreasing gradient of expression. The
aspecific staining in the lamina propria is due to mouse IgG cross-reaction from the secondary antibody. (d) Smad4 IHC analysis of a
tumor from a 12-month-old Smad4þ /E6sad mouse shows positive staining of tumor cells. Staining of stromal cells is due to mouse IgG
cross-reaction from the secondary antibody. (e) Smad4 IHC analysis of a tumor from a 15-month-old Smad4þ /E6sad mouse shows
an area of negatively stained parenchymal cells within an otherwise positive tumor. (f) b-Catenin IHC analysis of a tumor from a
15-month-old Smad4þ /E6sad animal. The more dysplastic area of the lesion mainly shows membranous staining.
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this age, four out of 10 (40%) tumors showed LOH. In
older mice (18 months), the fraction of tumors present-
ing LOH at the Smad4 locus increases (9/14: 64%) in
accordance with our own previously published results
obtained with mice older than 18 months (Hohenstein
et al., 2003).
In the majority of the cases (n¼ 10/10 LOH negative
and n¼ 7/10 LOH positive), the above data could
be confirmed by direct sequence analysis of the Smad4
gene amplified by PCR from tumor DNA samples.
The frameshift visible in the chromatogram of an
Smad4þ /E6sad normal mucosa control sample and due to a
single-nucleotide (A) deletion in the exon 6 splice acceptor
site of the mutated allele, is lost or clearly reduced in the
tumor samples previously shown by CA repeat markers to
carry LOH at the Smad4 locus (Figures 2b and c).
To further confirm the observed haploinsuffciency
and late-onset LOH in Smad4E6sad GI tumors, we
performed immunohistochemistry (IHC) on tumor
sections with a Smad4-specific antibody (B-8; see
Material and methods) (Wilentz et al., 2000; Salovaara
et al., 2002). Normal gastric and small intestinal mucosa
displayed positive staining for Smad4 in all cases,
although the intensity of expression was reduced in
gastric mucosa when compared to the intestinal
epithelium. In the latter, a gradient of expression was
observed along the crypt-villus axis, with strong positive
nuclei in the crypt, and cytoplasmic staining in the apical
part of the villus, similar to the pattern reported by
Salovaara et al. (2002) in normal human colonic mucosa
(Figure 1c).
Tumors derived from Smad4þ /E6sad mice up to 12
months of age showed in all cases (n¼ 4) positive
staining for the protein (Figure 1d). Only in few tumors
collected at 14 and 15 months of age (1/6 and 2/5,
respectively), loss of Smad4 protein expression was
detected in a ‘patchy’, heterogeneous pattern: Smad4-
negative foci were scattered among otherwise positive
tumor cells (Figure 1e) (Table 2).
Overall, the results of our LOH and IHC analyses
of GI tumors from Smad4þ /E6sad mice at different
ages are consistent with the idea that complete
loss of Smad4 function is a late event in tumor
progression.
Table 2 LOH and IHC analysis of Smad4E6sad intestinal tumors
Age (months) No. of tumors LOH incidence IHC staining
6 NA NA NA
9 10 0/10 (0%) +
12 10 0/10 (0%) +
15 10 4/10 (40%)  (patchy)
18 14 9/14 (64%)  (patchy)
NA, not applicable.
Figure 2 LOH analysis by direct sequencing of the Smad4 intron
5–exon 6 boundary from tumor and normal DNA samples. The
arrow indicates the nucleotide position (A) deleted in the
Smad4E6sad allele. (a) Wild-type sequence from normal intestinal
epithelium. (b) Heterozygous sequence from a normal mucosa of a
Smad4þ /E6sad mouse. (c) Loss of the wild-type Smad4 allele in
intestinal tumor from an 18-month-old Smad4þ /E6sad mouse. (d)
Loss of the Smad4E6sad allele in a TAS tumor. (e) Loss of the wild-
type Smad4 allele in a CAS tumor.
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It is well established that constitutive activation of the
Wnt/b-catenin signal transduction pathway, caused by
either Apc or Ctnnb1 (b-catenin) mutations, represents a
rate-limiting event in intestinal tumor formation. b-
Catenin nuclear accumulation is the hallmark of Wnt
signaling activation and was analysed by IHC on tumor
sections from Smad4þ /E6sad mice. No b-catenin nuclear
accumulation was observed in Smad4þ /E6sad tumors, even
at later stages of tumor development, thus indicating
that Wnt signaling does not play a major role in Smad4-
driven intestinal tumorigenesis (Figure 1f).
Tumor incidence and distribution in Trans (TAS) and Cis
(CAS) Apcþ /1638N/Smad4þ /E6sad compound mutant mice
To further investigate the role of the Smad4 gene in GI
tumor initiation and progression, we have bred Smad4þ /
E6sad mice with the Apcþ /1638N mouse model, previously
developed in our laboratory (Fodde et al., 1994). In the
mouse genome, both the Apc and Smad4 tumor
suppressor genes are located on chromosome 18.
Therefore, two different types of compound hetero-
zygous mice were generated: in Trans Apcþ /1638N/
Smad4þ /E6sad (TAS), where the two mutations are
present on two different chromosome 18 alleles, and in
Cis Apcþ /1638N/Smad4þ /E6sad (CAS), obtained by back-
crossing TAS animals with C57BL/6 mice. In agreement
with the genetic distance between the two tumor
suppressor loci (33 cM), the two mutations were found
on the same chromosome 18 allele in approximately
15% of the offspring.
The TAS and CAS mouse models showed distinctive
phenotypes when compared to the single mutation
littermates (Table 3) (Figure 4). For the present study,
we analysed eight TAS (four female and four male
subjects) and seven CAS (two female and five male
subjects) mice.
The TAS lineage is characterized by a normal
development, growth, and adult size. At age 6–7
months, mice present with an average of 20 tumors
along the GI tract (range: 12–28), mainly in the
duodenum. No neoplastic lesions were observed in the
colon. The tumor multiplicity in TAS animals is
significantly higher when compared to the Apcþ /1638N
and Smad4þ /E6sad littermates (Po0.001, Mann–Whitney
rank sum test) (Table 3). Histological analysis showed
that the tumors were mainly villous or tubulovillous
adenomas with foci of severe dysplasia and malignancy,
similar to what has been observed in late stage Apcþ /1638N
tumors (Figure 3a). In two animals (age 6 and 7
months), adenocarcinomas with frank invasion of the
muscolaris mucosa and submucosa were also observed
(Figure 3b). All TAS mice also displayed desmoid
tumors and cutaneous follicular cysts with similar
incidence and distribution as previously observed in
the Apcþ /1638N mouse model (Smits et al., 1998). Owing
to the high GI tumor multiplicity, TAS mice usually
became moribund at around 7–8 months of age
(Figure 4).
The CAS mouse model showed a more severe
phenotype when compared with TAS. CAS mice became
moribund at age 6 weeks; two out of nine CAS animals
were found dead at 5 weeks and were not included in the
analysis (Figure 4). Moribund mice were characterized
by frank anemia and spleen enlargement. Macroscopic
analysis of the intestinal tract revealed a very thin
dystrophic intestinal wall and the presence of an average
of 60 tumors per animal (range 22–88). Upon micro-
scopic analysis, we observed numerous smaller lesions
along the entire upper GI tract, previously referred to as
GIN (gastrointestinal intraepithelial neoplasia) or mi-
croadenomas (Figure 3d) (Boivin et al., 2003). The
polyps were either sessile or villous, and characterized
by mild to severe dysplasia, in some cases with evident
foci of malignant transformation, although no clear
submucosal invasion was detected among 57 CAS
tumors analysed here (Figure 3c).
LOH analysis of GI tumors from compound CAS
and TAS Apcþ /1638N/Smad4þ /E6sad mice
The LOH status at the Apc and Smad4 loci was
determined in 22 TAS and 16 CAS intestinal tumors.
LOH analysis at the Smad4 locus was carried out as
Table 3 Incidence and distribution of intestinal tumors in Apc1638N/Smad4E6sad compound TAS and CAS mice and their single transgenic
littermates
Genotype No. of
mice
Median age
(range)
Incidence
(%)
Tumor
multiplici-
ty/animal
Tumor range Histology Tumor localization
Smad4E6sad 6 8 months
(6–12)
67 5 2–6 Hyperplastic
polyps
S: 100%; P: 100%; D: 32%; J:55%; I:
23%; C: 12%
Apc+/1638N 7 8 months
(6–18)
100 4 1–10a Low to high dys-
plastic polyps
S: 25%; P: 88%; D: 100%; J: 38%; I:
0%; C: 19%
TAS 8 7 months
(3–8)
100 20 12–28a Low to high dys-
plastic polyps;
carcinomas
S: 100%; P: 100%; D: 100%; J: 87%;
I: 37%; C: 0%
CAS 7 5 weeks
(3–6)
100 60 22–88a Low to high dys-
plastic polyps;
microadenomas;
carcinoma in situ
S: 25%; P: 100%; D: 100%; J: 100%;
I: 42%; C: 0%
Po0.001, Mann–Whitney rank sum test. Tumor localization: incidence of one or more lesions in the corresponding part of the intestinal tract:
S¼ stomach, P¼ periampullar region, D¼ duodenum, J¼ jejunum, I¼ ileum, C¼ colon.
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Figure 3 Histopathology and IHC analysis of intestinal tumors from compound Apcþ /1638N/Smad4þ /E6sad. (a) A typical dysplastic
adenoma observed in TAS animals (HE staining). (b) An example of adenocarcinoma with extensive submucosal invasion from a TAS
mouse (HE). (c) Sessile villous adenoma from a CAS mouse with areas of severe dysplasia and cystic formation (HE). (d) A nascent
lesion or microadenoma observed in the duodenum of a CAS animal (HE). (e) Smad4 IHC analysis of a CAS tumor shows negative
staining, thus indicating LOH of the wild-type allele. (f) Smad4 IHC analysis of a small microadenoma from the same CAS mouse also
reveals LOH of the wild-type allele in the nascent lesion. Note the positively stained cells of the normal epithelial lining surrounding the
dysplastic area.
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described above. For the Apc gene, tumor DNA was
amplified with PCR primers specific for the wild-type
and targeted Apc1638N alleles (Smits et al., 1997).
Sixteen (73%) out of 22 TAS tumors showed LOH of
the wild-type Apc allele, 10 of which (45%) with
concomitant loss of the Smad4E6sad allele, as detected
by the 2 cM distal flanking marker d18Mit80 (Table 4).
Notably, none of the TAS tumors showed LOH at the
wild-type Smad4 allele. The LOH results were validated
by direct sequencing of tumor DNA around the
Smad4E6sad mutation site (exon 6 splice acceptor site).
Sequence analysis confirmed in all cases (10/10) the
results of the LOH analysis: where the loss of
the Smad4E6sad allele was assessed by radioactive PCR,
the frameshift, diagnostic for the presence of the
mutation in the DNA from normal intestinal mucosa,
was absent or strongly reduced in tumor samples
(Figure 2d). In the remaining six tumors (27%), no
LOH was detected at either loci, by either radioactive
PCR and direct sequencing.
Among the CAS tumors, 11 (69%) out of 16 were
characterized by LOH at the wild-type Smad4 locus and
the same percentage showed LOH at the wild-type Apc
allele. In seven cases (44%), loss of both the Apc and
Smad4 loci, and presumably of the entire chromosome
18, was observed. In only one CAS tumor, no LOH at
either locus was detected (Table 4).
To confirm the above LOH results, Smad4 IHC
analysis was performed on tumors from compound
heterozygous Apcþ /1638N/Smad4þ /E6sad mice. All TAS
tumors analysed by IHC (n¼ 6) showed positive
staining for the Smad4 protein, thus confirming that
LOH of the wild-type allele does not play a major role in
tumor onset of this genetic combination. Unlike the
TAS tumors, all CAS tumors analysed by IHC (n¼ 15)
were characterized by the complete absence of Smad4
staining, even at early stages of tumor formation, for
example, the microadenomas (Figure 3e and f). The
IHC data are in agreement with the LOH results
obtained by DNA-based analysis where the majority
of the tumors showed loss of wild-type Smad4 and Apc,
and presumably of the entire chromosome 18.
These results indicate that, although loss of Apc
function seems to represent the rate-limiting event in
tumor initiation in both types of compound Apcþ /1638N/
Smad4þ /E6sad mice, the presence of LOH or haploinsuffi-
ciency at the Smad4 gene differentially affects tumor
initiation in the CAS and TAS genetic combinations.
Discussion
The SMAD4 tumor suppressor gene has been shown to
be inactivated in human colorectal cancer during late
stages of the adenoma-carcinoma sequence (Takagi
et al., 1996; Thiagalingam et al., 1996; Koyama et al.,
1999; Miyaki et al., 1999). Owing to its relevance in GI
tumor initiation and progression, and its central role in
BMP/TGF-b signaling (Shioda et al., 1998; Itoh et al.,
Figure 4 Survival plot of the different mouse models analysed in the present study.
Table 4 Smad4 LOH and IHC analysis of tumors from compound Apc1638N/ Smad4E6sad (TAS and CAS) mice
Genotype No. of tumors LOH wild-type Apc LOH Smad4 Concomitant LOH IHC SMAD4
TAS 22 16/22 (73%) 10/22a (45%) 10/22 (45%) +
CAS 16 11/16 (69%) 11/16b (69%) 7/16 (44%) 
aLoss of Smad4 E6sad mutant allele. bLoss of Smad4 wild-type allele.
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2000; Fink et al., 2003), several investigators have
generated Smad4-mutant mouse models to elucidate the
mechanisms and the cellular consequences of its loss of
function in intestinal cancer (Sirard et al., 1998; Takaku
et al., 1999; Xu et al., 2000). In general, heterozygous
Smad4þ / mouse models are predisposed to the devel-
opment of multiple polyps of the upper GI tract, with
variations in polyp numbers, histology, and onset,
possibly due to differences in mutation type, for
example, causing distinct defects in BMP/TGF-b
signaling, and/or in genetic background. Among these,
the Smad4þ /E6sad mouse model has been previously
reported and described by us as a model for serrated
and hyperplastic adenoma due to a null mutation in the
Smad4 gene. In man, a consistent percentage of invasive
colorectal carcinomas seems to originate from serrated
and hyperplastic polyps (Jass, 2001; Makinen et al.,
2001; Hawkins et al., 2002). From this perspective, the
Smad4þ /E6sad mouse is an interesting model to study
alternative routes of intestinal carcinogenesis, other than
the classic adenoma-carcinoma sequence.
In the present study, we first further characterized the
phenotypic features of Smad4þ /E6sad mice on an inbred
C57BL6 genetic background, and investigated the
mechanisms of somatic Smad4 inactivation during GI
tumor development and progression.
Onset of gastric and periampullary polyp formation
occurs in Smad4þ /E6sad mice between 6 and 9 months of
age with 100% penetrance. Notably, penetrance of
upper GI polyps was reported to be incomplete at
around this age in other Smad4 models (Takaku et al.,
1999; Xu et al., 2000). Smad4þ /E6sad mice were also
affected by tumors in more distal locations along the
intestine, namely in the duodenum, ileum, and in fewer
cases in the colon. Also, unlike the Smad4 model
described by Xu et al. (2000), Smad4þ /E6sad mice did not
develop any carcinomas up to 18 months of age.
Differences in the genetic background of the analysed
mice may partly explain these discrepancies, as shown
by the exclusive presence of gastric and periampullary
tumors in the original F1 (129C57BL/6) Smad4þ /E6sad
animals (Hohenstein et al., 2003), whereas on the B6
background we also observed several tumors through-
out the intestinal tract. However, differences in the
molecular consequences of the targeted mutations may
also underlie the phenotypic features of the individual
models. In the case of the Smad4E6sad mutation, the splice
acceptor mutation in exon 6 was shown by both RT–
PCR and Western analysis to significantly affect mRNA
stability and thus represent a bona fide null allele
(Hohenstein et al., 2003). Unfortunately, similar mole-
cular analyses were not reported for the other models
which does not allow us to exclude that the above
phenotypic differences are partly due to specific
genotype–phenotype correlations at the Smad4 locus
(Takaku et al., 1999; Xu et al., 2000).
The histopathologic analysis of Smad4mutant tumors
at different ages showed a slow but continuous
progression from initial hyperplastic lesions to more
advanced stages with clear dysplasia, similar to what has
been observed in human CRC. In GI tumors from
Smad4þ /E6sad animals, LOH of the wild-type Smad4
allele was only detected in advanced cases of tumor
progression, with the majority of the tumors retaining
heterozygosity in mice up to 12 months of age. IHC
analysis with an antibody directed against the Smad4
protein confirmed that complete loss of Smad4 function
is a late event in tumor progression, at first limited to
more dysplastic areas of the neoplasms. These observa-
tions confirm the previous report by Xu et al. (2000),
where tumors up to 0.4 cm in size were shown to retain
the wild-type Smad4 allele. Accordingly, somatic muta-
tion analysis in cases of Familial Juvenile Polyposis
(FJP) caused by SMAD4 germline mutations showed
LOH in only 9% (1/11) (Howe et al., 1998) and 23% (4/
17) (Woodford-Richens et al., 2000) of the polyps, thus
suggesting that a tumor suppressor gene dosage reduc-
tion, rather than its complete functional inactivation,
characterizes the initial steps of SMAD4-driven GI
tumor initiation and progression in mouse and man. We
have previously shown that dosage variations in Wnt/
b-catenin signaling differentially affect stem cell dif-
ferentiation and multiorgan tumor predisposition in
Apc-mutant mice (Gaspar and Fodde, 2004). Similarly,
dosage fluctuations in BMP/TGF-b signaling in hap-
loinsufficient Smad4 intestinal cells may occasionally
trigger epithelial hyperplasia either in combination with
somatic mutations at genes other than Smad4, or due to
gene dosage fluctuations under a putative BMP/TGF-b
signaling threshold. In fact, impairment of BMP
signaling may very well underlie tumor onset in
Smad4þ /E6sad mice, as inhibition of this pathway has
been reported to result in the formation of numerous
ectopic crypt units and frequent occurrence of intrae-
pithelial neoplasia in mouse (Haramis et al., 2004).
During tumor progression, complete loss of Smad4
function blocks BMP and TGF-b signals from being
transduced to the nucleus and is likely to underlie
progression towards malignancy.
To further expand on the role of Smad4 haploinsuffi-
ciency in intestinal tumor initiation and progression,
and to study putative interaction between Wnt activa-
tion and BMP/TGF-b signaling impairment, we have
bred Smad4þ /E6sad animals with Apcþ /1638N, a mouse
model previously developed in our laboratory, mainly
characterized by tumors of the GI tract, desmoids, and
epidermal tumors (Fodde et al., 1994; Smits et al., 1998).
As both the Apc and Smad4 genes are located on mouse
chromosome 18, compound heterozygous Apcþ /1638N/
Smad4þ /E6sad mice were generated and studied in both
the in trans (TAS) and in cis (CAS) genetic combina-
tions. Both compound animals are characterized by an
increase in tumor multiplicity, progression, morbidity,
and mortality when compared to the single littermates.
In CAS animals in particular, the presence of the two
mutations on the same chromosome resulted in an
extremely severe phenotype.
Notably, the compound heterozygotes generated in
our study substantially differ from the Dpc4þ /;
ApcD716þ / in trans and cis models previously reported
by Takaku et al. (1998). In this study, the in trans
compound mice do not show phenotypic differences
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when compared with the single Apcþ /D716 littermates.
Also, the in cis compound mice are characterized by a
decrease in polyp number and an increase in polyp size,
with accelerated tumor progression and malignant
transformation, still without affecting the survival.
The explanations for these phenotypic discrepancies
may both reside in the difference in genetic background
(B6 vs mixed 129/B6), and in the different molecular
nature of the Smad4- and Apc-targeted mutations
employed in the two studies. Indeed, the relatively mild
intestinal tumor phenotype characteristic of Apcþ /1638N
mice is in sharp contrast with the severe morbidity of
Apcþ /D716 animals with more than 500 GI tumors at 3
months of age. Also, the demonstrated hypomorphic
nature of the Apc1638N mutation encoding for residual b-
catenin regulating activity (Smits et al., 1999; Kielman
et al., 2002) is likely to differ from ApcD716 resulting in a
truncated Apc protein deprived of any b-catenin down-
regulating activity with putative dominant-negative
effects (Takaku et al., 1998). In the presence of such a
highly penetrant Apc mutation, the Smad4 mutation
does not affect the tumor initiation event, whereas its
effects are noticeable in the Apcþ /1638N genetic back-
ground.
Loss of BMP signaling in CAS tumors upon loss of
the Smad4 wild-type allele can also contribute to the
extremely severe phenotype observed in these mice.
Notably, BMP signaling has been described to suppress
Wnt signaling, ensuring a balance in the control of stem
cell self-renewal (He et al., 2004). Loss of BMP-driven b-
catenin regulation in CAS tumors may result in further
enhancement of Wnt/b-catenin signaling to the nucleus
and increased tumor formation.
An additional difference, although precise phenotypic
comparisons between mouse strains in different animal
facilities are not straightforward, consists in the
apparently more severe intestinal tumor phenotype of
Smad4þ /E6sad mice in comparison with the targeted
Smad4 allele described by Takaku et al. (1998, 1999)
(Hohenstein et al., 2003).
Here, we show that in both the TAS and CAS
animals, approximately half (44%) of the tumors have
concomitant LOH of the Apc and Smad4 loci in the
same chromosome, possibly as the result of homologous
somatic recombination between homologs (Haigis and
Dove, 2003). Notably, in TAS polyps, tumor formation
is driven by the loss of wild-type Apc (73% of the
tumors) rather than by the loss of the wild-type Smad4
allele (none observed). Hence, LOH at the Apc locus is
the rate-limiting event for tumor formation in TAS
mice. However, Smad4 haploinsufficiency clearly affects
Apc-driven tumor initiation as indicated by the in-
creased tumor multiplicity in TAS animals when
compared with Apcþ /1638N. Smad4 haploinsufficiency
effects on Apc-driven tumor formation and progression
can explain this result. First, as reported here and
elsewhere, the observed Smad4 haploinsufficiency in
mouse and human polyps indicates that BMP/TGF-b
signaling dosage fluctuations may contribute ‘fertile soil’
for polyp formation in the intestine. This may positively
affect Apc-driven tumor formation both before and after
the second hit at the wild-type Apc allele, possibly
due to cumulative and/or synergistic effects of the
concomitant signaling dosage defects. Accordingly, it
has been shown that induction of TGF-b signaling in a
nontransformed epithelial cell line reduces APC protein
levels at the post-transcriptional level, and increases
b-catenin mRNA and protein levels, causing its nuclear
accumulation and transcriptional activation of Wnt
downstream targets (Satterwhite and Neufeld, 2004).
Wnt and TGF-b signaling may also cooperatively
regulate a subset of downstream targets. Expression of
the growth factor gastrin, a well-known Wnt target gene
and GI-cancer promoter in mouse (Koh et al., 2000), is
finely regulated by synergistic complexes of TGF-b/
Smads and Wnt/b-catenin transcription factors (Lei
et al., 2004).
In conclusion, our results confirm that Smad4
haploinsufficiency is sufficient for intestinal tumor
initiation and that loss of the wild-type allele underlies
more advanced stages of tumor progression and
dysplastic changes. More importantly, the analysis of
the compound TAS and CAS mice has revealed a role
for BMP/TGF-b signaling in Apc-driven tumor forma-
tion and possibly during progression towards malig-
nancy. Reporter assay analysis of Wnt and BMP/TGF-b
signaling activity in different genetic combinations
and identification of the specific downstream targets
will open the way for tailor-made therapeutic
intervention.
Materials and methods
Mouse strains and tumor samples
All Apcþ /1638N mice employed in this study were on an inbred
C57BL/6Jico (B6) background. The employed Smad4þ /E6sad
mice were derived from F5-F8 backcross generations to C57BL/
6 of the original F1 129Ola/C57BL/6Jico Smad4þ /E6sad founder
(Hohenstein et al., 2003). The in Trans Apcþ /1638N/Smad4þ /E6sad
(TAS) compound animals were generated by breeding
Smad4þ /E6sad with Apcþ /1638N mice. The presence of both
mutations in individual littermates is indicative of the TAS
genotype.
The in Cis Apcþ /1638N/Smad4þ /E6sad (CAS) model was
obtained by backcrossing TAS animals with wild-type
C57BL/6J mice. As both genes localize to the same chromo-
some 18, the presence of both mutations in individual
littermates from TASC57BL/6J matings is indicative of a
recombination event that has brought the mutant Apc- and
Smad4 alleles on the same chromosome 18. In agreement with
the genetic distance between the two tumor suppressor loci
(33 cM), the two mutations were found on the same chromo-
some 18 allele in approximately 15% of the offspring.
Tumors were obtained by macroscopic dissection of the GI
tract and overnight fixation in Notoxs (Earth Safe Industries,
Inc., Bellemead, NJ, USA), as previous described (Smits et al.,
1997), or after 4 h in 4% paraformaldehyde (PFA). Tumor
sections were stained with hematoxylin and eosin (HE) and the
histopathological analysis was performed using standard
classification criteria (Boivin et al., 2003). The term polyp in
this context was used to describe a macroscopic lesion
that protrudes in the GI lumen. By histopathological
analysis, the polyps were than defined as hyperplastic or
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dysplastic-adenomatous polyps if they showed, respectively,
gross thickening or proliferative dysplasia of the mucosa.
Laser capture microdissection and DNA extraction of intestinal
tumors and normal mucosa
We employed laser capture microdissection (LCM) to obtain
pure tumor cell populations from selected areas of paraffin-
embedded tissue sections. In total, 10 mm Notox-fixed sections
were deparaffinized, rehydrated, and briefly stained by HE.
Consecutive sections were carefully microdissected using a
PALMs MicroBeam microscope system (PALM Microlaser
Technologies AG-Bernried, Germany). On average, 3000 cells
were isolated from each designated area. For DNA isolation,
LCM material was resuspended in 100ml of extraction buffer
(100mM NaCl, 10mM TrisHCl pH¼ 8.0, 25mM EDTA
pH¼ 8.0, 0.5% SDS) with 0.6mg/ml Proteinase K, and
incubated overnight at 601C. After phenol/chloroform and
chloroform extraction, DNA was precipitated for 30min at
201C with 200 ml of 100% ethanol, 50ml 7.5M NH4Ac, and
10 mg GenEluteTM linear polyacrylamide (Sigma), and sus-
pended in 15ml TE4 buffer (10mM Tris–HCl pH 8.0, 0.1mM
EDTA).
LOH analysis at the Apc and Smad4 genes
LOH analysis of the Apc gene was performed using three
primers that amplify in a single PCR reaction both the wild-
type and the targeted Apc1638N allele, as previously described
(Smits et al., 1997). LOH analysis of the Smad4 gene was
carried out by genotyping the microsatellite repeat markers
d18Mit81 and d18Mit80, informative in the employed
Smad4þ /E6sad mice, located 7 and 2 cM, respectively, proximal
and distal to the Smad4 gene on chromosome 18. PCR
products were resolved on 6% polyacrylamide gels and
quantified using a Typhoont 9410 and ImageQuantt TL
(Molecular Dinamics). LOH was scored when the allelic ratio
of the two bands, normalized for the average ratio of normal
controls, was X1.5 (Smits et al., 1997).
LOH analysis by sequence analysis
The following primer pair was employed to PCR amplify the
Smad4E6sad mutation site within the intron5/exon6 boundary:
Smad4 F1-GGACAGCAGCAGAATGGATT and Smad4
R1-ATGGCCGTTTTGGTGGTGAG.
PCR products were sequenced in both directions using the
same primers. Sequencing was performed on an ABI 3700
capillary sequencer (Applied Biosystem, Foster City, CA,
USA) according to the manufacturer’s instructions.
Immunohistochemical analysis of Smad4 and b-catenin
Notox and PFA-fixed paraffin-embedded tumor sections
(4 mm) were immunostained with mouse monoclonal antibo-
dies direct against Smad4 (clone B-8, sc-7966, Santa Cruz
Biotechnology, Santa Cruz, CA, USA; dilution 1:100) and b-
catenin (Transduction Laboratories, clone 14; dilution 1:200).
The specificity of the B-8 antibody has been previously tested
and validated (Wilentz et al., 2000; Salovaara et al., 2002).
After antigen retrieval treatment (10min boiling in Tris-EDTA
pH 8.0), endogenous peroxidases were inactivated by 1%
H2O2/PBS. A preincubation step of 30min in 5% nonfat dry
milk in PBS was followed by incubation with the specific
antibody overnight at 41C in preincubation buffer. Sections
were then incubated and stained with the Envision HRP-
ChemMate kit (DAKO) for the Smad4 antibody, and with a
goat antibody against mouse IgG/IgM conjugated with
peroxidase (Jackson ImmunoResearch Laboratories) for b-
catenin. The evaluation of Smad4 IHC staining was performed
after brief hematoxylin counterstaining of the slides.
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Abstract 
The SMAD4 gene is a tumor suppressor involved in pancreatic and colorectal 
tumorigenesis. In Smad4-mutant mouse models, haploinsufficiency characterizes the 
development of gastro-intestinal polyps with initial retention of the wild type allele and 
protein expression in tumor tissues. Here, we show that, in mouse embryonic and intestinal 
cells heterozygous for a targeted Smad4 null mutation, Smad4 protein levels correlate with 
gene copy number with reduced expression. Also, retention of protein expression was 
confirmed in human polyps from SMAD4 germline mutation carriers. Reporter assay 
analysis confirmed that mouse Smad4+/- cells exert intermediate inhibitory effects on both 
TGF-β and BMP signalling. Expression profiling of homo- and heterozygous ES cells 
identified a subset of Smad4 dosage-dependent transcriptional target genes encompassing, 
among others, members of the TGF-β and Wnt signalling pathways. Our results show that 
Smad4 haploinsufficiency results in the alteration of TGF- β /BMP signal transduction and 
in the differential expression of a subset of target genes likely to underlie intestinal polyp 
formation. 
 
Introduction 
Haploinsufficiency is defined as the condition where mutation or loss of a single allele is 
sufficient to alter the phenotype of a diploid cell (Payne & Kemp, 2005). 
Haploinsufficiency at a tumor suppressor locus may overcome the need for the somatic loss 
or mutation of its wild type allele, predicted as the rate-limiting event for tumor 
development by the Kundson’s two-hit model  (Knudson, 1971) (Fodde & Smits, 2002). To 
date, experimental evidence for haploinsufficiency in cancer predisposition comes from the 
analysis of tumors obtained from mouse models or from hereditary cancer patients carrying 
heterozygous null mutations at known tumor suppressor genes. The absence of the second 
hit in a subset of these tumors has been attributed to inactivation of the remaining allele by 
alternative mechanisms such as epigenetic silencing, mutations in non-coding sequences, or 
to limited sensitivity of the employed mutation detection protocol. However, bona fide 
haploinsufficiency has been demonstrated for a subset of tumor suppressor loci including 
ATM (Lu et al., 2006),  PTEN (Kwabi-Addo et al., 2001), BRCA2 (Arnold et al., 2006), 
LKB1 (Miyoshi et al., 2002), BLM (Goss et al., 2002), Nkx3.1 (Magee et al., 2003), and 
Tp53 (French et al., 2001). 
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SMAD4 is an intracellular mediator of the TGF-β and BMP signal transduction pathways. 
Binding of the TGFBRII receptor to the TGF-β ligand triggers its heterodimerization with 
the TGFBRI receptor and to the phosphorylation of members of the SMAD family of 
intracellular mediators, namely SMAD2 and SMAD3. These receptor-activated SMADs 
bind to SMAD4 and translocate the complex to the nucleus where it modulates the 
transcription of a broad spectrum of target genes involved in cell growth inhibition, 
apoptosis, differentiation, and matrix production (Duff & Clarke, 1998; Heldin et al., 
1997). Somatic SMAD4 gene mutations are found in 30-40% of sporadic CRC (Salovaara 
et al., 2002), whereas germline SMAD4 mutations are responsible for a subset of patients 
affected by Familial Juvenile Polyposis (FJP) (Roth et al., 1999; Woodford-Richens et al., 
2000), an autosomal dominant intestinal cancer syndrome. Previously, we and others 
(Alberici et al., 2006; Xu et al., 2000) showed that Smad4–mutant mouse models develop 
gastro-intestinal polyps with initial retention of the wild type Smad4 allele and with 
complete functional loss only at later stages of tumor progression. 
In the present study, we explored the possibility that TGF-β downstream target genes may 
be affected in a dosage-dependent fashion by SMAD4 haploinsufficiency. To this aim, 
Smad4 haploinsufficient mouse cells were analyzed for their TGF-β and BMP signaling 
levels and genome-wide transcription and compared with their Smad4 proficient and 
deficient counterparts. Moreover, we analyzed intestinal tumors from FJP patients with 
established germline SMAD4 mutation to validate the haploinsufficiency model in human 
tumorigenesis. 
 
Results  
Smad4 protein haploinsufficiency in Smad4+/- cells  
Haploinsufficiency of the Smad4 gene has been previously shown to underlie 
gastrointestinal tumor development in two different mouse models (Xu et al., 2000; 
Alberici et al., 2006). In order to shed light on the molecular and cellular mechanisms 
underlying this defect, we set to evaluate Smad4 protein expression in wild type 
(Smad4+/+), hetero- (Smad4+/E6sad), and homozygous (Smad4E6sad/E6sad) embryonic stem (ES) 
cells derived from pre-implantation blastocysts obtained by breeding of C57Bl6/J 
Smad4+/E6sad mice (Hohenstein et al., 2003; Alberici et al., 2006).  
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Two independent heterozygous and homozygous ES clones were analyzed by western blot 
with the B-8 antibody (Wilentz et al., 2000a; Wilentz et al., 2000b), as shown in Figure 1A. 
Homozygous Smad4E6sad/E6sad ES lysates do not reveal any protein expression, whereas both 
heterozygous clones show a consistent reduction in protein expression when compared with  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  
SMAD4 western blot analysis demonstrates haploinsufficiency at the protein level in ES 
and adult intestinal cells from Smad4+/E6sad mice. A. ES cell lysates loaded at two 
different amounts of protein; B. Normal intestinal tissue lysates from wild type and 
Smad4+/E6sad mice. 
wild type ES cells, thus confirming haploinsufficiency at the protein level in Smad4+/E6sad 
cells. Moreover, western blot analysis performed on intestinal cells from Smad4+/E6sad mice 
indicated that protein haploinsufficiency is not limited to ES cells but is also confirmed in 
adult tissues (Figure 1B). 
Smad4 haploinsufficiency affects both TGF-β and BMP signaling 
The Smad4 protein acts, together with the receptor-activated Smads, as the main signal 
transducer for the TGF-β family of signalling pathways, namely TGF-β and BMP. To 
determine whether the observed reduction of Smad4 expression in Smad4+/E6sad cells 
impairs these signalling routes, we first measured the levels of the Smad2/Smad3/Smad4  
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nscriptional complex in the Smad4-mutant and wild type ES cells by a TGF-β sensitive
GA-MLP-luciferase reporter assay system (De
Figure 2.  
Reporter assay analysis of Smad4-mutant and wild type ES cell lines. A. TGF-β reporter 
(CAGA-luc ) and B. BMP reporter assay were carried out in wild type (+/+), 
Smad4+/E6sad (+/-), and Smad4E6sad/E6sad (-/-) ES cell lines. Normalized CAGA-luc and 
BRE-luc levels are indicated for each cell line. In C. TGF-β reporter assays analysis was 
t after transfec ion with a Sm d4-expressing vector. Each b r represents the 
ge of three independent experiments.  
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avera
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As the type II TGF-β receptor (TGFBRII) is expressed in ES cells at insufficient levels to 
provide significant activation of TGF-β signaling (data not shown), we co-transfected the 
ES cells with an expression vector (pCMV5 TBRII) encoding for the type II TGF-β 
receptor (Wrana et al., 1992) together with the reporter assay constructs.  
As shown in Figure 2A, Smad4E6sad/E6sad ES cells show a dramatic decrease in TGF-β 
signaling activity when compared with the wild type control. Moreover, the decrease in 
activity is already present  in the two independent Smad4+/E6sad ES clones, both showing a 
level of luciferase activity intermediate between wild type and homozygous cells.  
The Smad4-mutant ES lines were furthermore analysed for their BMP signalling activity. 
To this aim, we transfected the ES cells with the BRE- luc reporter assay, previously shown 
to be specifically responsive to BMP signalling levels (Korchynskyi & ten Dijke, 2002) 
together with a constitutively active ActR-I receptor (Korchynskyi & ten Dijke, 2002). As 
shown in Figure 2B, the results clearly demonstrate that, as for TGF-β signaling, Smad4 
protein haploinsufficiency results in a decrease of BMP signal transduction activation, at an 
intermediate level between that of wild type and homozygous cells. Also, rescue of Smad4 
expression in homozygous Smad4E6sad/E6sad ES cells by transfection with a Smad4 
expression vector (Nakao et al., 1997) was able to restore TGF-β signaling levels thus 
indicating that the observed inhibitory and dosage-dependent effects are Smad4-specific 
(Figure 2C).  
SMAD4 IHC analysis of Juvenile Polyps confirms haploinsufficiency in human 
tumors 
SMAD4 germline mutations characterize a fraction of patients affected by the Juvenile 
Polyposis Syndrome (JPS). This autosomal dominant condition is characterized by the 
presence of hamartomatous polyps in the GI tract with early onset and increased cancer 
risk. In order to determine whether haploinsufficiency at the human SMAD4 gene features 
the initial step of juvenile polyp formation, i.e. without somatic mutation or loss of 
heterozygosity (LOH) of the wild type SMAD4 allele as previously reported in Smad4-
mutant mouse models for intestinal polyposis (Xu et al., 2000; Alberici et al., 2006), we 
performed SMAD4 immuno-histochemical (IHC) analysis of polyps from JPS patients 
known to carry established germline  mutations in the SMAD4 gene. Out of a total of five 
unrelated cases, two showed clear retention of SMAD4 expression in large areas of the 
polyps (Figure 3A and B). In the remaining cases, SMAD4 IHC was instead on average 
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negative, with only few scattered groups of cells characterized by weak nuclear staining 
(Figure 3C). Notably, the polyps characterized by retention of SMAD4 staining are the 
smallest in our series, measuring 0.4 x 0.6 cm. and 0.4 x 0.5 cm. respectively. Juvenile 
polyps with loss of SMAD4 staining measured instead between 2x2  and 3x3 cm, thus 
suggesting that complete loss of SMAD4 function only occurs at a later stage of juvenile  
Figure 3.   
Immunohistochemical analysis of SMAD4 protein expression performed on polyps 
from three unrelated Familial Juvenile Polyposis patients with established SMAD4 
germline mutation. A. Polyp with SMAD4 nuclear staining. B. Polyp with 
heterogeneous SMAD4 expression pattern with patches of positively and negatively 
staining tumor cells. C. SMAD4 negative juvenile polyp.   
 
polyp progression, whereas the initial step of polyp formation occurs in haploinsufficient 
cells, i.e. without loss of the SMAD4 wild type allele. These observations are in agreement 
with our own previous study on intestinal polyps from the Smad4+/E6sad mouse model where 
complete loss of Smad4 protein expression occurs at late progression stages in tumors 
characterized by increased dysplasia (Alberici et al 2006).  
Overall, these results indicate that, in partial disagreement with Knudson’s two-hit model 
for tumor formation, somatic loss of the wild type allele is not a rate-limiting event in 
SMAD4-driven intestinal polyp formation both in man and mouse. Tumor formation occurs 
in a haploinsufficient genetic background with reduced SMAD4 protein expression levels 
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as shown above (Figure 1) and with intermediate inhibitory effects on the TGF-β and BMP 
signaling pathways (Figure 2). 
Expression profiling analysis reveals a subset of Smad4 dosage-dependent transcripts. 
As described above, Smad4 haploinsufficiency negatively affects both TGF-β and BMP 
signal transduction. Next, we wanted to characterize the effects on gene transcription 
caused by the different TGF-β and BMP signalling levels observed in Smad4+/E6sad and 
Smad4E6sad/E6sad cells, in an attempt to elucidate the downstream pathways and putative 
cellular alterations which underlie tumor formation and progression. To this aim, genome-
wide expression profiling analysis of total RNA samples from wild type, Smad4+/E6sad and 
Smad4E6sad/E6sad ES cells was performed with the Affymetrix MOE430 2.0 array 
encompassing over 39.000 transcripts. Two independent clones for each genotype were 
used for the expression profiling analysis. 
A set of differentially expressed genes was identified in both heterozygous and 
homozygous cells when compared with Smad4+/+ cells, thus showing that Smad4 
haploinsufficiency is sufficient to affect transcription of a subset of downstream target 
genes. These dosage-dependent Smad4 target gene signatures provide a unique opportunity 
to study the differential effects of haploinsufficiency and complete loss of Smad4 function 
at the molecular and cellular level. In order to focus on genes with Smad4 dosage-
dependent expression patterns, we crossed the lists of genes differentially expressed 
(compared with wild type cells) with a threshold of p<0.01 for the homo- and p<0.05 for 
the heterozygous cells. This approach led to the identification of 79 individual gene 
transcripts differentially expressed in both Smad4-mutant genotypes when compared with 
Smad4+/+ ES cells including 31 up- and 48 down-regulated genes, respectively. Among the 
79 gene signature, 24 and 40 transcripts represent functionally annotated genes in the up- 
and down-regulated group, respectively (Table 1). The presence of the Smad4 gene itself 
within the list of downstream target corroborates the validity of our approach. Among the 
functionally annotated and differentially expressed entries, several functional categories are 
represented: members of known signal transduction pathways (e.g. Mdm2, Axin2, Smad7, 
Zak), growth factors (Fgf5, Fgf8, Igfbp3, Lefty2), immunity related genes (Irgm, Il23a, 
Cxcl14), and trascription factors (Nrip1, Eomes, Stat3, Cnot6, T brachyury homolog) 
among others. Notably, when the fold changes levels relative to these 79 genes are plotted 
to follow their behaviour according to the Smad4 genotypes, a gradient of transcriptional 
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response becomes apparent, thus indicating a Smad4 dosage-dependent control of 
downstream target gene expression (Figure 4).  
 
Figure 4. Expression profiling analysis of the subset of 79 genes (corresponding to 88 
Affymetrix probes) found to be differentially expressed in both Smad4+//E6sad and 
Smad4E6sad/E6sad ES cells. The fold changes are represented as (log2) ratio values. 
Quantitative real-time RT-PCR validates Smad4-dosage dependent target genes in 
intestinal tissues from Smad4+/E6sad mice 
To determine whether the Smad4 dosage-dependent genes identified by expression 
profiling of Smad4–mutant ES cells are similarly affected by differential expression also in 
the intestine of adult Smad4+/E6sad mice, we analyzed the mRNA levels of a selection (n=6) 
of the 79 genes by quantitative real-time RT-PCR on laser-capture microdissected (LCM) 
normal intestinal cells obtained from 2 wild type and 3 heterozygous animals. This 
methodology allows highly quantitative measurements of target gene expression and can be 
performed on the limited amounts of mRNA extracted from microdissected epithelial cells. 
The selected genes are all known to be expressed in the gastrointestinal tract and are 
characterized by at least one fold change level in the ES cells expression profiling data 
(log2>1). As a control, we also performed qPCR analysis of Smad4 gene expression, 
expected to be reduced in the normal intestine of Smad4+/E6sad mice when compared with 
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wild type animals. As internal reference standard, we employed the crystallin zeta quinone 
reductase-like 1 (Cryzl1) gene, previously shown to retain constant expression levels 
between wild type and Smad4-mutant ES and adult intestinal cells by expression profiling 
(data not shown). The primers used for the qPCR analysis are listed in Supplementary 
Table 1. As shown in Figure 5, both up- (Prkar1b and Tgb1) and down-regulated (Smad7, 
Irgm, Arts-1 and Igfbp1) genes showed consistent changes in gene expression levels in 
Smad4+/E6sad normal intestine when compared with the wild type tissues, concordant with 
the ES cells expression profiling results. 
 
Figure 5.  
Quantitative PCR analysis of a selection of six genes differentially regulated in 
Smad4+/E6sad cells. Gene expression was quantified in normal intestinal tissues from 
two wild type (WT) and three Smad4+/E6sad (Smad4) animals and is plotted as ratio 
over the reference gene, as explained in the Material and Methods. Each bar 
represents the average of three independent experiments.  
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able 1.  
Sequences of the prim
ers em
ployed for the qPC
R
 analysis.  
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Discussion  
The precise molecular events that occur during the very first steps of tumor formation are 
still poorly understood. In the case of tumour suppressor genes (TSGs), the two-hit model 
predicts that the somatic loss or mutation of the wild type allele is an absolute requirement 
to trigger tumour formation. However, over the last few years it has become clear that in a 
subset of TSGs this rate-limiting event does not accompany the initial steps of tumor 
formation (Santarosa & Ashworth, 2004). In these cases it is plausible to assume that 
haploinsufficiency, i.e. the functional loss of a single TSG allele, can already affect normal 
cell function and homeostasis, possibly in a synergistic fashion with other  genetic or epi-
genetic somatic hits at unrelated cancer genes. 
Mouse models carrying targeted loss of function mutations at the Smad4 tumor suppressor 
gene (Alberici et al., 2006; Xu et al., 2000) represent illustrative  examples of 
haploinsufficiency, as GI-tract tumors initially develop in these animals by retaining the 
wild type Smad4 allele and its reduced protein expression. Here, we show that  Smad4 
haploinsufficiency results in dosage-dependent inhibition of TGF-β and BMP signalling, 
two well-known pathways controlling epithelial cell proliferation and differentiation and 
likely to underlie tumorigenesis in these mice. Expression profiling of the Smad4 
haploinsufficient cells confirmed the existence of a subset of target genes whose expression 
is specifically regulated by different Smad4 protein (and presumably TGF-β and BMP 
signalling) dosages. 
In the hapoinsufficiency model, the steady-state levels of a tumor suppressor gene product 
fluctuate around a mean threshold value that, in case of haploid gene expression, is approx. 
50% of the diploid state (Cook et al., 1998).  However, transient fluctuations below critical 
threshold levels may affect proper protein function and cellular homeostasis. Tissue-
specific differences in the expression of tumor suppressor proteins and their spatial 
distribution within specific tissues, as illustrated by the gradient of SMAD4 protein 
expression observed along the crypt-villus axis in the GI tract, are likely to play relevant 
roles in modulating the phenotypic outcome of haploinsufficiency. Also, specific organs 
may be differentially exposed to environmental mutagens thus increasing the chance of 
synergistic somatic hits. In JPS patients carrying heterozygous SMAD4 germline mutations 
and in Smad4+/- mice, haploinsufficiency features all somatic cells but exert a tumor 
phenotype predominantly in the GI tract, possibly due to additional exposure to oxidative 
and chemical stress in the intestine. Alternatively, the rapid epithelial turnover 
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characteristic of the mammalian intestinal tract may represent a microenvironment 
particularly susceptible to the observed effects of SMAD4 haploinsufficiency on and TGF-
β and BMP signalling and on specific downstream transcriptional targets.   
Polyps from JPS patients with SMAD4 germline mutations were previously shown to carry 
second hit mutations at the wild type allele only in 9% (1/11) (Howe et al., 1998) and 23% 
(4/17) (Woodford-Richens et al., 2000) of the cases. In the present study, we validated 
these observations by IHC analysis. Small hamartomatomas from JPS patients with 
established germline SMAD4 mutations retain protein staining, whereas  bigger and more 
advanced polyps are either negative or ‘patchy’, with small areas of weak protein staining.  
Haploinsufficiency of the SMAD4 gene has also been shown to be relevant in the context of 
sporadic colorectal carcinoma development. Several studies based on coupled LOH and 
mutation analysis of sporadic colorectal cancers have failed to identify two independent 
mutation hits in the SMAD4 gene in the majority of the cases (Mamot et al., 2003;  Hadzija 
et al., 2004). These negative results are generally attributed to lack of sensitivity of the 
employed mutation-detection protocol, or to sampling bias (e.g. early tumor stages). 
Recently however, Tatsuya and co-workers (Ando et al., 2005) demonstrated that only 1 
out 25 CRC cases with allelic imbalance at the SMAD4 gene locus harbor additional 
mutations in the remaining allele, confirming the possibility that SMAD4 gene dosage 
reduction may indeed play a role in sporadic colorectal cancer. Moreover, it has been 
shown that complete loss of SMAD4 expression in CRC associates with poor prognosis 
(Alhopuro et al., 2005). Reduced tumor SMAD4 protein levels were also associated with a 
significant decrease in disease-free and overall survival after potentially curative surgery in 
Dukes C colorectal cancer patients (Alhopuro et al., 2005). In the same study, SMAD4 
mRNA levels predicted treatment response in Dukes C patients. Accordingly, SMAD4 
mRNA and protein levels were found to further decrease in lymph node metastases when 
compared to primary tumors. Overall, the combined genetic and protein expression data 
from both JPS patients and mouse models support a model for SMAD4-driven 
tumorigenesis where the initial mutation leads to haploinsufficiency and increased 
susceptibility to intestinal tumor formation due to specific effects on TGF-β and BMP 
signalling and on the transcription of a subset of downstream targets. Bi-allelic inactivation 
of SMAD4 leading to its complete functional loss and even more severe transcriptional and 
signaling defects, predominantly occurs at later stages of malignant progression.  
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The genes shown to be differentially up- or down-regulated in a Smad4 dosage-dependent 
fashion include well-known members of signal transduction pathways (Table 1). The 
MDM2 protein, for example, acts as a major regulator of the tumor suppressor p53 by 
targeting it for proteosomal degradation (Momand et al., 1992), and plays a role as negative 
regulator of RB (Xiao et al., 1995). Mdm2 up-regulation, as observed in Smad4+/E6sad cells, 
may favor tumor transformation by inhibiting p53-mediated transactivation (Sdek et al., 
2005) and by destabilizing RB.  
The scaffold protein Axin2 (conductin) has been previously implicated in canonical Wnt 
signaling pathway and CRC pathogenesis (Liu et al., 2000). Loss of Axin2 function leads to 
defects in cell cycle regulation and apoptosis through the transcriptional activation of Wnt 
downstream targets such as c-Myc and Cyclin D1, among others. The observed Axin2 
downregulation in Smad4+/E6sad cells may indicate a cross-talk between TGF-β and Wnt 
signal transduction already in haploinsufficiency. However, TOP-Flash reporter assays of 
Smad4+/E6sad and Smad4E6sad/E6sad ES cells did not show significant increase in Wnt/β-
catenin signaling when compared with wild type cells (unpublished).  
The expression of two known downstream targets of the TGF-β pathway, namely Smad7 
and Tgfb1, is also affected by Smad4 haploinsufficiency. Smad7 is both a well-
characterized inhibitor of TGF-β signaling and itself a TGF-β downstream target, possibly 
as the result of a negative regulatory loop. Smad7 down-regulation, as observed in the 
Smad4+/E6sa ES cells, likely reflects the observed inhibition of TGF-β signaling. Tgfb1 is an 
extracellular protein with only poorly characterized functions. The up-regulation of the 
Tgfb1gene in Smad4+/E6sa ES cells possibly reflects its highly significantly over-expression 
in sporadic CRC (Buckhaults et al., 2001).   
Down-regulation of the insulin growth factor binding protein Igfbp3 in Smad4+/E6sa ES and 
intestinal cells may also represent a relevant initial alteration in tumor formation. Igfbp3 
has been described as tumor suppressor gene (Xi et al., 2006), due to its role in the 
regulation of cell proliferation and apoptosis. In addition, methylation of its  promoter and 
expression silencing has been observed in 50% of the CRC cases analyzed (Tomii et al., 
2007).  
TGF-β signaling defects play important roles not only in tumor cells but also in their direct 
microenvironment (Bierie & Moses, 2006). Communication between tumor and stromal 
cells through different cytokines and growth factors actively regulates and promotes tumor 
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progression. TGF-β-mediated regulation of the tumour microenvironment can occur at 
different levels including cell-autonomous signaling, stromal–epithelial interactions, 
inflammation, immune evasion and angiogenesis. Recently, Kim et al showed that 
transgenic animals engineered to induce loss of Smad4 exclusively in the T-cell 
compartment develop intestinal lesions characterized by expansion of the stromal 
compartment reminiscent of JPS polyps (Kim et al., 2006). Moreover, further support of the 
role of Smad4 dosage effects in tumor initiation came from the observation in the same 
study according to which loss of a single Smad4 allele resulted in polyp formation and 
hyperplasia in the GI tract, similar to what previously observed in our Smad4+/E6sa model 
(Alberici et al., 2006). Although in our model the specific contribution of the stromal 
component to the neoplastic process cannot be dissected from that of the parenchymal 
tumor cells due to the constitutive nature of Smad4 haploinsufficiency in these animals,  the 
observation that more advanced lesions show complete loss of Smad4 expression might 
indicate a progression model where total loss of TGF-β and BMP signaling in the ephitelial 
compartment is necessary for full-blow carcinogenesis. 
In conclusion, it is likely to assume that Smad4 haploinsufficiency results in intestinal 
polyp formation not only by the direct inhibition of TGF-β and BMP signaling and their 
downstream effectors in both the parenchymal cell and its direct microenvironment, but 
also through a number of more indirect and/or independent downstream targets thus 
affecting a broad spectrum of cellular functions including apoptosis, cell cycle regulation, 
cell adhesion, immune response, and others. 
  
Material and methods 
Animal models and tissue samples 
The Smad4+/E6sad mouse model (Alberici et al., 2006; Hohenstein et al., 2003) is available 
on the inbred C57Bl/6J background. Mice were maintained under a 12 hour light-dark 
cycle and fed with standard diet and water ad libitum. All experiments on mice were 
performed in accordance with institutional and national guidelines and regulations. Frozen  
laser capture microdissected (LCM) intestinal tissues (approx. 6000 cells) were collected 
using a PALM MicroBeam microscope system as previously described (Alberici et al., 
2007). 
Generation of Smad4-mutant ES cell lines 
109
Chapter 5  
Smad4+/E6sad mice were inter-bred and the resulting blastocytes were harvested after 
fertilization at 3.5 dpc. Flushed pre-implantation blastocytes were then individually 
cultured on 96-well dishes coated with mouse embrionic fibroblasts (MEFs) as previously 
described (Matise M.P., 2000). Two independent ES cell lines were generated for each 
genotype.   
Smad4 western analysis  
Equal amounts (40 μg) of protein lysates were separated on 12% SDS polyacrylamide gels, 
and further subjected to immunoblotting according to standard procedures. Several studies 
have validated the specificity and sensitivity of the B-8; sc-7966 monoclonal antibody 
against SMAD4 (Santa Cruz Biotechnology) to detect alterations of protein expression in 
both mouse and human specimens  (Wilentz et al., 2000a; Wilentz et al., 2000b). The B-8; 
sc-7966 primary antibody was for western analysis at a 1:100 dilution. Peroxidase-
conjugated secondary antibodies (Jackson Immunoresearch) were visualized with an 
enhanced chemiluminescence (ECL) system (10 ml Sodium Luminol from Sigma in 0.1 M 
Tris-HCl, pH 8,6 + 100 uL Enhancer  (para-hydroxyl-Coumaric acid from Sigma, in 
DMSO) + 3 uL H2O2). 
Reporter assay analysis 
ES cells grown on tissue culture dishes coated by mitotically inactivated primary MEFs 
were transfected by Lipofectamine 2000 (Life Technologies) with 250 ng of the reporter 
plasmid [(CAGA)12-MLP-luciferase for the TGF-β signaling or BRE-luciferase for the 
BMP signaling] , 100 ng of receptor-expressing vector [TGFBRII or, for BMP signaling, a 
constitutively active form of ALK2]  (Wrana et al., 1992; Korchynskyi & ten Dijke, 2002)  
(all kindly provided by Prof. P. ten Dijke), and 5 ng of a Renilla reniformis luciferase-
expressing vector. For the rescue experiments, 100 ng of the Smad4-pCMV5 expression 
vector (Nakao et al., 1997) were transfected together with (CAGA) 12-MLP-luciferase and 
TGFBRII. After 24 hours, ES cells transfected with the (CAGA)12-MLP-luciferase were 
stimulated with recombinant human TGF-β  (50pmol) for 1 hour before to measure the 
luciferase activities with the luminometer Fluoroskan Ascent CF (Labsystems) using  the 
Dual Luciferase Reporter Assay system (Promega). Luciferase activities were evaluated as 
ratio of (CAGA)12-MLP-luciferase vs Renilla luciferase levels for 3 different experiments, 
each carried out in triplicate. 
Immuno-histochemical analysis  
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Formalin-fixed, paraffin embedded intestinal polyps were prepared as 4 μm sections and 
immunostained with the mouse Smad4 B-8; sc-7966 monoclonal antibody directed against 
Smad4 (Santa Cruz Biotechnology Inc., dilution 1:100). After antigen retrieval treatment 
(10 min boiling in Tris-EDTA pH 8.0), endogenous peroxidases were inactivated by 1% 
H2O2/PBS. A 30 min. pre-incubation step in 5% non-fat dry milk in PBS, was followed by 
incubation with the Smad4 antibody overnight at 4°C in pre-incubation buffer. Sections 
were then incubated and stained with the Envision HRP-ChemMate kit (DAKO). Smad4 
IHC staining was evaluated after brief hematoxilin counterstaining of the slides. 
Expression profiling analysis 
Total RNA was isolated using the RNeasy Midi Kit (QIAGEN) by lysing the ES cells 
directly in culture dishes; an extra DNase step on the column was performed according to 
manufacturer’s instructions. RNA was labelled using the GeneChip One-Cycle Target 
Labeling and Control Reagents kit, and hybridized to the MOE430 2.0 Affymetrix 
oligonucleotide arrays, a comprehensive whole mouse genome expression platform 
encompassing more than 39,000 transcripts, according to manufacturer’s instructions. Raw 
signal intensities were extracted and summarized from cel-files, followed by normalization 
using RMA (Robust Multi-Array Average expression measure) implemented in the 
Bioconductor package affylmGUI (Wettenhall & Smyth, 2004). No filtering was applied to 
the data. A Bayesian linear regression model was used to detect differentially expressed 
genes implemented in the Bioconductor package LIMMA (Smyth, 2004; Smyth, 2005). All 
Bioconductor packages were used with R statistical Computing Software v2.2.1 (Team, 
2005). 
Quantitative real-time RT-PCR analysis   
Total RNA was extracted from laser-capture microdissected tissues by using the RNeasy 
Micro Kit (Qiagen). cDNA was synthesized by SuperScript™ II Reverse Transcriptase 
(Invitrogen) with the Oligo(dT)  primer20  (Invitrogen). Each PCR was carried out in 
triplicates in 25 μl volumes using 1 μl of cDNA and SYBR® Green Dye (Applied 
Biosystems) on the MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad). 
Primers sequences are listed in Supplementary Table 1. Standard curves for the target genes 
and the reference Cryzl1 gene were generated and the normalization and ratio  
were calculated as described (Pfaffl, 2001). 
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6.1.  CIN in the adenoma-carcinoma sequence 
 
The debate around the role of chromosomal instability (CIN) in cancer onset and/or 
progression has been going on for decades. In the most simplistic scenario, 
mutations leading to CIN are selected for in tumor cells because aneuploidy 
enhances the rate of LOH at tumor suppressor genes and upregulates oncogenes 
by allelic gains. However, excessive DNA damage resulting from increased 
genomic instability does not represent a direct growth advantage as it is 
deleterious for the individual cell  and it is rather likely to decrease its fitness 
compared with cells with intact genome surveillance through activation of 
programmed cell death (apoptosis).  Only ‘just-right’ levels of chromosomal 
instability will allow the tumor cells to acquire the gene mutations necessary to 
overcome the natural selection barriers (see Fig.1).  
The origin of CIN and its role in tumor initiation or progression are still controversial 
issues in cancer research (Rajagopalan & Lengauer, 2004). However, two more 
recent lines of evidences clearly indicate that CIN is likely to represent a very early 
event along the adenoma-carcinoma sequence in colorectal cancer: 1. the notion 
that loss of APC function results in mitotic defects and in chromosomal instability 
(Fodde et al., 2001; Kaplan et al., 2001); and 2. the observation according to which 
aneuploidy occurs at very early stages in colorectal cancer development in man 
(Giaretti, 1994; Bardi et al., 1997; Shih et al., 2001; Cardoso et al., 2006). In 
Chapter 3 of this thesis, we established that in Apc-mutant mouse models for 
intestinal tumorigenesis aneuploidy is also observed at very early adenoma stages 
(Alberici et al., 2007). The assessment of chromosomal instability by a quantitative 
assay such as BAC array-CGH demonstrated not only that even initial intestinal 
lesions, namely small low dysplastic adenomas, already present characteristic 
features of CIN with frequent chromosomal gains and losses, but also that all of the 
early adenoma from Apc+/1638N animals were invariably aneuploid. These data, 
obtained from Apc-mutant mouse models and from FAP patients carrying germline 
APC mutations clearly point to a central role of the APC tumor suppressor not only 
in regulating Wnt/b-catenin signaling, but also in chromosomal segregation at 
mitosis. In fact, it is now known that APC localizes at and takes part in several 
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structural complexes and pathways involved in mitosis (i.e. kinetochore, 
microtubules, centrosomes and spindle checkpoints) that are also implicated in the 
origin of both numerical and structural chromosomal defects (Introduction, 
paragraph 1.4).   
To date, considerable experimental evidence proving the causative role of APC in 
mitotic defects and chromosomal instability have been published  (Fodde et al., 
2001; Kaplan et al., 2001; Green & Kaplan, 2003; Dikovskaya et al., 2004). More 
recently, by means of RNA interference, Draviam and colleagues (Draviam et al., 
2006) demonstrated that APC knockdown results in defects in movement and 
orientation of sister chromatids at  the metaphase plate. Moreover, these defects 
lead to a low though significant level of chromosome missegregation accompanied 
by chromosome loss during anaphase. 
Chromosomal instability in CRC tumors is likely to confer the neoplastic cell with 
random somatic mutations from which those providing growth advantages will be 
selected. In yeast, more than 100 genes involved in mitotic spindle assembly and 
dynamics, chromosome metabolism, cell-cycle regulation, and checkpoint control 
has been proved to cause chromosomal instability (Spencer et al., 1990). In the 
majority of the cases, the human homologues of these genes has been 
characterized, though only a few mutations have been found in tumors so far 
(Cahill et al., 1998; Shichiri et al., 2000; Imai et al., 1999; Rajagopalan et al., 2004).  
One could argue that mutations in these ‘genome integrity’ genes would result in 
excessive genetic instability and apoptosis. APC mutations instead, possibly 
together with other mutations that drive “mild” mitosis defects (see Introduction), 
could confer the “just-right” type of CIN able to escape the checkpoint surveillance 
machinery, as it has been recently demonstrated (Draviam et al., 2006). 
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Figure 1. Overcoming selection barriers during tumor formation and progression. 
In normal cells (a), the intrinsic rate of instability is low. As none of the cells 
contains the genetic alteration required to overcome the selection barriers, tumour 
formation is prevented. Tumour cell precursors (b), are characterized by an 
increased level of genetic instability. In this case, the broad cellular heterogeneity 
virtually guarantees that at least one of the cells contains the requisite genetic 
alteration to overcome the selection barrier and proceed in tumour progression. If 
the level of genetic instability is too high (c), the damage accumulated from cell 
division rapidly rises above the threshold for viability – apoptotic pathways are 
activated and cell death ensues. At the level of the cellular population, this leads to 
extinction. Not enough cells reach the first selection barrier to select a malignant 
clone effectively. 
Reprinted from "Genetic instability and darwinian selection" Trends in Cell Biology 
Vol 9 (Dec 12) 1999 Cahill DP, Kinzler KW, Vogelstein with permission from 
Elsevier. 
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6.2.  Accommodating haploinsufficiency of tumor suppressor genes in the 
adenoma-carcinoma sequence  
The classical mechanism that explains how loss of a tumor suppressor gene leads 
to tumor formation is represented by Knudson’s “two hits hypothesis” (Knudson, 
1971). Using a mathematical model of cancer incidence in hereditary and sporadic 
retinoblastoma, Alfred Knudson postulated that in somatic cells two mutations at a 
putative recessive cancer predisposition locus are necessary to trigger 
tumorigenesis. This model was proven in 1996 when, after the cloning of the RB  
tumor suppressor gene, loss of heterozygosity (LOH) and mutation analysis 
revealed biallelic inactivation of this gene in retinoblastoma (Friend et al., 1986).   
Hence, tumor suppressor genes are recessive at cellular level and require 
complete (i.e. biallelic) loss of function in order to manifest the neoplastic 
phenotype. 
In general, gene expression levels in diploid organism reflect the combined 
transcription of both alleles even though for many genes a single functional allele is 
sufficient to maintain normal protein synthesis and activity. Recently however, 
experiments performed in our and other laboratories contributed to clarify that 
specific tumor suppressor genes encodes for proteins whose function is dependent 
on dosage levels and where monoallelic inactivation may already exert phenotypic 
consequences. To date, several studies have shown that mutation or loss of a 
single allele is sufficient to reduce protein dosage and subsequently alter the 
cellular phenotype (Payne & Kemp, 2005) (see also Chapters 4 and 5).  This gene 
dosage effect is often referred to as haploinsufficiency. Haploinsufficiency at a 
tumor suppressor locus may overcome the need for a somatic hit at the wild type 
allele as a rate-limiting event for tumor development.  
Despite the concept of haploinsufficiency has been known already for several 
decades from classic Drosophila genetic studies, only with the recent availability of 
mouse models carrying targeted gene defects and technologies able to measure 
subtle but consistent variation in gene/protein expression levels, it was possible to 
deliver experimental evidences for the effects of mono-allelic mutations on tissue 
homeostasis. The first experimental evidence supporting a role for 
haploinsufficiency in tumorigenesis came from the analysis of the p27 gene in 
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human neoplasia and knockout mice  (Pietenpol et al., 1995; Nakayama et al., 
1996; Kiyokawa et al., 1996). Tissues from p27+/- mice express approx. 50% of this 
cyclin-dependent kinase inhibitor involved in the regulation of cell cycle. 
Heterozygous mice show an intermediate tumor phenotype between wild type and  
p27-/- animals when challenged with 1,2-dimethylhydrazine, an agent that induces 
adenomas and adenocarcinomas in the colon (Philipp-Staheli et al., 2002). More 
importantly, heterozygous animals retain the expression of the wild-type allele in 
the corresponding colorectal tumors, thus in apparent contradiction with the "two 
hits" model. This evidence, in combination with the fact that the reduction of 
p27Kip1 expression is frequently observed in human colorectal cancer often in 
correlation with poor prognosis (reviewed in Hershko & Shapira, 2006), suggests 
that haploinsufficiency of specific tumor suppressor genes may exert a modifying 
effect on gastrointestinal (GI) tumors onset and progression. Since this 
observation, several studies have shown haploinsufficiency at genes known to be 
involved in gastrointestinal tumorigenesis, as summarized in Table 1. In fact, the 
availability of specific heterozygous mouse models in inbred genetic background to 
examine the different stages of intestinal carcinogenesis, allows to test the 
contribution of different dosage of tumor suppressor genes to tumor development 
and progression. 
In Chapter 4 and 5, we have examined the mechanisms and consequences of 
Smad4 haploinsufficiency in intestinal tumorigenesis. Previous evidence for a role 
of SMAD4 haploinsufficiency in altering intestinal homeostasis was provided by the 
observation that gastrointestinal hamartomas from patients affected by juvenile 
polyposis syndrome (JPS) and carrying germline SMAD4 mutations, almost 
invariably retain the wild type allele (Howe et al., 1998). Our SMAD4 IHC analysis 
of JPS polyps from SMAD4 mutation carriers and of GI tumors from Smad4+/- 
mutant mice has provided further evidence for SMAD4 haploinsufficiency during 
the initial stages of tumor formation (Alberici et al., 2006; Alberici et al. 2007, 
submitted).  
The possibility that loss of expression of a single SMAD4 allele characterizes a 
distinct subset of CRC patients might have important clinical consequences.  
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Table1.  List of haploinsufficient genes implicate in gastrointestinal tumor formation 
 
 
 
Gene  
 
Function   
 
Human cancer association  
 
 
Haploinsufficient phenotype 
 
RAD51B 
 
Homologous recombination, 
double-strand breaks (DSB) repair 
Risk modifier in BRCA2 carriers 
Chromosome fragmentation and increase 
aneuplody in HCT116 CRC cell line (Date et 
al., 2006)  
APC 
Wnt signal transduction; mitotic 
spindle  
 
Familial Adenomatous Polyposis; sporadic 
colorectal cancer 
 
Responsible for a fraction of FAP patients 
without truncating APC (Sieber et al., 2002)   
(Yan et al., 2002)  (Venesio et al., 2003)  
 
FEN1 
 
Endonuclease involved in DNA 
replication and repair 
 
To date, rarely mutated in sporadic cancer  
 
Increase number of adenoma and carcinoma 
in Apc+ /-/Fen+/- mice compared with Apc+ /-
/Fen+/+   animals (Kucherlapati et al., 2002)  
MSH2  DNA mismatch repair  
Mutated both in hereditary and sporadic  
CRC with microsatellite instability (Fishel et 
al., 1993)  
 
Increase of frameshift mutations in mouse 
colon (Zhang et al., 2002)  
Reduced induction of sister -chromatid 
exchanges (SCEs) by methyl nitrosourea 
(MNU) in mouse (Bouffler et al., 2000)  
BLM RecQ DNA elicase, DNA repair Bloom Syndrome 
 
Enhanced tumor formation in Bml+/-  mice 
(Goss et al., 2002) 
 
CDH1 
 
Cell-cell adhesion 
Mutation in many carcinoma  (Hajra & Fearon, 
2002) and in CRC (Kanazawa et al., 2002)  
 
Increased tumor formation in Apc+/-/Ecad+/-   
mice compared with Apc+ /-/ Ecad  +/+   animals 
(Smits et al., 2000)  
 
PTEN 
 
Phosphatase involved in signal 
transduction 
Harmatomatous syndromes (e.s. Cowden 
syndrome), multiple sporadic cancer types 
(Simpson & Parsons, 2001) , colon cancer  
(Liu et al., 2004)  
PTEN+/-  induces increase of prostate 
adenocarcinoma and PIN in a transgenic 
adenocarcinoma of mouse prostate (TRAMP) 
mice (Kwabi -Addo et al., 2001) 
LKB1 Protein Kinase 
Peutz-Jeghers syndrome, mutated in  
lung, pancreatic and biliary cancer. Allelic loss 
at the LKB1 locus relatively frequently in 
sporadic colon cancers (Forster et al., 2000) 
Spontaneous gastric and intestinal adenomas 
in LKB1+ /-  mouse (Miyoshi et al., 2002)  
APAF-1 
 
Mitochondrial apoptotic 
pathway 
 
B-CLL (Sturm et al., 2006) , glioblastoma, 
melanoma, and CRC  (Yamamoto et al., 2000)  
 
Allelic imbalance of APAF-1 locus at 12q23 is 
associated with progression of colorectal 
carcinoma (Umetani et al., 2004)  
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It has been previously shown that loss of SMAD4 expression in CRC associates 
with poor prognosis (Alhopuro et al., 2005). Reduced tumor SMAD4 protein levels 
were associated with significant decrease in disease-free and overall survival after 
potentially curative surgery in Dukes C colorectal cancer patients. Also, SMAD4 
mRNA levels predict treatment response in Dukes C patients. Accordingly, SMAD4 
mRNA and protein levels were found to further decrease in lymph node 
metastases when compared to primary tumors. 
Mathematical modeling of the effects of gene dosage reduction from diploidy to 
haploidy indicates that haploinsufficiency phenotypes might result from stochastic 
fluctuations in gene and protein expression below a critical functional threshold 
(Cook et al., 1998), as illustrated in Fig.2.   In this model, the steady-state gene 
product levels fluctuate around a mean. In case of haploid gene expression, this 
mean is 50% of the diploid state. However, transient fluctuations below the 50% 
level could reach a critical threshold and eventually result in null-like phenotypes 
for the gene in question and the pathway it regulates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Model of the variance in gene expression between a diploid and a 
haploid cell for a specific allele. In this stochastic model there is more variance in 
the haploid than in the diploid system, thus in the haploid system the level of gene 
expression gene may approach 10% of the wild-type. Adapted from (Cook et al., 
1998). Copyright (1998) National Academy of Sciences, U.S.A; reprint with 
permission. 
Diploid
Haploid 
G
en
e 
E
xp
re
ss
io
n 
L
ev
el
 
Time
Chapter 6 
 
 
Activity, concentration and spatial role distribution of a protein within a specific 
tissue context are also likely to play key roles in determining the haploinsufficient 
phenotype. Indeed, signaling proteins like SMAD4 and b-catenin are known to be 
express as a gradient along the crypt-villus axis in the intestinal epithelium 
(Salovaara et al., 2002 ; Batlle et al., 2002).  
In Chapter 5, the identification by expression profiling of genes whose expression 
in ES cells and in gastrointestinal tissue is altered in response to SMAD4  
haploinsufficiency, indicates how gene dosage imbalances may alter cellular 
homeostasis and predispose to GI neoplasia.   
As indicated by the experimental results presented in Chapter 5, it is plausible to 
postulate that Smad4 haploinsufficiency triggers intestinal polyp formation by 
inhibition of TGF-b /BMP signaling and their downstream effectors, thus affecting 
cell proliferation rates and apoptosis, but also through a number of more indirect 
and/or independent downstream targets (Table 1, Chapter 5). Hence, a broad 
spectrum of cellular functions may be affected which include apoptosis (through 
decrease of p53 activity by Mdm2 upregulation), cell cycle and adhesion (possibly 
through Wnt signaling activation by Smad7 and Axin2 downregulation), immune 
response (upregulation of TNF activity), and possibly many others, as illustrated in 
Figure 3. 
 
 
Figure 3. Hypotetical model for the molecular and cellular consequences of Smad4 
haploinsufficiency on intestinal homeostasis and cancer onset. 
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It is interesting to note that in some cases gene dosage defects manifests 
exclusively in a context where other genetic alterations are already present. This 
“compound haploinsufficiency” effect has been proven by breeding mouse models 
carrying targeted mutations in genes such as Blm and E-Cadherin with Apc-mutant 
animals already known for their predisposition to GI tumorigenesis (Goss et al., 
2002;  Smits et al., 2000). Whereas in the latter model tumor onset is invariably 
accompanied by LOH at the wild type Apc allele, its characteristic tumor multiplicity 
and progression rates are affected by the Blm+/- and E-Cadherin+/- genetic  
background without additional somatic hits. These results suggest that compound 
haploinsufficiency at specific gene loci, either germline or somatic, may modify the 
individual’s predisposition to tumor formation by more subtle effects on the 
expression of downstream targets involved in signaling networks and genome 
stability.  
To date, given the present knowledge and experimental evidence, we cannot rule 
out a role for haploinsufficiency at the APC gene. In fact, Yan and co-authors (Yan 
et al., 2002), by employing a highly quantitative method, challenged the concept 
that a modest decrease of APC tumor suppressor gene expression, even below 
the 50% reduction that results from heterozygosity for a null allele, may result in 
the development of attenuated forms of polyposis. Similar conclusions were 
reported in an independent study where low APC mRNA expression levels were 
observed in patients with mild FAP phenotype (Venesio et al., 2003).  
In a study performed by D’Abaco and colleagues (D'Abaco et al., 1996), normal 
colonic epithelial cell lines established from the Immorto-Apc+/Min model and 
transfected in vitro with the H-Ras oncogene show the typical spindle-shaped 
appearance of transformed cells and develop tumors in immune-deficient recipient 
mice when compared to the parental line. Notably, these cells retain the wild type 
Apc allele. These experiments not only confirm a synergism between Apc and Ras  
in tumorigenesis (see also Chapter 2 and the next paragraph) but also 
demonstrate how tumorigenesis might proceed without loss or mutation of the wild-
type Apc allele. 
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Heterozygosity for mutations and/or polymorphisms at disease-causing or 
susceptibility genes are detected in many CRC tumors, as shown for instance by 
many LOH studies. As discussed above, these defects are likely to contribute to 
the progression of colorectal cancer simply by reducing expression levels of the 
corresponding proteins.   
 
6.3.  Signal transductions cross talk 
 
In Chapter 2 and 4 of this thesis experiments are described where different mouse 
models characterized by defects in key elements of pathways involved in the 
homeostasis of normal intestinal epithelia are interbred. The purpose of these 
studies was to measure the effects that these interactions, which mimic the genetic 
alterations most frequently observed along the adenoma-carcinoma sequence, 
may exert at the phenotypic and molecular level in the gastrointestinal tract. Four 
possible outcomes might be expected when comparing the compound animals with 
their single mutant counterparts: no effect, antagonism, a cumulative effect, or 
synergisms. In the specific case of the combinations of Apc mutations with defects 
in the KRAS and Smad4 genes, the analysis revealed that compound animals 
were affected by dramatic enhancement of the tumor phenotype when compared 
with the Apc-only mutant mice. 
The main challenge is then represented by the elucidation of the cumulative or 
synergistic nature of these interactions at the molecular level. The latter is often a 
daunting task as different signal transduction pathways known to regulate 
homeostasis in normal intestinal epithelial cells may interact and cross talk at 
different levels. In order to dissect and elucidate the nature of these biochemical 
and genetic interactions we made use of embryonic stem (ES) cells that 
recapitulate the genetic defects in the compound transgenic mice. These isogenic 
cell lines allowed us to perform accurate signalling measurements by reporter 
assays. Next, transcriptome and immunohistochemistry (IHC) analysis of intestinal 
tumors and ES cells were performed to validate the putative involvement of specific 
members of the Wnt, Ras and TGF-b signalling cascades and their cross talk. 
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Cross talk between RAS/RTKs and Wnt signaling  
Ras proteins play a direct causal role in human cancer as shown by the occurrence 
of H-, N-, and KRAS mutations at varying frequencies in different tumor types (Bos, 
1988). In colorectal cancer, nuclear accumulation of b-catenin, the hallmark of Wnt 
signaling activation, and oncogene KRAS activation characterize the majority of the 
cases. Moreover, the concomitant activation of these two pathways identify a 
subset of patients with poor prognosis (Zhang et al., 2003). By generating the 
compound Apc /KRAS mouse model as described in Chapter 2, we succeeded in 
recapitulating the molecular events underlying malignant transformation 
characteristic in this subset of CRC patients. These mice are characterized by 
increased intestinal tumor multiplicity and progression, with early morbidity and 
mortality (Janssen et al., 2006). Recently, Andrew Clark and colleagues obtained 
similar results by employing different Apc and Kras mutant alleles (Sansom et al., 
2006). Also, it has been previously demonstrated that primary intestinal cells with 
compound heterozygous  ApcMin/Ras mutations grow in vitro under both permissive 
and non-permissive conditions, and are able to form tumors when transplanted in 
immune-deficient recipient mice (D'Abaco et al., 1996) .These data elegantly 
demonstrate that a single defective Apc allele and an activated Ras gene are 
sufficient to elicit malignant transformation of normal colonic epithelial cells. 
Hence, there is ample in vitro and in vivo experimental evidence that the 
combination of gain and loss of function mutations at the KRAS oncogene and 
APC tumor suppressor gene respectively, underlie tumor onset and progression 
towards malignancy in the GI tract. However, the question still remains whether 
these marked cellular and phenotypic effects are the results of a cumulative (i.e. 
additive) or synergistic (i.e. cross-talk) interaction between the Wnt and RAS 
signalling pathway.  Beside its known signalling role through the RAF-MAPK 
pathway in inhibiting apoptosis and promoting cell cycle and growth (Kerkhoff & 
Rapp, 1998), RAS exerts other effects possibly related to the acquisition of the 
transformed phenotype. Cell-cell adhesion and cytoskeleton interactions are 
modified upon RAS oncogenic transformation in vitro and this effect has been 
proved to be caused by a decreased interaction between b-catenin and E-cadherin 
at the adhesion junction (Kinch et al., 1995). Moreover, loss of b-catenin/E-
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cadherin colocalization at the cell membrane has been associated with the 
development of metastatic cancers (Daniel & Reynolds, 1997). Accordingly, we 
evaluated the interaction between b-catenin and E-cadherin by in vitro and in vivo 
assays and observed a decrease in E-cadherin-bound b-catenin levels in 
compound KRAS/Apc tumor cells when compared to single mutant controls 
(Janssen et al., 2006). Upon RAS activation, intracellular tyrosine kinase activity is 
increased leading to Tyr-phosphorylation of many target proteins among which b-
catenin (Kinch et al., 1995). In particular, b-catenin tyrosine phosphorylation at 
residue 654 has been shown to cause the dislocation of b-catenin from E-cadherin 
(Roura et al., 1999), while the inhibition of tyrosine kinase activity abolish this effect 
with restoration of b-catenin/E-cadherin colocalization at the cell membrane (Kinch 
et al., 1995). Upstream of RAS, activation of receptor tyrosine kinases (RTKs) such 
as EGFR (epidermal growth factor receptor) and HGF/SF (hepatocyte growth 
factor; scatter factor) receptor, has been shown to induce scattering of human 
cancer cells via tyrosine phosphorylation of b-catenin (Shibamoto et al., 1994).  It 
has been proposed that Src might represent the main tyrosine kinase directly 
responsible for b-catenin phosphorylation (Roura et al., 1999). However, it is 
plausible that additional RAS-activated protein kinases contribute to the sub-
cellular compartmentalization of b-cat enin through its phosphorylation at specific 
Tyr residues.  
Activation of RAS and RTKs may regulate b-catenin function and activity by two 
distinct mechanisms. First, Ras/RTK-mediated b-catenin Tyr-phosphorylation 
results in loss of cell-cell adhesion by disturbing the functionality of the adherens 
junction functionality through E-cadherin destabilization and loss of contact with the 
actin cytoskeleton (Daniel & Reynolds, 1997). These effects on cell-cell adhesion 
underlie epithelial to mesenchymal transitions (EMT) and are known to contribute 
to local invasion and distant cancer metastasis. A second outcome of Ras/RTK-
dependent b-catenin phosphorylation is represented by the increase of b-catenin 
signaling pool in the cytoplasm.  The release of Tyr-P b-catenin from E-cadherin at 
the adherens junctions is likely to result in its intracellular accumulation and 
increased Wnt signal transduction activity to the nucleus where b-catenin binds 
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TCF/LEF1 transcription factors thus modulating the expression of Wnt target 
genes. 
Notably, the Ras/RTK -mediated effects on b-catenin signaling and cell adhesion 
function appear necessary for malignant transformation in the context of loss of 
APC function. However, they are insufficient to efficiently initiate tumorigenesis in 
the intestine in the presence of functional APC. Single villin-KRas transgenic mice 
occasionally develop few intestinal tumors at over 1 year of age, thus only after a 
long latency that allows the acquisition of somatic synergistic p53 mutations. 
Moreover, the exclusive presence of KRAS mutations in human ACF does not 
confer dysplastic characteristics and the lesions appear to be quiescent when 
compared to those encompassing both APC and KRAS defects (Jen et al., 1994).  
Therefore, it appears that loss of APC function is the rate-limiting event for tumor 
initiation through the constitutive activation of Wnt/b-catenin signaling. However, 
this is necessary but insufficient for full-blown b-catenin nuclear translocation and 
further enhancement of Wnt signaling activity is necessary for tumor progression 
towards malignant transformation. The latter is achieved upon KRAS/RTK -driven 
tyrosine phosphorylation of b-catenin and the consequent increase of its signaling 
pool. The effects of this increase of the transcriptional activity of b-catenin only 
become noticeable in the context of loss of APC function, i.e. upon loss of proper 
b-catenin regulation by the destruction complex.  
The cross-talk between the RAS-RAF-MAPK and Wnt signalling cascades is likely 
to occur at different levels. For example, both pathways modulate expression 
levels, protein activity and stability of cyclin D1 and c-Myc, together with other 
important factors implicated in the regulation of cell cycle progression (He et al., 
1998; Tetsu & McCormick, 1999;  Sears et al., 1999). The Wnt/RAS cooperation 
also operates on the activity of another member of the destruction complex, 
namely the Ser-Thr protein kinase GSK-3b. Oncogene RAS activation can inhibit 
GSK-3b kinase activity thus further contributing to the deregulation of intracellular 
b-catenin levels (Li et al., 2005). 
Angiogenesis has also been shown to be stimulated in a synergistic fashion by Wnt 
and RAS signaling. Proficient vascularization is a key factor for tumor growth and 
Vascular Endothelial Growth Factor (VEGF) represents the main agent to positively 
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regulate neo-vascularization. Zhang and co-authors (Zhang et al., 2001) showed 
that not only VEGF represent a downstream target of Wnt signaling, but also that 
the concomitant presence of oncogenic KRAS mutations further increase the 
transcription of this very growth factor.  
In conclusion, the coordinated pattern of synergistic gene regulation between Wnt 
and Ras signal transduction is likely to affect a broad spectrum of genes with 
distinct roles the pathogenesis of colon cancer. 
 
Cross talk between TGF-b and WNT signaling 
Recently, emerging data have suggested the presence of multiple levels of 
interaction between Wnt and two related signal transduction pathways, namely 
TGF-b and BMP (see Appendix 2). Members of the TGF-b family of signalling 
factors are involved in a broad spectrum of cellular activities related to growth and 
development in a variety of tissues, including the gastrointestinal tract (Massague, 
1998). Once ligand-activated by phosphorylation of the activated receptors, SMAD 
proteins migrate to the nucleus, where they recruit others transcriptional factors 
thus stimulating the expression of target genes implicated in the regulation of 
relevant biological functions. A specific aspect of this signaling pathway is that, 
depending on the cellular type and context, the net effect of the cellular response 
to TGF-b might be either growth arrest (thus explaining the classical tumor 
suppressing function of TGF-b), or the transition from benign to malignant 
carcinoma, with structural changes of the extracellular matrix, stimulation of 
angiogenesis and depression of the immune response. Whether TGF-b signaling is 
transduced as a growth inhibiting or promoting stimulus is likely to depend on 
tissue-specific differences in the distribution of nuclear cofactors that bind to 
specific subsets of target genes thus modulating their transcriptional activation.  
Several transcriptional elements of the Wnt pathways have been shown to 
participate into Smad complexes in the nucleus. The first evidence of a physical 
interaction between TGF-b and Wnt signaling components was demonstrated in 
Xenopous (Nishita et al., 2000; Letamendia et al., 2001). These two independent 
sets of experiments showed that in the nucleus Smad4 interacts with Wnt DNA 
binding transcription factors TCF/LEF1 to activate transcription of the Xtwn gene. 
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The possibility of Smad regulation of LEF1 target elements was shown to result not 
only from the physical interaction of these proteins, but also from the presence of a 
DNA Smad Binding Element (SBE) adjacent to the LEF1 binding site. 
Subsequent to these observations, a synergistic action of Wnt/TGF-b was 
identified for additional target genes in mammalian tumor cell lines. 
Gastrin is a gastrointestinal hormone and growth factor shown to represent a 
downstream target of the Wnt signaling pathway (Koh et al., 2000). Incompletely 
processed gastrins (progastrin and glycine-extended gastrin) are capable of 
inducing colonic proliferation both in vitro and in vivo (Koh et al., 1999; Stepan et 
al., 1999; Aly et al., 2001; Singh et al., 1996; Baldwin, 1994). The combination of 
TGF-b and Wnt signaling in gastric adenocarcinoma cells results in a strong 
synergistic promotion of Gastrin gene expression, as shown by the presence of a 
complex composed of Smad proteins, TCF4, and b-catenin in malignant cells (Lei 
et al., 2004), that possibly accelerates the neoplastic process in the GI tract. 
Wnt/b-catenin and Smad4-dependent signaling pathways can also cooperatively 
drive the transcription of the homeobox-containing gene MSX2 (Hussein et al., 
2003). Activation of the MSX2 promoter by Wnt and Smads is dependent on 
p300/CBP, as also shown for the murine gastrin promoter (model proposed in 
Figure 4).  These results show how Wnt and TGF-b can interact and act 
cooperatively in tumorigenesis.  However, antagonist effects between these 
signaling pathways have also been demonstrated in the regulation of the c-Myc  
oncogene, a key regulator of cell-cycle progression (Sasaki et al., 2003). In the 
presence of Wnt ligand but in the absence of TGF-b signals, TCF-4/b-catenin binds 
to its responsive element within the c-Myc promoter, thus activating its transcription 
(Figure 5). Upon combined Wnt and TGF-b signaling, Smad3 nuclear translocation 
dislocates b-catenin from the c-Myc promoter and represses its transcriptional 
activity. 
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Figure 4. Model for intersection of TGF-b/Smad and Wnt pathways. The 
interaction between the Smad3/4 and b-catenin/TCF complexes is mediated by 
TCF4, but this interaction could occur at adjacent TCF and SBE sites (shown in A), 
at isolated TCF sites (shown in B), or at isolated SBE sites (shown in C). In B, the 
Smad3/4 complex functions as a co-activator, whereas in C, the b-catenin/TCF4 
complex acts as a co-activator. The additional recruitment of the cofactor 
p300/CBP, known to interact with both Smad3/4 and b-catenin, is also shown.  
From "The Murine Gastrin Promoter Is Synergistically Activated by Transforming 
Growth Factor-b/Smad and Wnt Signaling Pathways" THE JOURNAL OF 
BIOLOGICAL CHEMISTRY 2004 Shi Lei, Alexander Dubeykovskiy, Abhijit 
Chakladar, Lindsay Wojtukiewicz, and Timothy C. Wang 
Reprint with permission from Editor 
However, TGF-b signalling does not affect Wnt-driven transcriptional activation of 
the c-Myc gene when the LEF-1/b-catenin complex binds to the c-Myc promoter 
instead of TCF-4/b-catenin (Figure 5). Hence, enhanced LEF-1 expression, 
frequently observed in colon cancer, may underlie the malignant behavior 
characteristic of a subset of advanced CRCs that fail to undergo growth arrest 
upon TGF-b signaling.  
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The above mentioned synergistic and antagonistic outcomes of Wnt/TGF-b cross-
talk occur at the transcriptional level. However, additional levels of regulatory 
interaction can also be envisaged. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Model showing how the increased expression of LEF-1 may release the 
repression of c-myc expression induced by TGF-ß. Reprinted from "Lymphoid 
enhancer factor 1 makes cells resistant to transforming growth factor beta-induced 
repression of c-myc" Sasaki, T., Suzuki, H., Yagi, K., Furuhashi, M., Yao, R., Susa, 
S., Noda, T., Arai, Y., Miyazono, K. & Kato, M. (2003). Cancer Res , 63, 801-6. With 
permission from the Editor. 
 
It has been reported that oncogenic b-catenin or loss of APC function in human 
colon cancer cells lead to the expression and secretion of the TGF-b family 
member BMP4 (bone morphogenetic protein 4) (Kim et al., 2002) possibly 
representing an alternative mechanism, though yet to be entirely elucidated, of 
Wnt/TGF-b cross-talk in the deregulation of differentiation of colorectal cancer 
cells. The BMP signaling pathway has been implicated in the early steps of gut 
development and plays a central role in intestinal epithelial homeostasis. BMPs 
molecules moreover, are expressed in the stromal compartment of the villus. 
Accordingly, phosphorylated SMAD1, 5, and 8, indicative of active BMP signalling, 
show a gradient of nuclear expression in epithelial cells from the crypt (no 
expression) to the villus (highest levels of expression). 
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In Chapter 5, we showed that a Smad4 loss of function mutation affects in a 
dosage-dependent fashion the expression of several target genes. In particular, 
both in heterozygous (Smad4+/-) and more pronouncedly in homozygous (Smad4-/-) 
ES cells, the transcription of Conductin (also known as Axin2) is down-regulated. 
Conductin, together with APC, GSK-3b and Axin1, participates in the destruction 
complex that regulates the activity of b-catenin along the Wnt signaling cascade 
(Appendix 1). Mutations in Conductin have been frequently reported in CRCs with 
DNA mismatch repair defects (microsatellite instable tumors, MSI) (Liu et al., 2000) 
and also in the germline of few familial cases (Lammi et al., 2004). Taken together, 
it appears that defective TGF-b signaling, resulting from Smad4 mutations, may 
directly affect and increase Wnt signaling. Loss of BMP signaling, by targeted 
inactivation of its main receptor (BMPR1a), causes an expansion of the mouse 
intestinal stem cell population leading to the formation of intestinal polyps with 
concomitant Wnt signaling activation (He et al., 2004). 
Also, loss of PTEN function causes activation of Akt, thus positively contributing to 
nuclear b-catenin accumulation in intestinal stem cells (Persad et al., 2001). Since  
BMP is able to increase PTEN protein levels by inhibiting its degradation by the 
proteasome (Waite & Eng, 2003), the net effect of BMP activation is the inhibition 
of Wnt signaling in the intestinal crypt, thus regulating the proliferation of the stem 
and transient amplifying compartments (Figure 6). The Smad4-mutant mouse 
model described in this thesis (Chapter 2) might also be affected, to a certain 
extent, by the same mechanism with net increase of Wnt signaling. However, b-
catenin IHC analysis of gastrointestinal polyps from these animals did not show 
evidence of nuclear accumulation. 
Additional Wnt/TGF-b interactions take place outside the nucleus. In adult 
mesenchymal stem cells (MSCs), TGF-b1 induces rapid nuclear translocation of b-
catenin in a Smad3-dependent manner, independently of changes in b-catenin 
stability and phosphorylation status (Jian et al., 2006). This synergistic cooperation 
between TGF-b and Wnt signaling in the specific MSC cellular context controls 
self-renewal and differentiation.  
Reporter assay analysis of TGF-b signaling in the Apc1638N/1638N ES cells revealed 
an increase of signaling activation (Alberici et al. manuscript in preparation), as 
Discussion 
 
 
also confirmed in wild type ES transiently transfected by  Apc-specific siRNAs. 
Notably, the same effect was not observed in Wnt-stimulated ES cells, thus 
indicating a possible direct effect of APC down-regulation on TGF-b signaling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Illustration of the regulatory cross-talk network between BMP and Wnt 
signalings mediated by PTEN-PI3K pathway that controls the stem cell behaviour 
and the transition between quiescent and activated states. This network allows a 
balanced control of stem cell-renewal through a convergent downstream 
component.  
From Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3z. By Qian 
T. et al    Cell Cycle. 2005 Feb;4(2):215-6. Reproduced with permission. 
 
An additional Wnt/TGF-b connection has been shown between Axin1 and Smad3 
that can explain our reporter assay data: Axin1 binds to Smad3 and promotes his 
phosphorylation by the membrane-bound type I receptor TGFBRI, with the total 
effect of increasing TGF-b signaling (Furuhashi et al., 2001). The same net 
increase in TGF-b signaling is further substantiated by the observation that Axin1 
also contributes to the downregulation of the inhibitor Smad7 through sequestration 
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and polyubiquitination-mediated degradation  as represented in Figure 6    (Liu et 
al., 2006) 
In conclusion, as illustrated in this PhD thesis, the elucidation of the complex 
network of interactions among different signalling pathways in colorectal cancer 
have  contributed  to  the  improved   understanding   of  how  adult  intestinal  cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Model for a scaffolding roles of Axin in TGF-b signalling (Liu et al., 2006).  
Following ligand stimulation, Axin promotes Smad3 phosphorylation causing the 
dissociation of Smad3 from the receptor complex. Axin acts as well onto Arkadia  
(Ark) to facilitate Smad7 polyubiquitination, independently of TGF-b signalling, thus 
leading to Smad7 degradation. 
 
regulate stemness, commitment to specific cell-fates, and proliferation. 
Understanding the cellular context in which these pathways converge and operate 
in specific cellular phenotypes will be crucial to elucidate the mechanisms that 
contribute to the overall preservation of intestinal homeostasis and thus identify the 
specific alterations in mechanisms that are responsible to the neoplastic process. 
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Summary 
 
 
SUMMARY 
 
Colorectal cancer represents not only the second leading cause of cancer-related 
death in Western world but also an ideal model to investigate and elucidate the 
genetic alterations that underlie tumor onset and progression, the so-called 
adenoma-carcinoma sequence. This sequence of events towards malignancy and 
metastasis is characterized by the progressive increase in signal transduction 
activity and chromosomal instability levels resulting from the accumulation of 
somatic mutations in specific tumor suppressor genes and oncogenes. 
Loss of function mutations at the APC tumor suppressor gene leading to aberrant 
Wnt signaling and the synchronous oncogenic KRAS  activation are early and 
frequent events in colorectal cancer, often associated with poor prognosis. In 
CHAPTER 2 we report the generation and analysis of compound 
KRASV12G/Apc+/1638N mutant mice.  These animals are characterized by increased 
tumor initiation and progression with enhanced morbidity and mortality. We 
demonstrated by in vitro and in vivo  analysis that activated KRAS, via tyrosine 
phosphorylation of b-catenin, leads to its release from E-cadherin at the adherens 
junctions, and to its consequent nuclear translocation and increased transcription 
of Wnt downstream target genes.  
Although chromosomal instability (CIN) characterizes the majority of human 
colorectal cancers, the contribution of genes such as APC, KRAS and p53 to this 
form of genetic instability is still a matter of debate. In CHAPTER 3 we have 
assessed chromosomal imbalances in tumors derived from mouse models of 
intestinal cancer, namely Apc+/1638N, Apc+/1638N/KRASV12G, and Apc+/1638N/Tp53-/-, by 
array-CGH (comparative genomic hybridization). All intestinal adenomas displayed 
chromosomal alterations, thus confirming the presence of a chromosomal 
instability defect at very early stages of the adenoma-carcinoma sequence. 
Moreover, loss of the Tp53 tumor suppressor gene, but not KRAS oncogenic 
activation, results in an increase of gains and losses of whole chromosomes in the 
Apc-mutant genetic background. Through the comparative analysis of the overall 
genomic alterations found in human and mouse intestinal adenomas, we identified 
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a subset of syntenic regions likely to encompass rate-limiting genes for intestinal 
tumor initiation and progression. 
The SMAD4 tumor suppressor gene, a key element for the transduction of TGF-b 
signals, is involved in the pathogenesis of pancreatic and colorectal cancers. In 
CHAPTER 4, the detailed analysis of intestinal tumors from Smad4+/E6sad mouse 
showed that loss of heterozygosity (LOH) of the wild type Smad4 allele is not an 
essential requirement for tumor formation and that complete loss of protein 
expression occurs only at later stages of tumour progression. Hence, 
haploinsufficiency underlies Smad4–driven tumor initiation in the GI tract. We have 
than bred Smad4+/E6sad with the Apc+/1638N model to generate two distinct 
compound heterozygous lines carrying both mutations either in cis (CAS) or in 
trans (TAS) on chromosome 18. Notably, both models show increased tumor 
multiplicities when compared with the single mutant littermates, though CAS mice 
are more severely affected. Phenotypic and molecular analyses indicate that 
Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and 
progression both prior to and upon loss of Apc function. Moreover, complete loss 
of Smad4 strongly enhances Apc-driven tumor formation. 
In CHAPTER 5 we defined the molecular defect resulting from SMAD4 
haploinsufficiency. In Smad4+/- and Smad4-/- ES cells derived from Smad4E6sad 
animals, the Smad4 protein expression level perfectly correlates with the gene 
copy number (~50% reduction in heterozygous cells and no protein expression in 
homozygous cells). Reporter assay analysis showed the presence of TGF-b and 
BMP signaling defects already in heterozygous cells in transduction pathways. 
Expression profiling of these ES cell lines allowed the identification of a shortlist of 
Smad4 dosage-related target genes involved in signaling, metabolism and 
regulation of the transcription. We validate a subset of these differentially 
expressed genes by real-time PCR on normal intestinal tissue from Smad4+/- mice, 
confirming the presence of a primary defect. IHC analysis of polyps from Familial 
Juvenile Polyposis patients carrying Smad4 germline mutations also retained 
Smad4 expression in the earliest stage of polyp formation, hence in agreement 
with the haploinsufficiency model.  
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These observations indicate that relatively small fluctuations in Smad4 levels in 
intestinal epithelial cells may contribute to alterations of cellular pathways and 
networks responsible for polyps formation without complete loss of Smad4 
function.  
In conclusion, this thesis aims to describe and illustrate the multiple interactions 
and mutual influences of defective signal transduction pathways in CRC and the 
mechanisms that are responsible for ‘just-right’ level of genetic instability. Both 
these elements contribute to the establishment of the multiple cellular defects 
necessary to promote tumor progression and malignancy. 
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SAMENVATTING 
 
Dikkedarmkanker is niet alleen de tweede oorzaak van kanker gerelateerd 
overlijden in de Westerse wereld, maar ook een ideaal model om de onderliggende 
genetische oorzaak van het ontstaan van tumoren en tumorprogressie, de 
zogenaamde adenoma-carcinoma reeks, te onderzoeken en op te helderen. De 
reeks van gebeurtenissen voorafgaand aan kwaadaardigheid en metastasering 
wordt gekarakteriseerd door een continue toename van signaaltransductie activiteit 
en mate van chromosomale instabiliteit als gevolg van de opeenhoping van 
somatische mutaties in specifieke tumor suppressor genen en oncogenen. 
Functieverlies gevende mutaties in het APC tumor suppressor gen die leiden tot 
een verhoogde Wnt signalering en een simultane oncogene KRAS  mutatie zijn 
vroege en veel voorkomende gebeurtenissen in dikkedarmkanker en vaak 
geassocieerd met een slechte prognose. In Hoofdstuk 2 vermelden we de 
generatie en analyse van samengestelde KRASV12G/Apc+/1638N mutante muizen. 
Deze dieren hebben een verhoogde tumor initiatie en progressie met een 
verhoogde morbiditeit en mortaliteit. We hebben door in vitro en in vivo analyse 
laten zien dat geactiveerd KRAS, via tyrosine fosforylering, b-catenine los maakt 
van E-cadherine in de adherent junctions, en dat deze als gevolg hiervan naar de 
kern gaat en de transcriptie van Wnt  gereguleerde genen verhoogt. 
Hoewel chromosomale instabiliteit (CIN) karakteristiek is voor een meerderheid 
van humane dikkedarmkankers, is de bijdrage van genen als APC, KRAS en p53 
in deze vorm van genetische instabiliteit nog steeds onderwerp van discussie. In 
Hoofdstuk 3 hebben we de chromosomale onbalans in tumoren afkomstig van 
muismodellen voor darmkanker, namelijk Apc+/1638N, Apc+/1638N/KRASV12G en 
Apc+/1638N/Tp53-/-, vastgesteld door middel van array-CGH (Comparitieve 
Genomische Hybridisatie). Alle darm-adenomen vertoonden chromosomale 
afwijkingen, daarmee de aanwezigheid van een chromosoominstabiliteitsdefect in 
erg vroege stadia van de adenoma-carcinoma reeks bevestigend. 
Bovendien resulteerde het verlies van het Tp53 tumor suppressor gen wél, maar 
oncogene KRAS activatie niet in een toename van winst en verlies van hele 
chromosomen in de Apc-mutant achtergrond. Door de vergelijkende analyse van 
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de algemene genomische veranderingen, gevonden in humane en muizen darm 
adenoma’s, identificeerden we een subgroep van syntenische regio’s die 
waarschijnlijk de snelheidsbepalende genen voor darmkanker initiatie en 
progressie bevatten. 
Het SMAD4 tumor suppressor gen, een sleutelfactor voor de doorgifte van TGF-b 
signalen, is betrokken bij de pathogenese van pancreas- en dikkedarm-kanker. In 
Hoofdstuk 4 liet de gedetailleerde analyse van darmtumoren van Smad4+/E6sad 
muizen zien dat verlies van heterozygotie (LOH) van het wild type Smad4 allel niet 
absoluut vereist is voor tumorvorming en dat een volledig verlies van 
eiwitexpressie  pas voorkomt in latere stadia van tumorprogressie. Daarom is 
haplo-insufficiëntie de oorzaak van Smad4 gedreven tumorinitiatie in het 
maagdarmkanaal. We hebben toen het Smad4+/E6sad met het Apc+/1638N model 
gekruist om twee verschillende, samengestelde heterozygote lijnen te maken die 
beide mutaties dragen in cis (CAS) of in trans (TAS) op chromosoom 18. 
Opvallend is dat beide modellen een verhoogd tumor aantal hebben vergeleken 
met de enkelvoudige mutante nestgenoten, hoewel de CAS muizen zwaarder zijn 
aangedaan. Fenotypische en moleculaire analyse laten zien dat Smad4 haplo-
insufficiëntie voldoende is om de tumor initiatie en progressie significant te 
beïnvloeden, zowel voor als na verlies van Apc functie. Bovendien versterkt een 
compleet verlies van Smad4 de Apc aangedreven tumor vorming zeer. 
In Hoofdstuk 5 hebben we het moleculaire defect achterhaald dat het gevolg is 
van SMAD4 haploinsufficiëntie. In Smad4+/- en Smad4-/- ES cellen afkomstig van 
Smad4E6sad dieren, correleert de mate van Smad4 eiwit expressie perfect met het 
aantal gen copieën (~50% reductie in heterozygote cellen en geen expressie in 
homozygote cellen). Reporter assay analyse liet zien dat TGF-b en BMP 
signaaltransductiedefecten reeds aanwezig zijn in heterozygote cellen. 
Expressie profilering van deze ES cellijnen maakte het mogelijk een shortlist op te 
stellen van Smad4 dosis-gerelateerde doel genen die betrokken zijn bij signalering, 
metabolisme en transcriptieregulatie. We valideerden een sub-set van deze 
differentieel ge-expresseerde genen door middel van real time PCR op normaal 
darm weefsel van Smad4+/- muizen, en bevestigden daarmee het bestaan van een 
primair effect. IHC analyse liet zien dat poliepen van Familial Juvenile Polyposis  
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patiënten die Smad4 kiembaan mutaties dragen ook de Smad4 expressie 
behielden in de eerste stadia van poliep vorming, dit in overeenstemming met het 
haploinsufficiëntie model. 
Deze observaties geven aan dat relatief kleine fluctuaties in Smad4 hoeveelheden 
in darmepitheel-cellen kunnen bijdragen tot veranderingen in cellulaire paden en 
netwerken en daardoor verantwoordelijk zijn voor poliepvorming zonder volledig 
verlies van Smad4 functionaliteit. 
Concluderend, dit proefschrift heeft als doel de veelvoudige interacties en 
wederkerige invloeden van defecte signaaltransductiepaden in dikkedarmkanker 
en de mechanismen die verantwoordelijk zijn voor een ‘precies-goed’ mate van 
genetische instabiliteit te beschrijven en te illustreren. Deze beide elementen 
dragen bij aan het ontstaan van de meerdere cellulaire defecten die nodig zijn voor 
het bevorderen van tumor progressie en maligniteit. 
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Appendix 1. The WNT/β catenin signal transduction pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A schematic representation of the canonical Wnt/β-catenin signaling pathway. 
(A) In the absence of Wnt ligand, β-catenin is earmarked for proteolytic degradation   
by the destruction complex. (B) Upon loss of APC function, or (C) in the presence 
of Wnt ligand, β-catenin accumulates in the cytoplasm and eventually translocates 
in the nucleus to act as transcriptional co-activator with T-cell factor/lymphoid 
enhancer (TCF/LEF) family. 
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Appendix 2. The TGF-β/BMP signal transduction pathways 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A schematic representation of the TGF-β (upper panel) and BMP (lower panel) 
signaling pathways. The specific ligand (TGF-β or BMP) binds to the receptor type 
2 (TGFBRII) which complexes with the receptor type 1 (TGFBRI) thus triggering its 
phosphorylation. The activated receptor is responsible for the phosphorylation of 
the specific R-Smads, which then bind the co-Smad (Smad4). The heterodimer 
translocates to the nucleus where it induces transcription of specific downstream 
target genes. 
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Appendix 3. The RAS/RTK signal transduction pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A schematic representation of the RAS/RTK signaling pathway. Activation of 
growth factor receptors in the cell membrane activates RAS through GDP-GTP 
exchange. With the following cascade of phosphorylation of the downstream 
members of the pathway MAPK and ERK, the RAS signaling results in the 
activation of factors that regulate the transcription of target genes. 
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From Chapter 1 Introduction:  
 
 
 
 
 
 
 
 
Figure 1. The adenoma-carcinoma sequence: a stepwise progression from normal 
epithelium to carcinoma due to a series of genetic changes. Macro- and 
microscopical representations of the progression changes are depicted. See text 
for details. 
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Figure 2. Schematic representation of the accumulation of alterations in different 
pathways along the adenoma-carcinoma sequence. In red are shown the genes 
frequently mutated in CRC. The different cellular alterations resulting from the 
accumulations of these signaling defects are listed in the right column.  
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From Chapter 1.4:  
 
 
igure 1. Schematic representation of the APC protein with its functional motifs. F
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Figure 2. Mitotic spindle defects in Apc mutant cells. In (a) a representation of a 
normal mitotic figure with localization of APC at the kinetochore and at the plus-
ends of the micro- 
tubules is shown. The hypothetical binding of APC on astral microtubules to the 
cortical anchor structure allows keeping the mitotic spindle parallel to the epithelial 
plane. In (b there is represented a mitosis in an APC mutant cell with defects in the 
spindle organization and the failure of the APC binding to the kinetochore and to 
the cortical anchor structure. In (c examples of spindles formed in Apc wild type 
and mutant ES cells lines are shown. In green the γ-tubulin staining marks the 
spindle, whereas in red the CREST/kinetochore structure is stained. Note in the 
Apc mutants the spindle abnormalities with most of the microtubules projecting in a 
chaotic manner in the cytoplasm. In the right Apc-/- picture, the white arrow 
designates an extra centrosome. 
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From Chapter 2: 
 
 
Figure 1, Panel B and C.  
Increased tumor multiplicity and progression in KRASV12G/Apc+/1638N mice (B) 
Macroscopic view of longitudinally dissected small intestinal tissue specimens 
representative for 6 months of age. No tumors can be observed in KRASV12G mice 
at this age, and few (2–4) lesions in Apc+/1638N mice. KRASV12G/Apc+/1638N (RasAPC) 
mice show abundant, multiple lesions throughout the upper GI tract. Scale bar = 1 
cm. (C) H&E stained sections from KRASV12G/Apc+/1638N animals. Left to right: 
benign adenoma at 3.5 months; in situ carcinoma at 3.5 months; invasive 
adenocarcinoma at 3.5 months; invasive carcinoma at 6 months. Scale bars = 200 
μm (upper row) and 50 μm (lower row). 
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Figure 4, Panel A. Proliferation and apoptosis rates in tumors from 
KRASV12G/Apc+/1638N mice. (A) Proliferation is increased in tumors from 
KRASV12G/Apc+/1638N mice (bottom) when compared with Apc+/1638N littermates (top) 
as shown by immunohistochemical detection of the proliferation marker Ki67. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5, Panel A. Increase in nuclear β-catenin accumulation in tumors from 
KRASV12G/Apc+/1638N mice. (A) Tumor sections from KRASV12G/Apc+/1638N mice (right 
panel) show increased nuclear β-catenin compared with tumors from Apc+/1638N 
animals (left panel). All tumor cells with strong (arrow) and mild (arrowheads) 
nuclear β-catenin staining were scored (see Results section). 
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Figure 6. Increase in nuclear β-catenin accumulation and Wnt/β-catenin signaling 
in Apc-mutant ES cells expressing KRASV12G. (A) Confocal microscopy analysis of 
β-catenin and E-cadherin intracellular distribution in wild-type E14 (WT), 
Apc1638N/1638N (A), Apc+/+/KRASV12G (R), and Apc1638N/1638N/KRASV12G (RA) ES cells. 
Note: nuclear accumulation of β-catenin in compound mutant cells (arrowheads), in 
addition to the normal localization at cell-cell contact sites. Overlay with DAPI 
(nuclear stain) to indicate the position of the nuclei. Yellow in the overlay indicates 
colocalization of β-catenin and E-cadherin at the cell-cell junctions, demonstrating 
the presence of β-catenin in adhesion complexes. (B) Pervanadate treatment 
induces β-catenin nuclear accumulation in Apc-mutant but not in wild-type ES cells. 
Nuclear β-catenin (green, arrows) is visible in Apc1638N/1638N (A) and 
Apc1638N/1638N/KRASV12G (RA) ES cells but not in wild-type cells. 
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From Chapter 3: 
 
Figure 1. Heat map visualization of the CGH results for the three groups of tumors 
analyzed in the present study. After normalization and two-log smoothing of the 
array CGH ratios from the 30 tumor samples and four normal intestinal epithelia, 
the data were loaded onto SpotFire Decision Site 8.1 to obtain the heat map here 
represented. Data are ordered in the X bar according to the sample genotypes as 
normal (N), Apc+/1638N (Apc), Apc+/1638N /KRASV12G (Ras), and Apc+/1638N/Tp53-/- 
(p53), and in the Y bar according to the chromosome and Mb position of the BAC 
clones (color code at both sides of the heat map). The color code of the samples 
indicates BAC copy number changes: green, loss; red, gain; and black, no change. 
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From Chapter 4: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
stopathology and immunohistochemical analysis of Smad4E6sad small 
testinal polyps at different ages and progression stages. (a) Polyp originated in 
e gastric epithelium from 12-month-old Smad4+/E6sad animal. Inset: higher 
agnification of hyperplastic region. Note the gastric epithelium (HE). (b) 
dvanced polyp from 15-month-old Smad4+/E6sad mouse showing areas of frank 
ysplasia. Inset: higher magnification of dysplastic region (HE). (c) Smad4 IHC 
nalysis of normal small intestinal epithelium from a Smad4+/E6sad animal shows 
uclear and cytoplasmatic staining with crypt-villus decreasing gradient of 
xpression. The aspecific staining in the lamina propria is due to mouse IgG cross-
action from the secondary antibody. (d) Smad4 IHC analysis of tumor from 12-
onth-old Smad4+/E6sad mouse shows positive staining of tumor cells. Staining of 
tromal cells is due to mouse IgG cross-reaction from the secondary antibody. (e) 
mad4 IHC analysis of tumor from 15-month-old Smad4+/E6sad mouse shows an 
rea of negatively stained parenchymal cells within an otherwise positive tumor. (f) 
 Catenin IHC analysis of tumor from 15-month-old Smad4+/E6sad animal. The more 
ysplastic area of the lesion mainly shows membranous staining. 
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Figure 3. Histopathology and IHC analysis of intestinal tumors from compound 
Apc+/1638N/Smad4+/E6sad. (a) A typical dysplastic adenoma observed in TAS animals 
(HE staining). (b) An example of adenocarcinoma with extensive submucosal 
invasion from a TAS mouse (HE). (c) Sessile villous adenoma from a CAS mouse 
with areas of severe dysplasia and cystic formation (HE). (d) A nascent 
lesion or microadenoma observed in the duodenum of a CAS animal (HE). (e) 
Smad4 IHC analysis of a CAS tumor shows negative staining, thus indicating LOH 
of the wild-type allele. (f) Smad4 IHC analysis of a small microadenoma from the 
same CAS mouse also reveals LOH of the wild-type allele in the nascent lesion. 
Note the positively stained cells of the normal epithelial lining surrounding the 
dysplastic area. 
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From Chapter 5: 
 
Figure 3.  Immunohistochemical analysis of SMAD4 protein expression performed 
on polyps from three unrelated Familial Juvenile Polyposis patients with 
established SMAD4 germline mutation. A. Polyp with SMAD4 nuclear staining. B. 
Polyp with heterogeneous SMAD4 expression pattern with patches of positively 
and negatively staining tumor cells. C. SMAD4 negative juvenile polyp.   
 
 
 
 
 
 
 
 
 
igure 4. Expression profiling analysis of the subset of 79 genes (corresponding to 
8 Affymetrix probes) found to be differentially expressed in both Smad4+/E6sad and 
mad4E6sad/E6sad ES cells. The fold changes are represented as (log2) ratio values. 
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From Chapter 6 Discussion: 
. 
lls 
mour 
vented. Tumour cell precursors (b) are characterized by an 
genetic instability. In this case, the broad cellular heterogeneity 
s that at least one of the cells contains the requisite genetic 
lteration to overcome the selection barrier and proceed in tumour progression. If 
e level of genetic instability is too high (c), the damage accumulated from cell 
ivision rapidly rises above the threshold for viability – apoptotic pathways are 
ctivated and cell death ensues. At the level of the cellular population, this leads to 
xtinction. Not enough cells reach the first selection barrier to select a malignant 
lone effectively. 
eprinted from "Genetic instability and darwinian selection" Trends in Cell Biology 
ol 9 (Dec 12) 1999 Cahill DP, Kinzler KW, Vogelstein with permission from 
lsevier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overcoming selection barriers during tumor formation and progression
In normal cells (a), the intrinsic rate of instability is low. As none of the ce
contains the genetic alteration required to overcome the selection barriers, tu
ormation is pref
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Figure 3. Hypothetical model for the molecular and cellular consequences of 
mad4 haploinsufficiency on intestinal homeostasis and cancer onset. 
 
 
Figure 6. Illustration of the regulatory cross-talk network between BMP and Wnt 
signalings mediated by PTEN-PI3K pathway that controls the stem cell behaviour 
and the transition between quiescent and activated states. This network allows a 
balanced control of stem cell-renewal through a convergent downstream 
component.  From Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-
3-3ζ. By Qian T. et al    Cell Cycle. 2005 Feb;4(2):215-6. Reproduced with 
permission. 
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